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ABSTRACT 
 
 
ADAM COCKRELL:  Insights into the Mechanisms of HIV-1 Cis Elements and Trans 
Factors Required For RNA Encapsidation and Transduction 
(Under the direction of Tal Kafri, M.D, Ph.D) 
The retroviral replication process is typically separated into early events of infection 
for the virus to enter a host cell, and late events that generate new viral particles. 
Encapsidation (late event) and early infection events are governed by several different cis 
elements located in the viral RNA, and viral, or cellular, trans factors (proteins). A number 
of viral encoded components have been identified to function in the encapsidation process, 
most notably the Gag polyprotein and genomic RNA cis elements in the 5’ untranslated 
region (UTR). Although conventionally associated with nuclear export of HIV-1 RNA, there 
is also a burgeoning role for the Rev/RRE in the encapsidation process. Additionally, cis 
elements of the RNAs encapsidated into viral particles may influence different early stages of 
infection into host cells. This dissertation employs an innovative approach that affords 
separation of cis and trans viral components to investigate their independent, and combined, 
effects on encapsidation and early events of infection that will be referred to as transduction. 
HIV-1 cis elements were reconstructed in the context of heterologous RNAs to assess 
encapsidation and transduction functions.  
This work demonstrates for the first time that the Rev/RRE system can augment 
heterologous RNA encapsidation independent of all cis elements from the 5’ UTR. In fact, 
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the Rev/RRE system appears to be required for specific and efficient encapsidation into HIV-
1 viral particles, a process more commonly associated with Gag recognition of the canonical 
packaging signal in the 5’ UTR. Premised on encapsidation of a heterologous RNA into 
HIV-1 viral particles, our findings define a functional HIV-1 packaging system as 
comprising the 5’ UTR cis elements, Gag, and the Rev/RRE system, in which the Rev/RRE 
system is required to make the RNA amenable to ensuing interactions between Gag and the 
canonical packaging signal for subsequent encapsidation. Lastly, we show that heterologous 
RNAs can conform to transduction properties commonly associated with HIV-1 viral 
particles. Furthermore, some heterologous RNAs exhibit an episomal profile in transduced 
cells that may have improved safety benefits over more conventional nonintegrating 
lentiviral vectors. These innovative vector systems may prove beneficial for therapeutic gene 
delivery to nondividing cells.   
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Chapter 1 
INTRODUCTION 
General Mechanisms of Viral Assembly and Genome Packaging  
The fitness of a virus is dependent upon the genetic material (DNA or RNA) that 
encodes structural and enzymatic proteins required to generate a viable viral particle capable 
of protecting and mobilizing the viral genome between cells within an organism, and more 
importantly between organisms. Viral fitness is a consequence of mutation rate of a viral 
genome and the rate at which mutations become fixed within a population (54), culminating 
in the selection of those mutations that are most beneficial at different steps of a virus’s 
replication cycle, within a particular host cell environment. Assembly of viral particles from 
individual capsid proteins to encapsidate the viral genome is a fundamental property shared 
by all viruses. Different viruses that infect organisms from all three domains of life 
(eukaryote, bacteria, and archaea) have been proposed to be evolutionarily similar based on 
the utilization of a common capsid structure for viral assembly (85, 113), and viruses 
assessed by comparative genomics reveal similarities in assembly and genome packaging 
(112, 114).  
Viruses have evolved two general strategies for packaging their genome into capsids 
(200). In the first strategy some viruses form capsids, and then package their DNA, or RNA, 
into the preformed capsids through the use of energy-dependent molecular motors (EDMM). 
The molecular motor strategy is predominantly associated with bacteriophages,  
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such as T4. Nonetheless, herpesviruses share an evolutionarily conserved capsid structure 
with tailed-bacteriophages (113), and have been shown to employ a similar EDMM-based 
genome packaging strategy (144). It is not known if adeno-associated viruses (AAV) share 
capsid protein structural similarities with bacteriophages, or herpesviruses, nonetheless a 
EDMM mechanism has been proposed to facilitate encapsidation of the single-stranded DNA 
(ssDNA) AAV genome into preformed capsid particles (205).  
The second strategy is independent of a molecular motor, therefore may be 
considered an energy-independent encapsidation mechanism. The viral genome is selected 
from the milieu of host cell RNAs through interactions of the viral capsid proteins with 
specific cis recognition elements in the DNA, or RNA, genomes to form a capsid around the 
genome during the assembly process. This mechanism is common to a variety of eukaryotic 
viruses including single-stranded RNA (ssRNA) viruses (Retroviruses (49) and Sindbis virus 
(211) and references therein), double-stranded RNA (dsRNA) viruses (Rotavirus (143)), 
segmented RNA viruses (Rotavirus & Influenza A virus (90)), and double-stranded DNA 
(dsDNA) viruses (SV40 (185)). Mounting evidence indicates that these two mechanisms of 
encapsidation can be distinguished from each other by measuring the mechanical properties 
of individual viral particle capsids using atomic force microscopy (186). In general, 
molecular motors appear to be necessary to package genomic material into viral capsids that 
are more rigid, or have a higher stiffness value, such as many bacteriophage & herpesviruses 
(186). The stiffness of retroviral capsids for murine leukemia virus (MLV) and human 
immunodeficiency virus (HIV) were determined to be much lower (109, 110), consistent 
with an RNA encapsidation mechanism that is independent of an EDMM mechanism. 
Furthermore, differences in capsid stiffness between immature and mature MLV and HIV 
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viral particles may contribute to both encapsidation and subsequent infectivity of a host cell 
(109, 110). Retroviruses have evolved unique biological properties that facilitate optimal 
RNA packaging to ensure efficient transfer of the genome to a host cell. 
 
Retroviral Replication and Genomic RNA Encapsidation 
The Retroviridae family of viruses comprises the Orthoretrovirinae and Spumaretrovirinae 
subfamilies, which can be distinguished at various stages of the viral replication cycle (46). 
Nevertheless, the genomic organization (Fig. 1) comprising gag (structural proteins), pro 
(protease), pol (reverse transcriptase and integrase enzymatic proteins), and env gene, the 
process of reverse transcription (RNADNARNAtranslation of structural & enzymatic 
proteins, Fig. 2), and packaging of full-length genomic RNA into nascent viral particles, are 
common to all retroviruses. The vast majority of retroviruses constitute the Orthoretrovirinae 
subfamily which is morphologically and biologically classified into the following genera: 
Alpharetrovirus, Betaretrovirus, Deltaretrovirus, Epsilonretrovirus, Gammaretrovirus, and 
Lentivirus. Although morphologically, and biologically, distinguishable, the viral particles 
have a number of common features (Fig. 3): i) an Env glycoprotein which is processed into 
the surface domain and transmembrane domain that is inserted into an outer envelope (lipid 
bilayer obtained from a host cell membrane); ii) a Gag polyprotein that is processed into the 
matrix (MA) protein just inside the envelope which surrounds the capsid (CA) protein that 
forms the protein shell protecting the two strands of genomic RNA lined with the 
nucleocapsid (NC) protein; and iii) a Pol polyprotein which is processed into enzymatic 
proteins including protease (PR), reverse transcriptase (RT), and integrase (IN) (46). After 
generation of the nascent, immature retroviral particle a series of protease cleavage events 
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process the Gag and Gag-Pro-Pol polyproteins into the individual aforementioned proteins 
which can be observed by electron microscopy as dramatic morphological changes that 
reveal condensation of the virion core structure, resulting in formation of an infectious viral 
particle.  
 The mature, nascent viral particle initiates infection through interaction of the 
envelope glycoproteins with host cell receptors on the plasma membrane (retroviral 
replication seen in Fig. 4) (for a comprehensive review see (46)). The viral envelope fuses 
with the host cell plasma membrane releasing the capsid, and its contents into the cytoplasm. 
The retroviral capsid goes through an uncoating process, and the replication complex reverse 
transcribes the genomic RNA into dsDNA forming a preintegration complex in the host cell 
cytoplasm. The preintegration complex enters the nucleus, and the viral genomic dsDNA can 
integrate into the host cell genome. Alternatively, DNA products of reverse transcription can 
result in the formation of episomal DNA forms that do not integrate, including: 2-LTR 
circles that form from non-homologous end joining of a linear viral DNA; 1-LTR circles that 
can be generated directly as a consequence of the reverse transcription process, or through 
homologous recombination of the viral LTR’s; linear viral DNAs that are not competent for 
integration; and mutant viral DNAs that may be generated by self-integration (34, 46, 169, 
203). Nonetheless, the primary source of a productive infection is traditionally associated 
with the integrated proviral DNA form. Proviral genomic DNA is transcribed into viral 
RNAs that are translated into structural and enzymatic proteins used to generate viral 
particles as described above. Retroviruses harbor a major splice donor at the 5’ end of the 
genome to promote differential expression of viral RNAs that encode envelope 
glycoproteins, or viral accessory proteins (41). This is most evident in lentiviruses that 
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encode a number of accessory proteins critical for the viral life cycle. Importantly, the full-
length genomic RNAs (gRNA) of all retroviruses are not only used as templates for 
generating structural and enzymatic proteins, but must also be encapsidated into newly 
formed viral particles. Therefore, each retrovirus should have a mechanism capable of 
distinguishing between viral encoded RNAs competent for translation, and those competent 
for packaging into newly forming viral particles.  
 Efforts to distinguish between RNAs competent for packaging, and those utilized for 
translation, have primarily focused on MLV, and primate lentiviruses including HIV-1 and 
HIV-2. At least three distinct mechanisms have been proposed to describe how retroviruses 
may accomplish this (10, 18, 26). In the case of MLV two separate pools of viral gRNAs 
may be partitioned in the cell such that one is used for encapsidation into newly forming viral 
particles and the other for translation (53, 122). For HIV-1 and HIV-2 it appears that a single 
pool of gRNA is generated for both translation and encapsidation; however data has 
indicated that the mechanisms may bifurcate in how the gRNAs achieve encapsidation (53). 
HIV-1 gRNA encapsidation is not dependent upon translation prior to encapsidation, whereas 
some evidence has indicated that HIV-2 may utilize a cotranslational packaging mechanism 
in which unspliced gRNA is captured upon translation of the Gag polyprotein (69, 101). A 
recent study, however, challenges this claim indicating that packaging of HIV-2 genomic 
RNA is very similar to that of HIV-1, excluding the potential for a cotranslational packaging 
mechanism (156). Furthermore, numerous studies demonstrate that MLV, HIV-1, & HIV-2, 
as well as other retroviruses, can be utilized as retroviral vectors, wherein a vector RNA 
(containing all cis packaging signals, but no genes encoding structural/enzymatic proteins), 
gag/pol genes (structural/enzymatic protein expression cassette lacking cis packaging 
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signals), and env gene (typically a heterologous glycoprotein commonly derived from 
vesicular stomatitis virus) are separated onto at least three independent expression cassettes 
to generate viral particles (42, 43) (Fig. 5). The Gag/Pol proteins act in trans with cis 
elements in the vector RNAs to promote packaging of the vector RNA into nascent viral 
particles, indicating that translation of the vector RNA is not necessary for packaging. Lastly, 
a cotranslational packaging mechanism does not explain how the Gag polyprotein can be 
generated in vast excess (~1500-2000 molecules per viral particle) but only support 
encapsidation of 2 molecules of gRNA. If a cotranslational mechanism were feasible there 
must be a mechanism that determines when and which Gag polyprotein selects its 
corresponding gRNA for encapsidation. Although lenitiviruses apparently utilize a single 
pool of gRNAs for packaging, alternative mechanisms may be more suitable for explaining 
the distinction between the translational and encapsidation fates of gRNAs, some of which 
will be elaborated upon below with regard to HIV-1. 
  
HIV-1 Cis Elements and Trans Factors That Facilitate Efficient & Specific Genomic 
RNA Encapsidation 
Specific & efficient encapsidation of viral RNA into HIV-1 particles requires the selection of 
viral RNA species from the milieu of host cell RNAs, necessitating several complex 
interactions between cis elements in the viral RNA genome and trans factors encoded by the 
virus, & host cell genome (41, 121). Following transcription of gRNA in the nucleus the 
RNA must exit the nucleus and traverse the cytoplasm to the plasma membrane where it is 
encapsidated into newly forming viral particles (97, 116) (Fig. 6). The fate of the gRNA may 
initially be determined in the nucleus through formation of ribonucleoprotein complexes 
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initiated by Rev interacting with the RRE cis elements in the RNA (41). The HIV-1 gRNA 
can be partitioned into different regions comprised of cis determinants that function at 
various stages of viral replication. Some of the most well defined cis elements are confined to 
the 5’ untranslated region (UTR) (Fig. 7). The 5’ UTR of the full-length gRNA is a ~350 
nucleotide long region that harbors a series of stem-loop structures that contribute to nearly 
every aspect of the viral life cycle including reverse transcription, integration, transcription of 
new viral RNAs, viral RNA splicing, translation into viral proteins and encapsidation of 
gRNA. An innovative biochemical technology called SHAPE (selective 2’-hydroxyl 
acylation analyzed by primer extension) was recently employed to examine the structure for 
first 10% of the genomic RNA comprising the entire 5’ UTR in virio and ex virio, at the 
single nucleotide level (Fig. 8) (214), as well as the entire HIV-1 RNA structure (212). 
Similar ex virio and in virio studies also revealed the structural significance of MLV genomic 
RNA for recognition by the MLV Gag polyprotein and for subsequent encapsidation into 
viral particles (64, 65). These high resolution structures provide strong evidence for 
nucleocapsid-RNA, as well as intra- and intermolecular RNA-RNA interactions as they exist 
in the mature viral particle. Also of note, at this point in the viral particle maturation the Gag 
and Gag-Pol precursor polyproteins are processed into their constituent proteins. Therefore, 
protein-RNA and RNA-RNA interactions may impose RNA structures in the mature viral 
particles resulting in conformations that are vastly different than those acquired during the 
process of encapsidation in the host cell. RNA may encounter various RNA-RNA and 
protein-RNA interactions in the form of ribonucleoprotein complexes in the host cell that 
may impart alternative RNA structural variations in the cytoplasm, which ultimately promote 
efficient transport and, consequently, RNA encapsidation. It may be of interest to perform 
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similar SHAPE analysis on viral RNAs in ribonucleoprotein complexes isolated from 
producer cells. Currently, mutational and genetic analysis combined with traditional 
biochemical and bioinformatic approaches provide insight into protein-RNA and RNA-RNA 
interactions that impact RNA structure and function within packaging cells.  
Nucleocapsid, in the context of Gag or Gag-Pol polyproteins, are the most common 
protein-viral RNA interactions known; nonetheless, particles can still assemble in the 
absence of NC (165). In the absence of RNA particle assembly cannot occur, making RNA 
the major constituent acting as a scaffold upon which subsequent Gag-Gag interactions 
assemble into viral particles (24, 27, 28, 35, 72, 127, 128, 150, 151). Viral and cellular RNAs 
can be utilized for retroviral particle assembly, as it is well established that retroviral 
particles package numerous cellular RNAs, especially in the absence of viral RNA (152, 161, 
162, 188). Furthermore, HIV-1 viral particles can be generated in vitro from purified Gag 
polyproteins only in the presence of nucleic acids (28, 72). The NC-viral RNA interaction 
provides a selective advantage for encapsidating viral RNA into nascent particles. However, 
in the absence of HIV-1 NC viral RNA is not selectively packaged, but rather cellular RNAs 
can be used as the scaffold and a determinant in the matrix (MA) protein of Gag was 
identified as an additional RNA interacting partner, thereby facilitating viral particle 
assembly (165, 166). Mutating both NC and the MA determinant resulted in loss of HIV-1 
particle assembly (166). Nucleocapsid and MA proteins can non-specifically interact with 
viral or cellular RNA in the absence of proper cis encapsidation signals in the gRNA.  
Encapsidation signals in the genomic RNAs of lentiviruses (HIV-1, HIV-2, SIV, & 
FIV) and simple retroviruses (MLV) have been defined through biochemical, mutational and 
genetic analysis (4, 21, 36, 49, 63, 79, 103, 120, 134, 135, 138-140, 170, 183, 197). The 
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major encapsidation signals are localized to the 5’ UTR of retroviruses. The conventional 
major cis packaging signal () for HIV-1 is a ~120 nucleotide long fragment  comprised of 
four stem-loop structures located in the HIV-1 5’ UTR, and extending into the 5’ end of the 
HIV-1 Gag coding sequence (49) (Fig. 7). The HIV-1 Gag polyprotein ensures specific and 
efficient encapsidation of viral gRNA through high affinity interactions of zinc fingers in the 
nucleocapsid (NC) portion of the Gag polyprotein with stem-loops 2, 3, and 4 in the gRNA 
(49). In addition to its capacity to interact with NC stem-loop 2 contains the major splice 
donor sequence which promotes the generation of alternatively spliced viral RNAs that 
encode all the accessory proteins, as well as the envelope glycoprotein required for viral 
infectivity. Stem-loop 4 includes the AUG translation initiation codon for Gag, and has also 
been determined to form a stem structure in long-range interactions with a region in the 5’ 
U5 (214) (Fig. 8), at least in the context of mature viral particles. Although HIV-1 
nucleocapsid does not interact strongly with stem-loop 1 this region contains a palindrome 
sequence termed the dimerization initiation site (DIS) in the GC rich loop that initiates the 
non-covalent dimerization of two molecules of single-stranded viral RNA, commonly 
referred to as a “kissing” interaction, and is thought to have an essential role in the 
encapsidation of viral RNA species (49, 95, 148, 168). Even though a preponderance of 
studies suggest a central role for the DIS in encapsidation of gRNA (reviewed in (168)), 
evidence indicates that the mechanism is more elaborate than simply dimerization of two 
single-stranded RNA molecules. Mutation of the dimerization domain and the entire stem-
loop 1 structure demonstrates that the DIS is important for replication in a T cell line, but not 
in PBMCs (84), indicating that cellular factors, and possibly additional viral factors can 
influence encapsidation.  Importantly, stem-loop 1 is present at the 5’ UTR of both full-
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length genomic RNA, as well as subgenomic, spliced, HIV-1RNAs competent for 
translation. An earlier model posited that the genomic RNA could conform to two states that 
would distinguish between RNA competent for translation and RNA to be directed for 
packaging: i) a long-distance interaction (LDI) conformation in which the DIS is occluded in 
a stem was suggested to be amenable for translation but not encapsidation; and ii) a branched 
multiple hairpin (BMH) structure in which the DIS is available for dimerization and 
interaction with Gag for subsequent encapsidation (49, 168). In contrast to the RNA switch 
model, evidence indicates that both conformations can support translation (2), and that the 
BMH conformation is favorable in both cellular HIV-1 RNAs and virion RNAs (167). 
Moreover, if dimerization were part of a selection process that determined the encapsidation 
potential of viral RNA then it might be expected that only full-length gRNA would form 
dimers competent for encapsidation; however, an in vitro study demonstrated that 
subgenomic RNAs can also form dimers and heterodimers (192). Apparently the HIV-1 DIS, 
as well as additional cis elements, serves a dominant role in the encapsidation process; 
however, additional viral and cellular components may also contribute to efficient and 
specific gRNA encapsidation.   
A bona fide packaging system could be considered one that confers an efficient and 
specific gain of encapsidation function upon a heterologous RNA. In the case of HIV-1 
transfer of the  cis packaging element to a non-HIV-1 (heterologous) RNA did not confer 
encapsidation of the RNA into HIV-1 viral particles (15), indicating that HIV-1  is not 
sufficient for encapsidation. In contrast, cis elements from MLV (~175 contiguous nucleotide 
region in the 5’ UTR) can readily support retroviral RNA packaging if relocated to a 
different position within homologous RNA (134), and is sufficient for encapsidation of 
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heterologous RNAs into MLV viral particles (3, 83). The HIV-1 packaging signal is more 
complex than that of MLV, requiring additional cis elements outside the canonical packaging 
signal. Independent studies using mutational analysis and genetic manipulation demonstrated 
that cis elements within the HIV-1 5’ R, U5, and PBS regions of the RNA may also function 
in gRNA encapsidation (37, 38, 81, 139). Heretofore, several HIV-1 inter- and 
intramolecular RNA-RNA, and protein-RNA, interactions were discussed as components of 
the RNA encapsidation mechanism. These various interactions are necessary cytoplasmic 
steps that prompt gRNA encapsidation at the plasma membrane. In order to present a gRNA 
amenable to RNA-RNA and protein-RNA interactions in the cytoplasm the gRNA must 
initially exit the nucleus after transcription and localize appropriately in the cytoplasm. 
Therefore, additional viral cis elements and trans factors may be required components of a 
packaging system that supports efficient and specific gRNA encapsidation. 
 
HIV-1 Rev/RRE (Rev Response Element) System and Nuclear Export, Translation, & 
Encapsidation of Viral RNAs 
HIV-1, as well as all lentiviruses, is considered a complex retrovirus because of additional 
accessory proteins required for a productive infection. Originally termed the art gene, Rev 
(regulator of expression of virion proteins) was identified as one of two accessory proteins, 
the other being Tat, which are absolutely required for transactivation of HIV-1 structural and 
enzymatic proteins (57, 195). Shortly thereafter a cis element within the env gene at the 3’ 
end of the genomic RNA, termed the Rev response element (RRE), was identified as the 
cognate sequence that the Rev protein recognizes in the gRNA (39, 132, 160, 187, 224). The 
HIV-1 Rev/RRE interaction has since been proposed to function in a number of processes 
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associated with viral replication including splicing regulation, nuclear export of full-length 
and partially spliced viral RNAs (i.e. intron-containing HIV-1 RNAs), enhancing translation 
of viral proteins, blocking integration of viral particles as a result of superinfection, and 
facilitating encapsidation of genomic viral RNA (reviewed in (68, 71, 199)).  
The RRE forms a series of stem-loops structures that is retained in both full-length 
HIV-1 gRNA and partially spliced viral RNAs, thereby making the RNA accessible to 
interaction with the Rev protein (Fig. 9) (176). Mutational mapping, combined with genetic 
analysis, revealed a number of functional domains in the Rev protein (86-88, 131, 133, 176). 
The most prominent feature of Rev is its ability to shuttle between the nucleus and 
cytoplasm. Rev protein has an arginine rich nuclear localization signal (NLS) that is involved 
in nuclear, and ultimately nucleolar, localization through interaction with importin- (7, 82). 
Shortly after transcription, Rev interacts with RRE-containing viral RNAs through a 
functional domain that overlaps the arginine-rich nuclear import signal (87, 176). In order for 
Rev to interact with its cognate RRE, RNA harboring the RRE cis element must be stabilized 
and retained within the nucleus; and, potentially localized to a nucleolar region that supports 
a stable interaction between Rev and the RNA.  Recognition of splice donor sequences by 
host U1 snRNA stabilizes RNA in the nucleus, even in the absence of active splicing, 
obviating RNA degradation (98, 124). Additionally, AU-rich cis repressor sequences (CRS), 
or instability (INS) elements, mapped primarily to RNA regions within gag, pol, and env, 
mediate RNA retention within the nucleus (40, 129, 153, 190). Genomic RNA and partially 
spliced subgenomic RNA harboring CRS elements were found to localize in nuclear regions 
similar to those of the Rev protein, but distinct from fully spliced transcripts; indicating a 
putative common locale for Rev and transcripts containing the RRE (16). Futhermore, 
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mutating the CRS elements allows for nuclear export of RNA, and subsequent protein 
expression, independent of the Rev/RRE system (66, 111). The interaction between Rev and 
the RRE may mask the NLS, thwarting nuclear import of Rev/viral RNA complexes so that 
Rev/RNA complexes can be efficienctly exported to the cytoplasm (199).  
Nuclear export of Rev/RNA complexes is mediated through a nuclear export signal 
(NES) in a leucine-rich region of the Rev carboxy terminus (131, 133) (Fig. 9). Unique to the 
Rev protein is the capacity to facilitate nuclear export of incompletely spliced viral RNAs, 
thus the Rev/RRE interaction can alter the ratio of unspliced/spliced viral RNAs by 
interfering with splicing (31, 55, 57, 77, 107, 108). Nuclear export of incompletely spliced 
viral RNAs is achieved by Rev bridging an interaction between the viral RNA and host 
chromosome region maintenance 1 (CRM1) nuclear export pathway (58, 59, 155, 163). Few 
cellular RNA have been determined to be exported through the CRM1 nuclear export 
pathway (ribosomal RNAs, U1 snRNA, SRP RNAs and very few cellular mRNAs) (91), 
most of which appear to be dependent upon RNA POL I or POL III mechanisms of 
transcription and are in the context of ribonucleoprotein (RNP) complexes comprised of 
adaptor proteins that bridge interactions between the RNAs and the CRM1 protein. Similarly, 
it has been proposed that Rev and incompletely spliced viral RNAs are part of a RNP 
complex, since numerous host cell proteins also impact Rev-dependent nuclear export, as 
well as downstream viral function that can interfere with HIV-1 replication (41, 71, 199, 
201).  
Nuclear export is a fulcrum of posttranscriptional regulation shared among 
retroviruses. The Rev/RRE system is a highly conserved mechanism employed among 
lentiviruses (119, 132, 145, 164, 174), whereas nuclear export of viral RNAs encoded by 
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type D simian retroviruses (SRV-1 and MPMV) is accomplished through a cis-acting 
constitutive transport element (CTE) in the RNA (20, 226). Identified CTE’s differ from the 
HIV-1 Rev/RRE system in that nuclear export is independent of both the CRM1 pathway and 
a virally encoded protein. The CTE recruits the cellular protein TAP/NXF1 to direct RNA 
out of the nucleus through the TAP/NXT1-dependent pathway (73). The TAP/NXT1 
pathway is the most common pathway utilized for nuclear export of spliced cellular mRNAs, 
as well as fully spliced mRNAs encoding Tat, Rev, and Nef proteins. Of note, the 
TAP/NXT1 pathway may also be utilized by simple retroviruses such as MLV, which do not 
encode an accessory protein for nuclear export, but rely upon cis elements within the 
packaging signal (106, 193), which presumably interact with cellular factor(s). The fact that 
lentiviruses have evolved the use of a Rev/RRE based system for nuclear export specifically 
through the CRM1 pathway indicates that this pathway of nuclear export may determine the 
cytoplasmic fate of viral RNAs and impact downstream biological processes at late stages of 
viral replication. A number of studies have demonstrated that proper viral assembly is 
governed by the pathway that the gRNA is exported from the nucleus to the cytoplasm (93, 
94, 149, 191, 201). These studies imply that the Rev/RRE system influences the assembly of 
nascent viral particles, and presumably may regulate virological functions that occur prior to 
(translation of viral RNAs), or coincident with (viral gRNA encapsidation) particle assembly.  
Nuclear export of viral RNAs is the dominant posttranscriptional regulatory 
mechanism associated with the Rev/RRE system; however, mounting evidence demonstrates 
that the Rev/RRE system is more than a nuclear export system (71).  Separating the nuclear 
export function of Rev from its impact on viral events in the cytoplasm, including viral RNA 
translation and encapsidation, has proved to be challenging. Rev mutants that impact 
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translation and encapsidation, but not nuclear export, have yet to be identified. Furthermore, 
using available Rev NLS mutants to restrict Rev function to the cytoplasm would also 
preclude interaction with the RRE-containing RNA in the nucleus, not to mention that 
mutants in the NLS may also directly impact its interaction with the RRE since these are 
overlapping functions. A well established method has been to fractionate cells into 
cytoplasmic and nuclear parts followed by RNA isolation, affording that ability to distinguish 
between Rev-dependent viral RNA nuclear export function and influences on translation or 
encapsidation. A number of reports indicate that Rev encourages the translation of RNAs 
with minimal impact on nuclear export (8, 9, 48, 70, 172). Evidence indicates that Rev 
augments polysome loading for ensuing translation, whereby translation is enhanced several 
hundred fold with a minimal increase in nuclear export of viral RNAs (48). Rev may 
influence translation through recruitment of cellular proteins as is evident from a recent study 
with the cellular methyltransferase protein, PIMT, which trimethylates the 5’ RNA cap of 
some HIV-1 RNAs as a regulatory mechanism for selective expression (221). Importantly, 
this mechanism was shown to be Rev-dependent, whereby Rev recruits PIMT to RRE-
containing RNAs. Interestingly, this study did not investigate the potential of encapsidating 
5’-cap trimethylated viral RNAs. Plausibly, this could be part of a mechanism that 
distinguishes between Rev-dependent RNAs targeted for translation compared to Rev-
dependent RNAs targeted for encapsidation. 
Similar to translation, encapsidation is a measure of the ratio of RNA encapsidated 
into viral particles relative to RNA available for encapsidation in the cytoplasm, thereby 
accounting for any changes in nuclear export. Early indications that the Rev/RRE system 
may be important for encapsidation of viral RNAs implicated regions within the HIV-1 env 
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gene (181). Further mutational analysis of the env gene, however, indicated that although 
regions within the env gene are important for encapsidation, the RRE itself was not essential 
for encapsidation (102). Moreover, partially spliced (RRE positive) and fully spliced (RRE 
negative) viral RNAs were shown to package with equal efficiency, but both were 
significantly less efficient than full-length RNAs (89). In opposition to these studies the 
RRE-deficient HIV-1 vectors were demonstrated to have much lower titers and less RNA 
packaged than vectors containing the RRE (125), indicative of a severe RNA packaging 
deficiency since mutation of the RRE had minimal influence on RNA exported to the 
cytoplasm. In consonance with this study HIV-1 derived viral vectors showed increases in 
vector titers with nominal changes in cytoplasmic RNA levels (5). Along these same lines the 
Rev proteins of HIV-1 and SIV were demonstrated to enhance encapsidation of gRNA into 
HIV-1, or SIV, viral particles, respectively (19). Moreover, the same study showed that the 
RRE was not absolutely necessary, but rather interactions between Rev and the RNA needed 
to be maintained for the observed augmentation in gRNA encapsidation. In addition to the 
RRE, Rev was identified to interact with a determinant in stem-loop 1 of the cis packaging 
signal (62). Mutational analysis of this determinant in the innate viral context disrupted RNA 
trafficking, as well as RNA encapsidation (67). Recent in vitro translation studies 
demonstrated that the cis determinant in stem-loop 1 is also important for Rev-mediated 
translation of viral RNAs, and that the RRE is not important for this effect (70). Moreover, 
translation was enhanced only when using moderate concentrations of purified Rev protein, 
but inhibited using high Rev concentrations. Potentially, the Rev concentration may act as a 
“switch” between translation (moderate Rev concentrations) and encapsidation (high Rev 
concentrations). It may be that both the RRE and cis determinant in stem-loop 1 of the 
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packaging signal are important for encapsidation of gRNA. Regardless, the interaction of  
Rev with the gRNA is predominantly mediated through the RRE (and putatively, additional 
cis determinants), and the Rev protein may influence not only nuclear export, but also 
translation and, as will be investigate in the work shown here, gRNA encapsidation.  
 
Introduction to Dissertation Research 
Efficient and specific encapsidation into HIV-1 viral particles is a process in which the RNA 
must travel from sites of transcription in the nucleus to sites of particle assembly at the 
plasma membrane (Fig. 6). As discussed above disparate studies have identified numerous 
HIV-1 cis elements in the gRNA (R, U5, PBS, , and RRE) and viral trans factors (NC and 
MA of the Gag polyprotein, and Rev) that may act upon the gRNA at different steps of the 
encapsidation process, not to mention host cell proteins, which are not addressed by the work 
in this dissertation. What is not currently clear is if these viral components can function 
independently of each other, and more importantly, how the concerted actions of multiple 
viral components cedes efficient and specific encapsidation of RNA into HIV-1 viral 
particles. The primary focus of this dissertation investigates the proposal that the 
combination of viral cis elements and trans factors function in a common pathway to achieve 
RNA encapsidation. Identifying components of the encapsidation mechanism has primarily 
been accomplished through loss-of-function studies by mutational/genetic analysis. Since 
many viral cis elements and trans factors have pleiotropic effects, it can be cumbersome to 
isolate direct cause and effect relationships. Loss-of-function studies may also preclude the 
ability to elucidate how components may function together. A bona fide packaging system 
could be considered one that is transferrable to a heterologous RNA, resulting in a gain of 
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encapsidation function. The work presented in this dissertation describes how heterologous 
RNA systems were employed to investigate: i) the independent effect of the HIV-1 Rev/RRE 
system, as well as Rev orthologues, on heterologous RNA encapsidation into HIV-1 viral 
particles (Chapter 2); ii) the collaborative effect of the cis elements in the 5’ UTR (R, U5, 
PBS, and ) and the Rev/RRE system on efficiency, and specificity, of heterologous RNA 
encapsidation (Chapter 3); and  iii) the unique transduction properties of heterologous RNAs 
packaged into HIV-1 viral particles, and how they may prove advantageous for gene therapy 
protocols (Chapter 4). Lastly, conclusions to this work and future perspectives will be briefly 
discussed (Chapter 5).  
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Figure 1. Retroviral Genome Organization. The proviral genome organization for a 
representative member of each genera of the orthoretrovirinae subfamily is depicted. Each 
genera contains two long terminal repeat (LTR) regions, a gag gene encoding structural 
proteins, a pro gene encoding protease, a pol gene that encodes reverse transcriptase and 
integrase, and an env gene encoding viral glycoprotein. The genera differ in the number of 
accessory proteins required for infection. Most complex are the lentiviruses with six 
accessory proteins two of which (Tat and Rev) are considered transactivators for viral 
replication.     
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Figure 2. Retroviral Reverse Transcription Process. Viral RNA packaged into a viral 
particle is reverse transcribed by the viral reverse transcriptase into viral cDNA. The viral 
cDNA, in the context of a preintegration complex, enters the nucleus and viral integrase 
mediates integration into the host cell genome to generate a proviral DNA. The proviral 
DNA is then used as the template to express viral RNAs that generate viral proteins, as well 
as full-length genomic RNA that is packaged into nascent viral particles. 
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Figure. 3. Features of Immature and Mature Retroviral Particles. The features depicted 
are common to retroviruses. Nascent viral particles are initially formed as immature viral 
particles containing two molecules of ssRNA (black lines) packaged into a protein shell 
comprised of Gag and Gag-Pro-Pol molecules surrounded by a lipid envelope with viral 
glycoproteins embedded. The viral particle undergoes a readily observable morphological 
reorganization upon processing of the Gag and Gag-Pro-Pol Glycoproteins into constituent 
proteins to form the mature, infectious, viral particle.  
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Figure 4. Replication Cycle of HIV-1 Lentivirus. Early replication steps. A mature viral 
particle initiates infection by attaching to the host cell membrane through interaction of the 
viral envelope glycoprotein with a host cell receptor(s). The viral envelope fuses with the 
host cell plasma membrane, releasing the capsid and its contents into the cytoplasm. An 
uncoating of the viral capsid occurs, the RNA is reverse transcribed into viral cDNA, and 
enters the nucleus as a preintegration complex (MA [matrix protein], IN [integrase protein], 
and Vpr [accessory protein] are viral constituents of preintegration complex), whereby the 
viral cDNA can integrate into the host cell genome. Late replication steps. The proviral 
genomic DNA can be transcribed into viral RNAs that are full-length, partially spliced, or 
fully spliced RNAs. The full-length and partially spliced RNAs are exported from the 
nucleus through an interaction with the viral encoded accessory protein, Rev. Viral RNAs 
can be translated into structural and enzymatic proteins used to generate viral particles, and 
two molecules of full-length genomic RNA are encapsidated into nascent viral paticles 
assembling at the plasma membrane.  
Adapted by permission from McMillan Publishers LTD. D’Souza, V and 
Summers, MF. How Retroviruses Select Their Genomes. Nature Reviews. 
Microbiology. 2005. (3) 643-655.  
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Figure 5. Retroviral Vector Production. For vector production the viral cis elements are 
separated from the viral trans elements onto individual plasmid constructs. Trans Elements 
(Packaging Construct). The trans genes (gag/pol) encode the structural and enzymatic 
proteins that form nascent viral particles. In this case the packaging system depicted is a 
Rev/RRE-independent system, whereby viral particles can be generated in the absence of the 
Rev protein. This system is frequently utilized in experiments throughout the dissertation, 
allowing direct examination of the impact of Rev on encapsidation of the RNA into viral 
particles. Cis Elements (Vector Construct). Viral cis elements can be readily manipulated 
in the context of the vector. The vectors depicted are a standard HIV-1 derived vector (top), 
and a MLV/HIV chimeric vector (bottom). The luciferase transgene, and CMV-GFP 
expression cassettes are used to monitor production and transduction, respectively. Vector 
particles are commonly pseudotyped with the vesicular stomatitis virus glycoprotein (VSV-
G) to confer vector particles with a broad host cell tropism. These constructs are 
cotransfected into 293T for vector production, and viral particles are harvested from the 
media.     
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Figure 6. HIV-1 Genomic RNA Encapsidation Process. Step 1. Concomitant with 
transcription of full-length and partially spliced RNAs, the Rev protein interacts with its 
cognate Rev Response Element (RRE) to mediate nuclear export via the CRM1 dependent 
pathway. Step 2. Genomic RNA has been demonstrated to localize to perinuclear 
microtubule organizing centers. Work proposed in this dissertation indicates that Rev may 
make genomic RNA more amenable to subsequent Gag-RNA interactions, possibly through 
cytoplasmic localization (see chapter 3). Step 3 & 4. Dimerization of two molecules of 
genomic RNA occurs in the cytoplasm, and initial interaction of Gag with the canonical cis 
packaging signal are thought to occur in the cytoplasm prior to localization of the RNA to 
sites of particle assembly at the plasma membrane. Step 5. Trafficking of Gag-RNA 
complexes to the plasma membrane may occur via endosomes or microtubules. Step 6. 
Assembly of nascent viral particles occurs at the plasma membrane through numerous Gag-
Gag interactions.    
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Figure 7. RNA Cis Elements in the HIV-1 5’ UTR. The 5’ UTR is comprised of a series of 
stem-loops that impact nearly every aspect of the viral life cycle. The TAR (trans-activating 
response) element and polyadenylation signal are located in the R region of the 5’ LTR. The 
U5 region harbors the att (attachment) sites at the 3’ boarder with the PBS (primer binding 
site). Cis determinants within these regions have been shown to have dominant roles in viral 
RNA transcription, reverse transcription, & integration. However, several regions have also 
been implicated in encapsidation. Stem-loops SL1, SL2, SL3, and SL4 comprise what is 
considered the canonical packaging signal () and have all been demonstrated to be critical 
for encapsidation of genomic viral RNA. SL1 harbors the dimerization initiation site (DIS) in 
the loop; SL2 contains the major splice donor for HIV-1; SL2, SL3, and SL4 are thought to 
mediate high affinity interaction with the nucleocapsid protein; and SL4 is part of the 5’ end 
that encodes the Gag polyprotein. Start site is indicated by AUG.  
 
Adapted by Permission from American Society for Microbiology. Clever, J.L., Miranda 
Jr., D., & Parslow, T.G. RNA Structure and Packaging Signals in the 5’ Leader Region 
of the Human Immunodeficiency Virus Genome. Journal of Virology. 2002. 76(23). 
12381-12387. 
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Figure 8. High Resolution SHAPE structure of the HIV-1 5’ UTR. A high resolution 
RNA structure of about the first 570 nucleotides of HIV-1 are depicted. The strucuture 
elucidated by SHAPE revealed a highly complex structure with a number of long-range 
intramolecular interactions in virio. The TAR and polyadenylation (polyA) stem-loop 
structures in the R region are indicated. In gray the tRNA(lys3) is demonstrated as interacting 
with the PBS. Stem-loops 1, 2, 3, and 4 are indicated, where part of stem-loop 4 as shown in 
figure 7 is in a long range interaction with part of the U5 region. The dimerization initiation 
site (DIS) and major splice donor (SD) are indicated. Lastly, regions that the nucleocapsid 
interacts with are highlighted in blue. See reference for details regarding the SHAPE 
technology and nucleotide color coding scheme. 
 
Adapted from PLOS Biology in accordance 
with the open access license. Wilkinson KA et 
al. High-Throughput SHAPE Analysis Reveals 
Structures in HIV-1 Genomic RNA Strongly 
Conserved Across Distinct Biological States. 
PLOS Biology. 2008. 6 (4) 883-899.  
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Figure 9. HIV-1 Rev and Rev Response Element (RRE). A. The Rev protein is comprised 
of multiple functional domains. Amino acids (aa) 12-29 and 52-60 constitute the two 
multimerization (M1 & M2) domains; aa 35-50 comprise the arginine rich motif (ARM) 
which governs nuclear/nucleolar localization signal (NLS) and overlaps with the RNA 
binding domain; and, aa 75-83 contain the leucine rich motif which constitutes the nuclear 
export signal (NES). B. The Rev Response element located in the RNA is a highly conserved 
element comprised of a series of stem-loop structures. The primary binding site for Rev is 
indicated by Rev B.S. and is primarily located in stem IIb. This RNA structure was obtained 
using the innovative SHAPE approach as described in the indicated manuscript. 
Adapted by permission from McMillan Publishers LTD. Watts JM et al. 
Architecture and secondary structure of an entire HIV-1 genome. Nature. 
2009. 460. 711-719. 
Chapter 2 
HIV-1 REV AUGMENTS ENCAPSIDATION OF HETEROLOGOUS RNAs INTO HIV-1 
VIRAL PARTICLES1 
Introduction 
Encapsidation of HIV-1 gRNA is conventionally associated with the canonical cis 
packaging signal () located in the HIV-1 5’ UTR of the gRNA, and extending into the 5’ 
end of sequence encoding the gag gene. Transfer of this sequence is not sufficient to support 
encapsidation (15), therefore additional viral cis elements and trans factors have been 
investigated for effects on encapsidation. Encapsidation of RNA into nascent viral particles 
assembling at the plasma membrane requires the RNA to traverse the entire cell following 
initial transcription of full-length RNA in the nucleus. Viral-dependent mechanisms must 
ensure efficient and specific encapsidation of gRNA during the entire process of viral RNA 
translocation to sites of particle assembly. Interaction of the HIV-1 Rev protein with its 
cognate RRE in the gRNA, concurrent with transcription in the nucleus, make it a strong 
candidate for conferring both specificity and efficiency onto the HIV-1 gRNA early in the 
process of viral RNA encapsidation. Rev’s ability to readily shuttle between the nucleus and 
cytoplasm allow it to influence viral RNA function in multiple capacities.  
 
                                                 
1A portion of the work in this chapter was published by Adam Cockrell, Henriette van Praag, Nicholas 
Santistevan, Hong Ma, and Tal Kafri, titled:The HIV-1 Rev/RRE system is required for HIV-1 5’ UTR cis 
elements to augment encapsidation of heterologous RNA into HIV-1 viral particles (45). 
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The primary function ascribed to the Rev/RRE system is nuclear export of full-length, 
and partially spliced, HIV-1 RNAs through the CRM1 nuclear export pathway (176, 199). 
This is a highly conserved mechanism with orthologues for human and non-human primate 
lentiviruses including HIV-1, HIV-2, & SIV, as well as the non-primate feline 
immunodeficiency virus (FIV), equine infectious anemia virus (EIAV), caprine arthritis-
encephalitis virus (CAEV), visna virus (VV), Jembrana disease virus (JDV), and bovine 
immunodeficiency virus (BIV) lentiviruses (119, 130, 145, 164, 174). Even the more 
distantly related complex retroviruses human T lymphotropic virus type 1 (HTLV-1) and 
type 2 encode an HIV-1 orthologue, the Rex accessory protein, of which HTLV-1 Rex 
nuclear export domain was shown to be functionally interchangeable with HIV-1 Rev (86). 
Employing a viral encoded protein for nuclear export is unique to complex retroviruses. 
Simple retroviruses, such as MLV, accomplish nuclear export independent of viral encoded 
proteins (106, 193).  
The nuclear export functions associated with the Rev/RRE have primarily been 
characterized using reporter systems (mainly chloramphenicol acetyltransferase [CAT], 
luciferase, or GFP), whereby successful translation of the reporter RNA is dependent upon 
the interaction of Rev with its cognate RRE in the RNA and subsequent nuclear export, as 
well as by measuring p24 capsid protein expression. Since these studies were predominantly 
designed to investigate Rev-dependent RNA nuclear export effects, additional downstream 
functions of Rev would have been difficult to detect. The conserved mechanism of Rev-
dependent nuclear export through the CRM1 pathway compels the logic that the CRM1 
pathway may dictate the fate of a viral RNA for downstream events of replication that occur 
in the cytoplasm. In line with this reasoning several reports demonstrate that the nuclear 
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export pathway may influence HIV-1 assembly (93, 94, 149, 191, 201). Protein expression 
assays facilitated the elucidation of Rev-dependent nuclear export through the CRM1 
pathway; however, alternative measurements are necessary to distinguish nuclear export 
from additional Rev functions in the cytoplasm (68, 71). 
In addition to nuclear export, an expanding body of data suggests that HIV-1 Rev can 
function in at least three additional capacities: i) enhancing translation of viral RNAs, ii) 
interfering with HIV-1 superinfections, and iii) influencing RNA encapsidation (68, 71). 
These functions are all downstream to nuclear export; therefore nuclear export is a priori. 
Distinguishing between Rev-dependent nuclear export and downstream events manifests the 
need to separate these functions. Studies have shown that Rev can enhance encapsidation 
efficiency by measuring RNA packaged into viral particles (directly and indirectly) relative 
to viral RNA available for packaging in the cytoplasm (5, 19, 67, 181). Previous studies have 
all examined the contribution of the Rev/RRE system to RNA encapsidation when the RRE 
is in the same RNA context as HIV-1 , as well as other HIV-1 cis elements, therefore the 
Rev/RRE effect may be masked by the more dominant packaging components. Studies 
shown here were executed based on the proposal that isolating the Rev/RRE system from the 
influence of HIV-1 cis elements (i.e. canonical packaging signal) involved in encapsidation 
would demonstrate the independence of the Rev/RRE system to influence RNA 
encapsidation. Here, the Rev/RRE system was reconstructed in the context of heterologous 
RNAs to investigate the influence of the Rev/RRE system on RNA encapsidation into HIV-1 
viral particles. The data demonstrate: i) for the first time that the HIV-1 Rev/RRE system can 
augment RNA encapsidation into HIV-1 viral particles in the absence of any canonical HIV-
1 cis packaging signals; ii) HIV-1 Rev-mediated encapsidation is specific to heterologous 
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RNAs harboring the RRE; iii) FIV Rev (FRev) could function similarly to HIV-1 Rev 
(HRev) to enhance titer, and presumably RNA packaging, into HIV-1 particles, but EIAV 
Rev (ERev) could not; iv) that the HIV-1 RRE is not absolutely necessary for encapsidation, 
but it is essential to maintain an interaction between HIV-1 Rev and RNA; and v) that 
nuclear export through the CRM1 pathway is not absolutely necessary for Rev-dependent 
enhanced encapsidation.  
 
 
Methods 
 
Plasmid Constructs. Murine leukemia virus (MLV) and MLV/HIV chimeric vector 
constructs were derived from the MLV vector, pLNCX (146). The fundamental MLV vector 
as described in Fig. 10A was developed as follows:  i) the WPRE (woodchuck hepatitis virus 
posttranscriptional regulatory element) was first subcloned into the EcoRI/HindIII sites of a 
pCLNCX self-inactivating (SIN) vector (154); ii) internal trans elements were replaced with 
a CMV-GFP cassette inserted by subcloning a BamHI/XhoI fragment from pTK113 (HIV-1 
vector in Kafri lab), also retaining the HIV-1 cPPT-CTS (labeled cPPT in Fig. 1A) in this 
fragment; iii) the 3’ SIN LTR was replaced with a complete MoMLV 3’ LTR from pLNCX 
by subcloning the HindIII/PmeI fragment; and iv) the firefly luciferase (originally obtained 
from pBI-GL, Clontech) was subcloned into the BamHI site of the MLV vector generating 
pTK1328, the basic MLV vector in Fig. 10A. All notations of plasmids beginning with pTK 
are for ease of reference to the plasmid library in the Kafri lab. All subsequent MLV/HIV 
chimeric constructs were derived from pTK1328 by inserting various HIV-1 cis elements. 
All HIV-1 cis elements were derived from a standard HIV-1 vector from our lab, such as 
pTK113 (215). The MLV/HIV RRE vector (pTK1332) was derived from the basic MLV 
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vector by subcloning a BamHI fragment (~850 bp) comprising the RRE into a BamHI site of 
pTK1328.  
 The parental EIAV (UNC SIN 6.1W-1) and FIV (pFLX-CPL) vector constructs were 
kind gifts from the laboratories of Dr. John Olsen and Dr. Gary Nolan, respectively. The 
FIV/HIV RRE was generated in the following series of cloning: i) The WPRE was subcloned 
into the Cip treated AleI site of pFLX-CPL (pTK652); and ii) a large NotI/SacII fragment 
from pTK494 containing the HIV-1 RRE was subcloned into the NotI/SacII sites of pTK652 
to generate pTK660. To generate the EIAV/HIV RRE chimeric construct a large NotI/SacII 
fragment containing the HIV-1 RRE, from pTK113, was subcloned into the NotI/SacII sites 
of UNC SIN 6.1W-1, yielding pTK728. Appropriate control constructs that contain the HIV-
1 cPPT were generated as follows. The following cloning series was used for EIAV: i) a 
BamHI/SacII fragment from pTK113 was inserted into the BamHI/SacII sites of pBlueScript 
(pTK729); and ii) the EcoRV/SacII fragment from pTK729 was subcloned into UNC SIN 6.1 
W-1 to generate the EIAV control (pTK730). For FIV control the following cloning series 
was executed: i) a PCR fragment containing the FIV cPPT from pCFW∆Env packaging 
construct (kindly provided by Dr. Gary Nolan) was cloned into the KpnI site of pTK652; and 
ii) a BamHI/XhoI fragment containing the HIV-1 cPPT & CMV-GFP cassette was klenow 
treated and subcloned into the EcoRV site of pTK653 to yield the FIV control, pTK665.  
 The HIV-1 derived constructs were generated as follows. The standard HIV-1 vector 
with luciferase in the 5’ end (pTK1363) was generated by subcloning a large fragment from a 
previously defined vector (pTK1305, described in chapter 3) into the NotI/XhoI sites of 
pTK1087 (a non-SIN HIV-1 vector with a complete U3 in the 3’ LTR and internal CMV-
GFP cassette). The HIV-1 ∆RRE vector (pTK1444) was derived from pTK1279 within 
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which the RRE was removed with NotI/BamHI. To generate pTK1444 the firefly luciferase 
gene was inserted into the EcoRI site of pTK1279. The HIV/9XMSRE ∆RRE construct 
(pTK1450) was derived from the following series: i) the MS2 9X response elements 
(pLMS29) were subcloned into the BamHI/SpeI sites of pBlueScript (pTK1448); ii) a 
NotI/BglII fragment containing the 9XMS2 response elements was then subcloned into 
NotI/BamHI sites of pTK1087 (pTK1449), while at the same time removing the HIV-1 RRE; 
and, iii) the firefly luciferase gene into the EcoRI site of pTK1449 to generate the 
HIV/9XMSRE ∆RRE construct, pTK1450.  
The packaging constructs supplying necessary structural/enzymatic proteins were 
4XCTE Gag-Pol (kindly provided by the laboratory of Dr. Christopher Baum), optimized 
Gag-Pol expression cassette (kindly provided by the laboratory of Dr. Donald Anson (60)), 
or NRF (215). Expression of structural/enzymatic proteins from 4X CTE Gag-Pol, and 
optimized Gag-Pol is independent of all HIV-1 accessory genes, and encodes the complete 
gag and pol genes. The NRF was described previously, but gag-pol gene expression is Rev-
dependent.  
The HIV-1 Rev protein was independently expressed from the EF-1 promoter in the 
E2F-Rev plasmid. The EIAV Rev expression cassette was a kind gift from the laboratory of 
Dr. John Olsen. The FIV Rev was initially obtained from the NIH AIDS reagent program and 
subcloned into NcoI/XbaI sites of pBlueScript (pTK1091). A CMV-FIV Rev expression 
cassette was then generated by subcloning a EcoRI fragment into pcDNA3.1zeo (pTK1095). 
The Rev-MS2 fusion was initially generated by PCR from a Rev-MS2 plasmid kindly 
provided by the laboratory of Dr. Thomas Hope. The Rev-MS2 PCR product was subcloned 
into the HindIII/NotI sites of pcDNA3.1zeo to generate pTK1163. In order to generate the 
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Rev-MS2 fusion the last amino acid of HIV-1 Rev was mutated from a glutamate to an 
aspartate (E116D), therefore a similar Rev positive control was generated by PCR to contain 
the E116D mutation. The PCR fragment was subcloned into the HindIII/NotI sites of 
pcDNA3.1zeo to generate the expression cassette, pTK1164. This construct was only used as 
a positive control in experiments where the Rev-MS2 fusion was employed. For experiments 
redirecting the nuclear export through the TAP/NXT1 pathway the following expression 
constructs were kindly provided by the laboratory of Dr. Marie-Louise Hammarskjold: 
RevM10-Tap fusion, RevM10 dominant negative mutant, NXT1, and TAP. The envelope 
protein was supplied from pMD.G, a VSV-G expressing construct.   
Cells. 293T cells were maintained in DMEM (Hyclone) supplemented with 10% FBS 
(Invitrogen). Media was also supplemented with a 100X Antibiotic-Antimycotic solution 
containing penicillin, streptomycin, and amphotercin B (Cellgro).  
Viral Particle Production and Concentration. Vector particles were produced by transient 
tranfection into 293T cells as described previously (44). Briefly, each 10cm dish of 293T 
cells was transfected with 15g vector, 10g packaging helper, 5g VSV-G envelope, and 
5g Rev expressing plasmids. Experiments with Rev-MS2 constructs were performed with 
10g of each Rev plasmid. Plasmid amounts were compensated for in experiments in the 
absence of Rev with the empty plasmid construct, pCI-neo (Promega). Vector particles were 
harvested in conditioned media 48-60 hours post-transfection and filtered through a 0.45m 
filter. Vector titers were determined by serial dilution on 293T cells and scoring for GFP 
positive cells using a Leica Leitz DMIRB inverted fluorescent microscope. Vector titers are 
expressed as values normalized to p24 (HIV-1 viral particles), or reverse transcriptase 
activity (MLV viral particles). The p24 assay and the reverse transcriptase assays are 
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described below. Concentration of vector particles was executed as done previously (44), 
with the exception that vector was purified over a single sucrose gradient, concentrated, and 
resuspended in 1X PBS.  
HIV-1 p24 Capsid Concentration. Details of this assay were described previously (100). 
Briefly, EIA/RIA plates were coated with p24 antibody (NIH AIDS Research and Reference 
Reagent Program, #3537) at 1:1000 dilution and incubated overnight at 4°C. After blocking, 
samples/standards were treated with a 1% triton x-100 sample buffer, diluted appropriately, 
and added to plate for overnight incubation at 4°C. After washing, polyclonal rabbit anti-p24 
antibody (NIH AIDS Research and Reference Reagent Program, #SP451T) at 1:300 was 
added to the plate, and incubated at 37°C for 3 hours. After washing, goat anti-rabbit IgG 
peroxidase (Pierce) at 1:15000 was added to the plate and incubated at 37°C for 2 hours. 
Assay was completed as described previously (100). Data used for titer normalization, and 
determining amount of viral particles for RNA isolation, are a mean of replicate samples. 
FACS Analysis. Details of this assay were described previously (44). Briefly, at the 
indicated times post-transduction cells were fixed, and GFP expression was assessed on a 
Dako CyAn flow cytometer at the University of North Carolina Flow Cytometry Core 
Facility. Data was analyzed with Summit v4.3.01 software (Dako).  
Luciferase Assays. Luciferase lysates were prepared by pelleting transfected 293T cells at 
the time of vector collection, and resuspending the pellet in 1X passive lysis solution 
(Promega). After freeze-thawing cell debris was pelleted by centrifugation for 15 minutes at 
14,000 rpm and 4°C. Equivalent volumes of supernatant were assayed for firefly luciferase 
expression using 100 µl luciferin reagent (Promega). Luminescence was measured with a 
Victor3 multilabel counter and Wallac 1420 Workstation software (Perkin-Elmer). Results 
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are expressed as relative light units (RLU)/mg protein. Protein concentrations were assayed 
according to manufacturer’s instructions for Pierce BCA Protein Assay kit. 
RNA Isolation. At 48-60 hours post-transfection vectors were harvested from the media, and 
cells were divided for luciferase assay, total protein, and cytoplasmic RNA/protein 
fractionation. Cells were removed from the plate by trypsinizing, and pelleted. The 
cytoplasmic fraction was separated by treating the pelleted cells with a MES (2-(N-
morpholino)ethanesulfonic acid) buffered 0.1% Triton X-100 solution (10mM MES pH 6.5, 
60mM KCl, 15mM NaCl, 5mM MgCl2, 250mM sucrose, 0.1% Triton X-100) + protease 
inhibitor minicocktail (Roche) + 200 units/ml RNase Inhibitor (Fermentas). Pellets were 
incubated 2 minutes on ice, and nuclei were pelleted at 1500 rpm and 4°C. The cytoplasmic 
supernatant fraction was collected and separated for RNA isolation and protein analysis. 
Cytoplasmic fraction was monitored by western blot analysis for the absence of nucleolin 
protein, compared to total cellular proteins. RNA was purified from the cytoplasmic 
supernatant using the PARIS protein and RNA isolation kit (Ambion). Manufacturer’s 
instructions were followed starting with addition of the 2X lysis/binding solution to an equal 
volume of cytoplasmic supernatant. Purified RNA was treated with DNase I Turbo (Ambion) 
for 1.5 hours at 37°C, and inactivated according to manufacturer’s instructions. RNA 
integrity and concentration were regularly assessed by agarose gel electrophoresis. 
Cytoplasmic RNA was then utilized for analysis in qRT-PCR and northern blot.  
 Isolation of RNA from vector particles was carefully executed so that all vectors 
packaged into HIV-1 viral particles were normalized for equivalent amounts of p24 prior to 
isolation. For each sample at the time of RNA isolation p24 equivalents of vector particles 
and 5x106 293T cells were concomitantly added to the RLT lysis solution in preparation for 
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column purification of the RNA with the RNeasy Plus Mini kit (Qiagen). Spiking the vector 
particles with 293T cells at time of purification has multiple advantages: i) 293T cell RNA is 
a carrier during RNA purification; ii) RNA can be easily quantified after purification; and iii) 
quantity and integrity of purified RNA can be monitored by agarose gel electrophoresis. For 
purposes of homogenization the lysed particles/293T cell RNA were passed through a 
QIAshredder column (Qiagen), and subsequently through a genomic DNA eliminator column 
provided with the RNeasy plus mini kit. Lysate was then purified through the RNA isolation 
column provided with the RNeasy plus kit. Purified RNA was treated with DNase I Turbo 
(Ambion) as described for cytoplasmic RNA. Vector particle RNA was then utilized for 
analysis in qRT-PCR and northern blot. RNA was isolated from MLV viral particles in a 
similar fashion, except that viral particles were normalized for equivalent amounts of MLV 
reverse transcriptase. The reverse transcriptase assay is described above.  
qRT-PCR. Purified cytoplasmic and vector RNA were heated to 65°C for 5 minutes prior to 
preparing each reverse transcription (RT) reaction. Each RT reaction was prepared at final 
concentrations of 1X RT Buffer (Qiagen OmniScript kit), 0.5mM each dNTP, 10 µM random 
prime nonamer, 10 units RNase Inhibitor (Fermentas), 500 ng RNA, and 4 units OmniScript 
reverse transcriptase (Qiagen).  As controls for the presence of contaminating DNA each 
reaction was also performed in the absence of reverse transcriptase. Reactions were executed 
for 1 cycle on a BioRad MyCycler at 37°C for 1 hour. Equivalent amounts of cDNA were 
used in the subsequent quantitative PCR reaction. Each qPCR reaction was prepared at final 
concentrations of 1X ABI Taqman mix (2X Taqman Gene Expression Master Mix, Applied 
Biosystems), 0.9 µM forward primer, 0.9 µM reverse primer, and 0.1 µM probe. Reactions 
were performed at 1 cycle of 50°C/2 minutes, 1 cycle of 95°C/10 minutes, and 40 cycles of 
38 
 
95°C/15 seconds + 60°C/30 seconds on a 7300 real time PCR system (Applied Biosystems). 
All MLV and MLV/HIV chimeric vector RNAs were detected with a primer/probe set to the 
luciferase gene: For Luc 5’-aggtcttcccgacgatga-3’, Rev Luc 5’-gtctttccgtgctccaaaac-3’, and 
probe #70 (Roche Universal Probe Library). All HIV derived vector RNAs were detected 
with the following primer/probe set: HIV PS For 5’-aagcagggagctagaacgatt-3’, HIV PS Rev 
5’-cccagtatttgtctacagccttc-3’, and probe #162 (Roche Universal Probe Library). All 
quantitative PCR reactions were normalized to an endogenous control reaction for TATA 
Binding Protein (TBP) using the following primer/probe set in independent reactions: For 
TBP 5’-gaaccacggcactgattttc-3’, Rev TBP 5’-tgccagtctggactgttcttc-3’, and probe #92 (Roche 
Universal Probe Library).  
 The levels of vector RNA (VRNA) and cytoplasmic RNA (CRNA) derived from the 
qRT-PCR data are expressed as arbitrary units (AU). The values were determined by 
normalizing the cycle threshold (Ct) for luciferase to that obtained for TBP, from each 
reaction. The calculation was as follows: 2-Ct, where the Ct is (Luc Ct – TBP Ct). 
Independent reactions were performed for each VRNA and CRNA sample. All isolated 
VRNA could be normalized to TBP since each sample was copurified with 293T cell RNA, 
as described above. Calculation of the encapsidation efficiency, where VRNA relative to 
CRNA is expressed as AU, was determined for each independent sample. The calculation 
was as follow: 2-Ct, where the Ct is (VRNA Luc Ct – VRNA TBP Ct) – (CRNA Luc Ct – 
CRNA TBP Ct). All relative encapsidation efficiencies are expressed as an average of at least 
three independent experiments with corresponding standard deviations (S.D.).  
Northern Blot Analysis. Cytoplasmic RNA was isolated as described, and vector RNA was 
isolated from concentrated vector particles. Vector RNA was prepared from equivalent levels 
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of p24, and at the time of isolation the samples were copurified with 293T cells as described 
above. Prior to resolving RNA on a denaturing formaldehyde agarose gel, RNA was 
denatured at 65°C for 10 minutes. Equivalent amounts of cytoplasmic RNA, and vector 
RNAs, were resolved on the gel. Northern blot analysis was performed under standard 
conditions. Probes were random prime labeled with 32P-dCTP (Easy Tide Deoxycytidine 
5’-triphosphate, Perkin-Elmer) at 37°C for 1 hour. The probe was a fragment generated to the 
GFP at the 3’ end of the vector RNA. Images were obtained on BioMax MR film (Kodak), or 
by phosphorimager (Molecular Dynamics Storm System).  
Western Blot Analysis. Cytoplasmic and total cell lysates were resolved by standard 
denaturing SDS-PAGE analysis on 10% gels and blotted to Hybond P membrane. 
Membranes were probed with rabbit anti-nucleolin (1ug/ml; Abcam, cat# ab22758-100) and 
rabbit anti-GAPDH (1:500; Santa Cruz Biotechnology, cat# FL-335). Detection was 
achieved by probing blots with goat anti-rabbit IgG peroxidase (1:40000; Pierce). Rev and 
Rev-MS2 fusion proteins were examined with mouse anti-Rev (1:200; Santa Cruz 
Biotechnology, cat# sc69729). Detection was achieved with a goat anti-mouse IgG 
peroxidase (1:500). All antibody incubations and washes were done in 1X PBST. Signals 
were detected using ECL (GE Healthcare). 
 
Results 
The HIV-1 Rev/RRE augments encapsidation of heterologous RNAs in the absence of 
canonical HIV-1 cis packaging elements. The Rev/RRE system was recently demonstrated 
to enhance encapsidation of a HIV-1 vector RNA into HIV-1 viral particles (19). In this 
previous work, however, the Rev/RRE system was examined in the context of HIV-1 vectors 
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that contain cis elements from the 5’ UTR including R, U5, PBS, and  regions that may also 
have contributed to the enhanced encapsidation. Additionally, the combination of the 
Rev/RRE system and cis elements from the 5’ UTR may have pleiotropic effects which 
impact other stages of the viral life cycle (i.e. reverse transcription (1)). To isolate 
encapsidation effects directly attributable to the Rev/RRE system we assembled a 
heterologous RNA system derived from murine leukemia virus (MLV) vector RNA (Fig. 
1A). Nuclear export of MLV vector RNA is autonomous (106, 193), a feature exploited to 
elucidate the effects of the Rev/RRE on HIV-1 processes (i.e. encapsidation). Heterologous 
vector RNAs were packaged into viral particles generated from a helper system (Gag/Pol-4X 
CTE) that does not rely upon the Rev/RRE system for nuclear export of RNA encoding the 
structural and enzymatic proteins (Fig. 10A). By circumventing dependence upon Rev for 
nuclear export of gag/pol RNA, and vector RNA, we could directly analyze the effect of Rev 
on encapsidation. The MLV/HIV RRE chimeric vector was constructed to express enhanced 
green fluorescent protein (eGFP) from an internal CMV promoter to provide an indirect 
indication of the RNA incorporated into viral particles (Fig. 10A). Vector titers were 
determined by scoring for GFP expression following transduction of 293T cells, and 
normalized to amounts of p24 capsid protein (Fig. 10B). Incorporation of only the HIV-1 
RRE into the heterologous MLV vector (MLV/HIV RRE vector) enhanced titers 11-fold in 
the presence of Rev. This is the first report that the Rev/RRE system can influence packaging 
of a foreign RNA into HIV-1 viral particles. These results indicate that the HIV-1 Rev/RRE 
system can impact titers of vectors devoid of HIV-1 cis elements known to affect RNA 
packaging. Furthermore, the Rev/RRE system conferred corresponding increases in 
transduction of 293T cells exposed to equivalent amounts of p24 capsid protein (Fig. 11A 
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and B), demonstrating that the Rev mediated increase in titer cannot be attributed to Rev 
effects on HIV-1 particle production. Since it is well established that the Rev protein 
enhances nuclear export of RNAs containing a RRE, observed increases in titers may be a 
consequence of augmented nuclear export. This possibility was investigated by measuring 
the cytoplasmic vector levels in the producer cells.  
The vectors were configured to indirectly assess cytoplasmic levels of vector length 
RNAs during production by situating the firefly luciferase gene such that it was included in 
the full-length vector RNA, but not in RNAs expressed from the internal promoter (Fig. 
10A). Luciferase expression in the 293T producer cells is indirect evidence for cytoplasmic 
RNA, and may be subject to translational influences. Luciferase levels were marginally 
affected by Rev, indicating that Rev did not influence nuclear export of the MLV/HIV RRE 
vector (Fig. 10C). Examining the titer/luciferase ratio (Fig. 10D) revealed that the effects of 
the Rev/RRE system primarily alter vector titers (14 fold) with minimal cytoplasmic 
changes. Reasoning that the Rev/RRE system may mediate packaging of vector RNA into 
HIV-1 viral particles we were encouraged to further explore the mechanism mediating RNA 
encapsidation. 
Encapsidation efficiency is a measure of RNA packaged into viral particles relative to 
the RNA available for packaging, in the cytoplasm. Vector RNA was isolated from viral 
particles in the media of 293T producer cells and vector producing cells were fractionated to 
obtain cytoplasmic RNA. Cytoplasmic separation was routinely monitored using western blot 
analysis for the absence of the nuclear specific protein, nucleolin, from the cytoplasm (Fig. 
12A). Additionally, total, cytoplasmic, and viral RNA was regularly monitored for RNA 
integrity and to ensure equivalent loading levels by resolving on formaldehyde denaturing 
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agarose gels (Fig 12B). In the process of isolating viral RNA samples are copurified with 
cellular RNA to serve as controls for RNA integrity, and amounts. Relative RNA levels in 
viral particles and cytoplasm of producer cells were examined by qRT-PCR and northern blot 
analysis (Fig. 13). In the absence of all HIV-1 5’ UTR cis elements Rev enhanced the levels 
of MLV/HIV RRE vector RNA in viral particles 6 fold compared to the MLV vector (Fig. 
13A), which is in line with what was observed for the titers (Fig. 10B). Compared to the 
basic MLV vector the Rev/RRE system did not impact cytoplasmic vector RNA levels (Fig. 
13B), thus the increase in RNA encapsidation is similar to that observed in viral particles, 7-
fold (Fig. 13C).  Northern blot analysis supported the observation that the Rev/RRE system 
could augment encapsidation independent of additional HIV-1 5’ UTR cis elements (Fig. 
13D). Specificity is also apparent from northern blot analysis, demonstrating that vector 
length RNA species is more efficiently packaged in the presence of Rev than a smaller RNA 
species (labeled as GFP generated from the internal promoter) lacking the RRE cis element. 
The HIV-1 Rev/RRE system can confer an encapsidation advantage onto a heterologous 
MLV vector RNA.  
The capacity of the HIV-1 Rev/RRE system to enhance encapsidation, and confer 
specificity, upon a heterologous RNA is not restricted to the MLV vector system. The HIV-1 
RRE was also incorporated into non-primate lentiviral vector RNAs, derived from feline 
immunodeficiency virus (FIV) and equine infectious anemia virus (EIAV), to examine RNA 
encapsidation into HIV-1 viral particles (Fig. 14A). HIV-1 viral particles were derived from 
the Rev/RRE-dependent ∆NRF packaging construct, which supplies Rev in trans (Fig. 14A). 
Incorporation of the RRE enhanced vector titers for both EIAV (14 fold), and FIV (18 fold), 
an indication that the Rev/RRE system may increase heterologous RNA encapsidation into 
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HIV-1 viral particles (Fig. 14B). These results were substantiated by northern blot analysis 
demonstrating significant Rev/RRE-dependent increases of EIAV, and FIV, vector RNAs 
into HIV-1 viral particles (Fig. 14C). Similar to the chimeric MLV/HIV RRE vector in the 
presence of Rev the smaller GFP species, lacking RRE, was nearly undetectable, even though 
an abundance of this RNA species could be detected in the cytoplasm. These results provide 
further evidence that the HIV-1 Rev/RRE system can confer specificity onto a heterologous 
RNA for encapsidation. Using the ratio of vector titers relative to the cytoplasmic RNA 
(northern blot) available for packaging, an indirect measure of the encapsidation efficiency 
showed that the HIV-1 Rev/RRE system could dramatically augment encapsidation of EIAV 
(13 fold) and FIV (16 fold) vector RNAs into HIV-1 viral particles (Fig. 14D). Combined 
with previous data, this work demonstrates that the encapsidation effect of the HIV-1 
Rev/RRE system is not restricted to a single RNA species, but rather heterologous transfer of 
the RRE to at least three different RNA species confers increased RNA packaging efficiency 
into HIV-1 viral particles.  
Importantly, this work also indicates that the HIV-1 Rev/RRE encapsidation function 
may be conserved among lentiviruses. Homologous Rev proteins derived from distantly 
related non-primate lentiviruses, EIAV (ERev) and FIV (FRev), revealed distinct titers, 
which are presumably related to RNA encapsidation effects (Fig. 15). FRev dramatically 
augmented titers of FIV vector RNAs containing the FIV RRE (83- & 134-fold) (Fig 15A). 
Since the FRev is augmenting titers of FIV vectors into HIV-1 viral particles, the data 
suggest that FRev may utilize an encapsidation mechanism also shared by HIV-1 Rev 
(HRev). In contrast ERev did not enhance titers of EIAV vector RNAs containing EIAV 
RRE, into HIV-1 derived viral particles (Fig. 15B). In both cases the HRev augmented 
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encapsidation of RNAs containing the HIV-1 RRE (Fig 15A & B). Apparently, ERev may 
utilize an encapsidation mechanism distinct from that of HRev and FRev.  
Overall, the data demonstrate that the HIV-1 Rev/RRE system can enhance 
encapsidation of heterologous RNAs into HIV-1 viral particles independent of the canonical 
HIV-1 packaging signal, as well as other 5’ UTR cis elements. Furthermore, HRev and FRev 
may utilize a common encapsidation mechanism, whereas ERev may mediate encapsidation 
in a unique manner. These data indicate that the Rev/RRE system may be a central 
component of a RNA encapsidation mechanism that is traditionally associated with cis 
elements in the 5’ UTR (R, U5, PBS, and ). Since the Rev/RRE system is central to 
encapsidation part of the mechanism to achieve specificity may comprise an independent 
function associated with the RRE and nuclear export through the CRM1 pathway. 
 
The HIV-1 Rev-enhanced encapsidation effect is dependent upon maintaining an 
interaction with the RNA. The abovementioned results demonstrated that HIV-1 Rev could 
augment encapsidation of heterologous RNAs upon transfer of the RRE cis element to a 
heterologous RNA. These data imply that Rev may interact with the RRE cis element to 
mediate encapsidation into HIV-1 viral particles. In addition, the HIV-1 RRE cis element 
may have a functional role in the encapsidation mechanism beyond maintaining an 
interaction between the Rev protein and the RNA to be encapsidated. This possibility was 
further investigated by initially deleting the RRE cis element from a typical HIV-1 vector 
RNA (Fig. 16A), and measuring vector RNA encapsidation in the presence and absence of 
HIV-1 Rev (Fig 16). Vector titers indicated that deletion of the RRE may have prevented 
RNA encapsidation (Fig. 16B), which was bolstered by measuring the titer-to-luciferase ratio 
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(Fig. 16C). In two independent experiments measuring encapsidation efficiency by qRT-PCR 
demonstrated that deletion of the RRE obviated the Rev-mediated encapsidation effect, 
compared to control HIV-1 vector RNA containing the HIV-1 RRE (Fig. 16D). These data 
insinuate that the Rev-mediated encapsidation effect is dependent upon the HIV-1 RRE. 
However, it is still a possibility that the RRE serves a role in the encapsidation mechanism. A 
better understanding can be gleaned by substituting the RRE with an alternative cis RNA 
binding element.  
 The bacteriophage MS2 system was previously employed to study the effects of Rev 
mutants on nuclear/nucleolar import and nuclear export (142). Along similar lines the HIV-1 
RRE was replaced with nine tandem copies of high affinity MS2 response elements in a 
standard HIV-1 vector RNA to generate HIV/9X MS2RE ∆RRE vector (Fig. 17A). 
Concomitantly, a fusion of the bacteriophage MS2 coat protein with the HIV-1 Rev protein 
was ectopically expressed during vector production in 293T cells to examine the effects on 
RNA encapsidation. Western blot analysis demonstrated overexpression of the Rev-MS2 
protein (Fig. 17B). The Rev-MS2 fusion was comparably functional to the Rev protein as 
demonstrated by standard HIV-1 vector titers (Fig. 17C), and titers normalized to luciferase 
(Fig. 17D). However, only the Rev-MS2 fusion protein augmented the packaging of HIV/9X 
MS2RE ∆RRE vector RNA into HIV-1 viral particles (7 fold), as measured by titer/luciferase 
ratio (Fig. 17D). These data indicate that the HIV-1 RRE is not necessary for enhanced 
encapsidation, but rather that an interaction should be maintained between the HIV-1 Rev 
protein and the RNA. However, RNA encapsidation with the Rev-MS2 system is not as 
efficient as the Rev/RRE system, which may suggest that the RRE is most desirable as the 
cognate Rev cis element; or, that it may be technically challenging to reproduce the Rev/RRE 
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interaction with a synthetic system. Further discussion of these concepts is shown below. 
Since Rev is important for efficient and specific encapsidation of RNA available in the 
cytoplasm; conceivably, the fate of RNA to be encapsidated in the cytoplasm may be 
determined by the nuclear export pathway.  
 
Rev-enhanced encapsidation does not require nuclear export through the CRM1 
nuclear export pathway. A number of reports have demonstrated that the nuclear export 
pathway can influence retroviral particle assembly (93, 94, 149, 191, 201). Presumably, the 
nuclear export pathway may also be part of a mechanism that determines the fate of RNAs in 
the cytoplasm. Nuclear export of full-length and partially spliced viral RNAs through the 
CRM1 nuclear export pathway is the primary post-transcriptional regulatory mechanism 
ascribed to the Rev/RRE system; therefore, the CRM1 pathway may also be central to 
efficient RNA encapsidation. To examine this possibility HIV-1 vector RNAs were 
redirected from the CRM1 pathway to nuclear export through the Tap/NXT1-dependent 
pathway (Fig. 18A).  The TAP/NXT1 pathway is the most common pathway utilized for 
nuclear export of spliced cellular mRNAs. A dominant negative Rev mutant (RevM10) 
contains a mutation in the nuclear export signal that prevents an interaction with CRM1 
(131); nonetheless, retains the ability to interact with the RNA. A RevM10-Tap fusion was 
employed to redirect RNA from the CRM1 pathway to the Tap/NXT1 pathway (Fig. 18A). 
This fusion was previously demonstrated to facilitate nuclear export in a CRM1-independent 
manner (74). The system was tested using a pMDL HIV-1 packaging construct whereby p24 
expression is Rev/RRE-dependent (Fig. 18B). Ectopic expression with the RevM10-Tap 
fusion and the NXT1 cofactor demonstrated high levels of viral particle production as 
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measured by p24 capsid protein in the media (Fig 18C), whereas the RevM10 mutant alone 
did not promote p24 expression. Therefore, the RevM10-Tap/NXT1 system mediates nuclear 
export in a CRM1-independent manner.  
 The nuclear export effect on encapsidation was investigated by ectopically expressing 
the RevM10-Tap/NXT1 system, and testing the capacity to encapsidate a standard HIV-1 
vector RNA with an RRE (Fig. 18A) into HIV-1 viral particles derived from a codon 
optimized HIV-1 Gag-Pol packaging system. This packaging system affords Rev-
independent and Tap-independent production of viral particles. The RevM10-Tap/NXT1 
system augmented vector titers 6 fold (Fig. 19A), indicating that there may be enhanced 
packaging of vector RNA. Cytoplasmic RNA levels may not be influenced by the RevM10-
Tap/NXT1 system since the titer/luciferase ratio (5 fold increase, Fig 19B) indirectly 
indicated a similar increase in packaging. These data were confirmed by qRT-PCR 
demonstrating that the RevM10-Tap/NXT1 system mediated a 7 fold increase in RNA 
encapsidation efficiency (Fig. 19C). Together, these two methods indicate that the Rev-
mediated encapsidation effect is not strictly dependent upon CRM1 nuclear export. However, 
the efficiency of the system does not achieve levels similar to that of wild-type HIV-1 Rev 
through the CRM1 pathway. Therefore, although not absolutely required for the Rev-
enhanced encapsidation effect, nuclear export through the CRM1 pathway is optimal for 
efficient RNA encapsidation. 
 
Discussion 
The objective of these studies was to understand the role of the HIV-1 Rev/RRE system in 
the sophisticated mechanism of selecting a RNA species from the milieu of host cell RNAs 
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to ensure efficient and specific encapsidation into nascent HIV-1 viral particles. Isolating the 
Rev/RRE system away from other HIV-1 cis elements demonstrated for the first time that the 
Rev/RRE system can augment encapsidation of heterologous RNAs into HIV-1 viral 
particles (Figs. 10-14). Importantly, encapsidation was achieved in the absence of more 
conventional HIV-1 cis packaging elements located in the 5’ UTR of the full-length HIV-1 
RNA. Nevertheless, the contribution of HIV-1 cis elements in the 5’ UTR to encapsidation 
should not be marginalized, and is addressed in Chapter 3 of this dissertation. Prior studies 
investigated a role for HIV-1 Rev in the encapsidation process in the presence of the major 
cis packaging elements in the 5’ UTR (5, 19, 67, 181); however the Rev effect could have 
been compounded by pleiotropic packaging effects of additional cis elements from the HIV-1 
5’ UTR. The capacity of the HIV-1 Rev/RRE to enhance encapsidation in the absence of 
other HIV-1 cis elements suggests that the interaction of the Rev protein with the RRE can 
make the RNA amenable to specific encapsidation into HIV-1 viral particles, and that the 
Rev/RRE system may impact encapsidation at steps preceding the involvement of cis 
elements in the 5’ UTR.   
A number of scenario’s may help explain the mechanism by which Rev functions in 
RNA encapsidation. A plethora of cellular proteins have been demonstrated to function as 
Rev/RRE cofactors, possibly as ribonucleoprotein complexes, that can influence nuclear 
import, splicing, nuclear export, RNA release, and subcellular localization, ultimately 
impacting viral replication in a positive or negative manner (41, 71, 199). Rev may localize 
the viral RNA in the cell cytoplasm, thereby facilitating efficient/specific encapsidation. 
Several cellular proteins have been shown to alter the location of Rev (47, 56, 80, 147, 180, 
189, 196, 222, 223). Recently the host cell double-strand RNA binding protein, NF90, was 
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demonstrated to alter the subcellular location of Rev and influence HIV-1 viral particle 
production (206); implying that the localization of viral RNA may also be altered. On the 
other hand, the HIV-1 Rev/RRE system may recruit host cell proteins that manipulate RNA 
structure or promote chemical modifications to the viral RNA that effect cytoplasmic 
processes such as translation and/or encapsidation. The host cell nuclear protein Matrin 3 was 
demonstrated to interact with RRE-containing RNAs (115, 220) and influence post-
transcriptional viral gene expression in a Rev/RRE-dependent fashion (220). Additionally, a 
recent report demonstrated that Rev can recruit the cellular methyltransferase protein, PIMT, 
which trimethylates the 5’ RNA cap of some HIV-1 RNAs as a regulatory mechanism for 
selective expression (221). Nevertheless, there is a dearth of evidence implicating host cell 
proteins in HIV-1 RNA packaging. The only host protein implicated in Rev/RRE-dependent 
packaging of HIV-1 viral RNA has been the RNA helicase protein DDX24, whereby down-
regulation of DDX24 was demonstrated to decrease the amount of HIV-1 RNA in viral 
particles (126). Most likely a Rev/RRE-dependent encapsidation mechanism should involve 
recruitment of cellular proteins, probably in the context of a ribonucleoprotein complex (41).  
A Rev/RRE-mediated RNA encapsidation mechanism may also be conserved among 
primate and some non-primate lentiviral Rev proteins. Data presented here suggest that FIV 
Rev may function similar to HIV-1 Rev (Fig. 15). Along these same lines previous data 
demonstrated that SIV Rev can also augment encapsidation of SIV RNA into SIV viral 
particles (19). Additionally, like HIV-1 Rev, both FIV and EIAV Rev proteins utilize a 
CRM1-dependent nuclear export mechanism (164). In contrast, EIAV Rev did not influence 
encapsidation of standard EIAV or EIAV/HIV chimeric vector RNAs into HIV-1 viral 
particles (Fig. 15B). This is despite the fact that HIV-1 Rev could enhance titers of 
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EIAV/HIV chimeric vectors (Figs. 14 & 15), and encapsidation of chimeric vector RNA into 
HIV-1 viral particles (Fig. 14). The unique properties of HRev, FRev, and ERev may be 
exploited to identify unique host cell factors that are common to HRev and FRev, but not 
ERev, thereby providing further insight into the RNA encapsidation process.  
Rev can clearly influence the utilization of viral RNAs for different late viral 
replication processes (i.e. translation & packaging) through interaction with the RRE. 
However, it is not clear if the RRE is absolutely necessary for Rev to mediate these late 
replication processes. Deletion of the RRE eliminated encapsidation of HIV-1 vector RNA 
(Fig. 16). Replacing the RRE with a heterologous RNA binding element (i.e. MS2 
bacteriophage coat protein response elements inserted in tandem into HIV-1 vector RNA) 
was sufficient to augment titers and encapsidation as indirectly measured by titer/luciferase 
(Fig. 17). These results are in agreement with previously published reports demonstrating 
that heterologous RNA binding elements are sufficient to support RNA packaging if the 
interaction between Rev and the vector RNA is retained (125). Nonetheless, the efficiency of 
encapsidation does not achieve levels comparable to those of the Rev/RRE system, as 
demonstrated here (Fig. 17), and in previous work (19). Although this may indicate that the 
RRE is important to maintain an efficient level of RNA encapsidation, technical differences 
in the systems may also explain the distinction. A central aspect of Rev function is the 
capacity to oligomerize on the RRE (52, 133, 177, 225). In the context of the Rev-MS2 
protein, Rev may be restricted to only forming dimers since each MS2 response element can 
recruit only two MS2 molecules (105), thereby possibly limiting Rev function. Notably, 
however, the Rev-MS2 fusion retained function similar to the Rev protein alone, yielding 
comparable titers of an HIV-1 vector with the RRE (Fig. 17). An alternative possibility is 
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that the Rev-MS2 fusion protein does not interact efficiently with the vector RNA to mediate 
subsequent encapsidation. The Rev protein is efficiently imported into the nucleus where it 
interacts with RRE-containing viral RNA. If the RRE is necessary for proper localization of 
viral RNA to sites amenable to interaction with the Rev protein, then replacing the RRE with 
the MS2 response elements may diminish the potential for this interaction to occur, thereby 
negatively influencing downstream events. In this case the RRE would be important for 
efficient RNA encapsidation.  
The Rev/RRE interaction governs nuclear export of full-length and partially spliced 
viral RNAs (i.e. those containing a HIV-1 RRE cis element) through the CRM1-dependent 
pathway. This is in contrast to the preponderance of spliced cellular RNAs which utilize the 
Tap/NXT1 pathway for nuclear export. Thus, there may be a reason(s), beyond nuclear 
export of intron-containing HIV-1 RNAs, that lentiviruses have evolved the use of the 
Rev/RRE system for nuclear export of viral RNAs through the CRM1 pathway. Presumably, 
the fate of viral RNAs in the cytoplasm may be subject to the pathway of nuclear export. A 
number of reports have indicated that HIV-1 viral particle assembly may be governed by the 
nuclear export pathway utilized by the viral genomic RNA (93, 94, 191, 201). All the same, 
replacing the Rev protein with a constitutive transport element (CTE) from Mason Pfizer 
monkey virus (MPMV) conferred HIV with the capacity to replicate, albeit the CTE-
containing virus was dramatically attenuated (50-100 fold) compared to virus with a 
functional Rev protein (20). CTE-containing RNAs utilize the Tap/NXT1 nuclear export 
pathway, which was the same pathway employed here to examine the effect of nuclear export 
on Rev-enhanced RNA encapsidation. Along similar lines data presented here demonstrate 
that the Rev-enhanced RNA encapsidation effect does not strictly require nuclear export 
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through the CRM1 pathway (Figs. 18 & 19); however, the encapsidation effect was 
significantly attenuated compared to a functional Rev/RRE system. Although these results 
infer that the CRM1 pathway may partially determine the efficiency of subsequent 
cytoplasmic events, the use of a RevM10 mutant fused to the Tap protein may have also 
inadvertently decreased the efficiency of the Rev protein.  
Overall it is clear that the Rev/RRE system positively influences the efficiency and 
specificity of late HIV-1 replication events that occur in the host cell cytoplasm. The 
significance of the Rev/RRE system is even more poignant when considering that these 
functions may be conserved among lentiviruses. Results presented here demonstrate that the 
RRE cis element and CRM1-dependent nuclear export are not necessary for Rev-mediated 
enhanced RNA encapsidation. However, the Rev/RRE system is apparently critical for all of 
these processes since in all cases efficiency was dramatically diminished when compared 
with the normal HIV-1 Rev/RRE system. These data insinuate that the Rev/RRE system may 
be a central component of a RNA encapsidation mechanism conventionally associated with 
cis elements in the 5’ UTR (R, U5, PBS, and ). The proposition that a complete 
encapsidation mechanism is the concerted effect of all these components is examined in 
Chapter 3.   
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Figure 10. HIV-1 Rev/RRE system augments vector titers. A. Full-length MLV/HIV 
chimeric vector RNAs are expressed from a CMV (cytomegalovirus) promoter in transfected 
293T cells. MLV and HIV cis elements can be distinguished by black underscore. Chimeric 
vector names are represented as MLV/HIV followed by corresponding HIV cis elements 
incorporated: RRE (Rev Response Element) and cPPT (central polypurine tract). Also 
incorporated are the WPRE (woodchuck hepatitis virus post-transcriptional regulatory 
element), FLuc (firefly luciferase gene), and GFP (green fluorescent protein gene). HIV-1 
Gag-Pol 4X CTE helper construct was used to express structural and enzymatic proteins to 
generate viral particles independent of HIV-1 Rev protein. B. Vector titers normalized to p24 
are shown in the absence (white bars) and presence (black bars) of Rev. The influence of 
adding HIV-1 cis elements to the MLV vector is indicated by fold increases in the presence 
of Rev relative to the standard MLV vector. C. Luciferase levels normalized to total protein 
are shown for each vector. D. Titers expressed as a ratio to luciferase are shown as arbitrary 
units (AU). Error for all bar graphs is expressed as ±S.D. All experiments were performed in 
triplicate. 
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Figure 11. Transduction of 293T cells with chimeric MLV/HIV vectors packaged into 
HIV-1 viral particles. A and B. 293T cells were transduced with equivalent amounts of p24 
capsid protein (50 ng), as determined for each of the indicated chimeric vectors. The 
influence of the HIV-1 Rev/RRE system on transduction was assessed by fluorescence 
microscopy (A) and FACscan analysis (B) at 7 days post-transduction. The percent GFP 
positive cells are indicated for each FACscan and 293T negative control (NC) cells are 
shown. 
 
 
55 
 
 
 
 
 
Figure 12. Cytoplasmic separation and RNA integrity. A. At the time of harvesting 
vectors total and cytoplasmic protein fractions were routinely collected from the producer 
293T cells to monitor separation of the cytoplasmic fraction. Equivalent amounts of total 
(TP) and cytoplasmic (CP) protein lysates were analyzed for nucleolin (a nuclear specific 
protein), and GAPDH, by western blot analysis. Three independent experiments are shown 
for the MLV/HIV RRE+RU5PS vector (described in chapter 3) packaged into HIV-1 
particles in the presence of Rev. B. Total (T), cytoplasmic (C), and viral particle (V) RNAs 
were routinely monitored for integrity by resolving equivalent amounts of RNA on a 
denaturing (foramaldehyde) 1.2% agarose gel, stained with ethidium bromide. The 28S and 
18S ribosomal bands are shown. At the time of RNA isolation viral particle RNA is 
copurified with cellular RNA, hense the dominant ribosomal bands in the viral particle RNA 
lanes.  
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Figure 13. HIV-1 Rev/RRE enhances encapsidation of chimeric MLV/HIV RNA into 
HIV-1 viral particles. A. Vector RNA was measured by qRT-PCR and expressed in 
arbitrary units (AU). RNA levels for all graphs are shown in the absence (white bars) and 
presence (black bars) of Rev. The influence of adding HIV-1 cis elements to the MLV vector 
is indicated by fold increases in the presence of Rev relative to the standard MLV vector. B. 
Cytoplasmic RNA was isolated from vector producer 293T cells at the time of vector 
harvesting. Relative RNA levels were obtained and recorded as done for vector RNA in part 
A. C. Efficiency of encapsidating RNA into HIV-1 viral particles is expressed as a ratio of 
vector RNA in viral particles to cytoplasmic RNA available for encapsidation. Relative 
levels are expressed like vector RNA in part A. D. Northern blot analysis of cytoplasmic and 
vector RNA isolated from MLV and MLV/HIV RRE in the absence (-) and presence (+) of 
Rev. Vector length RNA species were detected with a GFP labeled probe, as well as an 
additional RNA species (labeled GFP) generated from the internal CMV promoter. 
 
57 
 
 
 
 
Figure 14. HIV-1 Rev/RRE enhances encapsidation of chimeric EIAV/HIV and 
FIV/HIV RNAs into HIV-1 viral particles. A. Full-length EIAV/HIV and FIV/HIV 
chimeric vector RNAs are expressed from a CMV (cytomegalovirus) promoter in transfected 
293T cells. EIAV or FIV, and HIV cis elements can be distinguished by black underscore. 
Chimeric vector names are represented as EIAV/HIV, or FIV/HIV, followed by 
corresponding HIV cis elements incorporated: RRE (Rev Response Element) and cPPT 
(central polypurine tract). Also incorporated are the WPRE (woodchuck hepatitis virus post-
transcriptional regulatory element), and GFP (green fluorescent protein gene). HIV-1 ∆NRF 
helper construct was used to express structural and enzymatic proteins to generate viral 
particles, which ectopically supplies Rev. B. Vector titers normalized to p24 are shown in the 
absence (white bars) and presence (black bars) of the RRE. The influence of adding HIV-1 
cis elements to the EIAV, or FIV, vector is indicated by fold increases in the presence of Rev 
relative to the standard EIAV, or FIV, vector. C. Northern blot analysis of cytoplasmic and 
vector RNA isolated from EIAV, or FIV, and EIAV/HIV RRE, FIV/HIV RRE, in the 
absence (-) and presence (+) of RRE. Vector length RNA species were detected with a GFP 
labeled probe, as well as an additional RNA species (labeled GFP) generated from the 
internal CMV promoter. D. Efficiency of encapsidating RNA into HIV-1 viral particles was 
indirectly expressed as a ratio of vector titer to cytoplasmic RNA available for encapsidation, 
and expressed as arbitrary units (AU).  Error (where indicated) is expressed as ±S.D. 
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Figure 15. FIV Rev, but not EIAV Rev, augment titers of chimeric vectors packaged 
into HIV-1 viral particles. Vector titers normalized to p24 are shown in the absence (white 
bars) of any Rev, in the presence of HIV Rev (gray bars), and in the presence of FIV Rev 
(black bars, A) or EIAV Rev (black bars, B). A. Normalized titers were assessed for HIV, 
FIV, and FIV/HIV RRE chimeric vectors packaged into HIV-1 derived viral particles. B. 
Normalized titers were measured for HIV, EIAV, and EIAV/HIV RRE chimeric vectors 
packaged into HIV-1 derived viral particles.  
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Figure 16. HIV-1 Rev is dependent upon the RRE to augmet RNA encapsidation into 
HIV-1 viral particles. A. Full-length HIV-1 vector RNAs are expressed from a CMV 
(cytomegalovirus) promoter in transfected 293T cells. HIV cis elements are indicated by 
black underscore. Also incorporated are the WPRE (woodchuck hepatitis virus post-
transcriptional regulatory element), FLuc (firefly luciferase gene), and GFP (green 
fluorescent protein gene). The RRE was removed from the HIV ∆RRE construct. HIV-1 
Gag-Pol 4X CTE helper construct was used to express structural and enzymatic proteins for 
generation of viral particles independent of HIV-1 Rev protein. B. Vector titers normalized to 
p24 are shown in the absence (white bars) and presence (black bars) of Rev. The influence of 
removing the RRE from the HIV-1 vector is indicated by the fold increase in the presence of 
Rev. C. Titers expressed as a ratio to luciferase are shown as arbitrary units (AU). D. 
Efficiency of encapsidating RNA into HIV-1 viral particles is expressed as a ratio of vector 
RNA in viral particles to cytoplasmic RNA available for encapsidation. Two independent 
experiments are shown. Relative levels are expressed as arbitrary units (AU). All 
experiments were executed in the absence (white bars) and presence (black bars) of Rev. 
Error for bar graphs is expressed as ±S.D. 
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Figure 17. Rev-enhanced encapsidation in the absence of the HIV-1 RRE. A. The HIV-1 
RRE cis element was replaced with nine tandem copies of the MS2 response element derived 
from the MS2 bacteriophage to generate the HIV/9XMS2RE ∆RRE vector. B. Western blot 
analysis of Rev (E116D) and Rev-MS2 fusion protein. Proteins were identified with a mouse 
anti-Rev antibody. C. Vector titers normalized to p24 are shown in the absence of Rev(white 
bars), in the presence (gray bars) of Rev (E116D), or in the presence of the Rev-MS2 fusion 
protein. The influence of Rev and Rev-MS2 are indicated by fold increases relative to the no 
Rev. D. Titers expressed as a ratio to luciferase are shown as arbitrary units (AU). Error for 
all bar graphs is expressed as ±S.D. 
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Figure 18. Rev-dependent RNAs can be redirected from CRM1 nuclear export to the 
TAP/NXT1 nuclear export pathway. A. HIV-1 derived viral RNA is redirected from 
nuclear export through the CRM1-dependent pathway to the TAP/NXT1 pathway. B. To test 
the system an RRE-dependent gag/pol packaging construct was used, where p24 expression 
is only achieved in the presence of Rev. C. The concentration of p24 was measured in the 
media of 293T cells cotransfected with the packaging construct in the absence of Rev 
(negative control, NC), or in the presence of HIV-1 Rev; RevM10 (RM10, a Rev mutant that 
lacks the capacity for nuclear export); or, coexpression of RevM10-Tap fusion in the 
presence of NXT1 (RevM10 mutant maintains RNA interaction and precludes nuclear export 
via CRM1, while redirecting RNA through Tap/NXT1 pathway).   
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Figure 19. HIV-1 Rev can enhance RNA encapsidation through the Tap/NXT1 nuclear 
export pathway. A. Vector titers normalized to p24 are shown in the absence of Rev (NC) or 
in the presence of Rev; RevM10-Tap + NXT1; and Tap + NXT1. B. Titers expressed as a 
ratio to luciferase are shown as arbitrary units (AU). C. Efficiency of encapsidating RNA 
into HIV-1 viral particles is expressed as a ratio of vector RNA in viral particles to 
cytoplasmic RNA available for encapsidation. For all graphs the influence of each nuclear 
export factor is expressed as fold increase relative to the negative control. Error for bar 
graphs is expressed as ±S.D. 
 
 
Chapter 3 
HIV-1 CIS ELEMENTS IN THE 5’ UTR AND REV/RRE SYSTEM ARE REQUIRED 
FOR EFFICIENT AND SPECIFIC PACKAGING OF RNA INTO HIV-1 PARTICLES1 
 
Introduction 
The Rev/RRE system positively impacts encapsidation of heterologous RNA into 
HIV-1 viral particles in the absence of conventional HIV-1 cis elements (Chapter 2). 
However, it is well established that encapsidation is primarily mediated through cis elements 
in the 5’ UTR, predominantly protein-RNA interactions of the nucleocapsid with the 
conventional packaging signal, ψ (49, 149), and RNA-RNA dimerization via stem-loop 1 of 
ψ (49, 148). The conventional canonical cis packaging signal is a ~120 nucleotide fragment 
comprised of four stem-loop structures located in the HIV-1 5’ untranslated region (UTR), 
and extending into the 5’ end of the HIV-1 Gag coding sequence (4, 36, 49, 120, 138, 139). 
Interactions of the Gag polyprotein with stem-loops 2, 3, and 4 ensure efficient encapsidation 
of the gRNA (49, 149). In addition to , several reports indicate that cis elements in the HIV-
1 5’ R, U5, and PBS regions can also influence HIV-1 RNA packaging (37, 38, 81, 139). 
Apparently, the HIV packaging system is highly complex comprising multiple components 
that may function at different steps of a comprehensive packaging mechanism. 
 In general, the components that support efficient and specific lentivirus RNA 
packaging are not defined by a contiguous cis RNA element that can confer packaging onto a 
                                                 
1A portion of the work in this chapter was published by Adam Cockrell, Henriette van Praag, Nicholas 
Santistevan, Hong Ma, and Tal Kafri, titled:The HIV-1 Rev/RRE system is required for HIV-1 5’ UTR cis 
elements to augment encapsidation of heterologous RNA into HIV-1 viral particles (45).  
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heterologous RNA (15). Lentivirus cis packaging signals have predominantly been defined 
by mutagenesis, genetic, and functional studies. The most highly studied lentivirus packaging 
signal is that from HIV-1, with a number of different cis elements defined in the 5’ UTR as 
described above. Multiple cis elements, functioning as a composite packaging signal in the 5’ 
UTR, appears to be a feature conserved among lentiviruses, as indicated by data for HIV-2 
(63, 140), SIV (170, 197), and FIV (21, 103, 183). A number of lentivirus studies indicate 
that disparate cis elements from the 5’ UTR of a single viral genomic RNA may function 
through intramolecular interactions (50, 118, 183, 214). An innovative biochemical 
technology called SHAPE (selective 2’-hydroxyl acylation analyzed by primer extension) 
produced high resolution secondary RNA structures for the 5’ UTRs of HIV-1 in virio and ex 
virio (212, 214) (Fig. 8 from chapter 1) and FIV from in vitro transcribed RNA (104). These 
structures revealed long-range intramolecular RNA-RNA interactions between cis elements, 
which may be indicative of function. Conceivably, the concerted effort of multiple cis 
elements from the R, U5, PBS, and  regions of the 5’ UTR may be important for specific 
and efficient encapsidation.   
The cis packaging signals for simple retroviruses, on the other hand, appear to be 
distinct from lentiviruses in that defined, contiguous cis elements from the 5’ UTR are 
sufficient to mediate encapsidation. The murine leukemia virus (MLV) harbors a cis element 
of ~175 nucleotides, primarily in the 5’ UTR that can readily support retroviral RNA 
packaging if relocated to a different position within homologous RNA (134), and can bestow 
efficient packaging upon heterologous RNA (3, 83). Similarly, a ~160 nucleotide packaging 
signal for Rous sarcoma virus was sufficient to confer nearly 100% packaging efficiency for 
a heterologous RNA (12, 13). Furthermore, the R and U5 regions of the 5’ UTR from simple 
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retroviruses are not part of the transferrable packaging signal. Therefore, packaging systems 
for simple retroviruses are primarily comprised of a small contiguous cis element in the viral 
genomic RNA that can select the RNA from the milieu of host cell RNAs for encapsidation.  
Similar to simple retroviral packaging systems, it is anticipated that a genuine HIV-1 
packaging system could be expected to have cis elements and trans factors that impart a 
gain-of-function onto a foreign RNA for specific and efficient encapsidation into HIV-1 viral 
particles. As alluded to above, different studies indicate that efficient and specific RNA 
encapsidation into HIV-1 viral particles rely upon multiple components comprised of both cis 
elements in the RNA (R, U5, PBS, ψ, and RRE) and viral encoded trans factors (Gag protein 
and Rev). However, it is not understood if the RNA encapsidation mechanism is a single 
pathway relying upon the concerted effects of the various components. Studies from chapter 
2 were expanded whereby the 5’ UTR cis elements and Rev/RRE system were systematically 
reconstructed in the middle of a simple retroviral vector RNA (derived from MLV) to 
investigate the collective impact on the gain of encapsidation function into HIV-1 derived 
viral particles. The data demonstrate that: i) the HIV-1 Rev/RRE system is required for cis 
elements from the 5’ UTR to mediate encapsidation of a heterologous RNA; ii) the complete 
contingent of cis elements from the 5’ UTR (R, U5, PBS, and ) are required for 
encapsidation of a heterologous RNA; iii) a functional HIV-1 packaging system is composed 
of multiple components (including 5’UTR cis elements, nucleocapsid, and the Rev/RRE 
system); iv) the HIV-1 packaging system specifically selects for RNA encapsidation into 
HIV-1 viral particles, but does not influence encapsidation into MLV viral particles; and v) 
specific encapsidation of RNA mediated by the HIV-1 packaging system reduces nonspecific 
packaging of cellular RNAs. Additionally, the influence of cis elements from the canonical 
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packaging signal was further substantiated in the presence of the Rev/RRE system through 
mutational analysis of HIV-1 vector RNAs.  
 
Methods 
 
Plasmid Constructs. Murine leukemia virus (MLV) and MLV/HIV RRE chimeric vector 
constructs were generated as described in chapter 2 methods. The MLV/HIV RU5PS 
chimeric vector (pTK1442) was generated by subcloning a BamHI fragment into the BamHI 
site of pTK1328. The BamHI fragment was derived from a PCR amplified product originally 
cloned into pCR2.1-TOPO (Invitrogen) (pTK1428) and moved into the SmaI/Acc65I sites of 
pBlueScript (Strategene) (pTK1441). The PCR amplified product, comprising the HIV-1 R, 
U5, PBS, and canonical packaging signal which extends into the 5’ end of Gag, was 
generated with the following primers: HIV RU5 For 5’-
gcggccgcttaattaagggtctctctggttagaccagatctgagcc-3’; and HIV RU5Pack. Rev 5’-
gcggccgcttgctgtgcgg-3’. The MLV/HIV RRE+RU5 vector (pTK1439) was constructed by 
subcloning a PCR amplified fragment into the NotI site of pTK1332. The PCR amplified 
product was formally cloned into pCR2.1-TOPO (Invitrogen) (pTK1427). The following 
primers were used to generate a PCR product comprising the HIV-1 R and U5 regions: HIV 
RU5 For primer as described above and HIV RU5 Rev 5’-
gcggccgcactgctagagattttccacactgac-3’. The MLV/HIV RRE+PS vector (pTK1423) was 
constructed by subcloning a fragment, consisting of the canonical packaging signal and 
extending into the 5’ end of Gag and HIV-1 RRE, into the BamHI sites of pTK1332. Upon 
cutting with BamHI the existing RRE in pTK1332 would not be retained. The last construct 
in the series, the MLV/HIV RRE+RU5PS vector (pTK1440), was generated by subcloning 
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the NotI fragment from pTK1428 into the NotI site of pTK1332. The NotI fragment contains 
the HIV-1 R, U5, PBS, and canonical packaging signal extending into the 5’ end of Gag.  
The standard HIV-1 derived vectors are described in chapter 2 methods. The 
following is a description of how HIV-1 vectors with deletions in the canonical packaging 
signal () were generated. The following cloning series was used to generate the HIV-1 ∆  
vector: i) a MluI/NotI fragment, containing the 5’UTR from the HIV-1 vector pTK1087 was 
subcloned into pSL301 (Invitrogen) to generate pTK1221; ii) pTK1221 was used as a 
template for PCR around the entire plasmid wherein primers were designed to eliminate the 
canonical packaging signal, the region between the MluI/NotI sites was confirmed by 
sequencing to be correct with elimination of the canonical packaging signal, pTK1230; iii) 
the MluI/NotI fragment was subcloned into pTK1087 to generate pTK1240; and iv) the 
firefly luciferase gene was inserted into the EcoRI site of pTK1240 to produce the final 
construct, pTK1305 containing a deletion of the entire canonical packaging signal. The HIV-
1 ∆ SL1 construct was generated by the following cloning series: i) pTK1221 was used as a 
template for PCR around the entire plasmid wherein primers were designed to eliminate 
stem-loop 1, the region between the MluI/NotI sites was confirmed by sequencing to be 
correct with elimination of stem-loop 1, pTK1426; and, ii) the MluI/NotI fragment was 
subcloned into pTK1363 to generate the final construct, pTK1436 with a deletion of stem-
loop 1. The HIV-1 ∆ SL1,3,4 produced with the following cloning series: i) pTK1221 was 
used as a template for PCR around the entire plasmid wherein primers were designed to 
eliminate stem-loops 3 & 4, the region between the MluI/NotI sites was confirmed by 
sequencing to be correct with elimination of stem-loops 3 & 4, pTK1424; ii) pTK1424 was 
used as a template for PCR around the entire plasmid wherein primers were designed to 
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eliminate stem-loop 1, the region between the MluI/NotI sites was confirmed by sequencing 
to be correct with elimination of stem-loops 1, 3, & 4, pTK1429; iii) the MluI/NotI fragment 
was subcloned into pTK1363 to generate the final construct, pTK1437 with a deletion of 
stem-loops 1, 3, & 4. 
The packaging constructs supplying necessary structural/enzymatic proteins were 
4XCTE or NRF as described in chapter 2 methods. The Rev and VSV-G expression 
constructs are explained in chapter 2 methods.   
Cells, Viral Particle Production, and Concentration. All are described in chapter 2 
methods. Regarding experiments executed for packaging HIV-1 vector RNAs that were 
deleted of the entire canonical packaging signal (pTK1305); vector production for these 
experiments required cotransfection of 5g Tat expressing plasmid. In addition, the SODk0 
cells were used for experiments in which the absence of large T antigen was pertinent. These 
cells are derived from 293 cells, but lack the large T antigen, and are maintained in the same 
media as 293T cells, as described in chapter 2 methods.     
HIV-1 p24 Capsid Concentration. Details of this assay were described in chapter 2 
methods. 
MLV Reverse Transcriptase Assay. MLV reverse transcriptase activity was executed on 
vector particles (5 µl) harvested from the media by mixing with 25 µl of RT activity reagent 
(60mM Tris pH8, 0.6mM MnCl2, 90mM KCl, 0.125mg/ml Poly A [Roche], 6 µg/ml oligo 
dT16, 25mM DTT, 0.06% Triton X-100, and 0.25 mCi/ml 3H-TTP [MP Biomedicals]). After 
incubation for 1 hour at 37°C the entire volume was spotted onto DE81 anion exchange 
chromatography paper (Whatman), and placed into 5% Na2PO4 for 5 minutes at room 
temperature. The samples were washed at room temperature five times, for 5 minutes each, 
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with 5% Na2PO4 two times with water, and one time with 95% ethanol. The samples were 
dried, placed in scintillation fluid, and radioactivity was measured on a Beckman LS 6500 
scintillation counter. Values were recorded as CPM. Data used for titer normalization, and 
determining amount of viral particles for RNA isolation, are a mean of replicate samples.  
FACS Analysis. Details of this assay were described in chapter 2 methods.  
Luciferase Assays. Details of this assay were described in chapter 2 methods. 
RNA Isolation. RNA was isolated as described in chapter 2 methods. 
qRT-PCR. Quantitative RT-PCR was executed as described in chapter 2 methods. 
Additional primer-probe sets used to obtain data were directed to the large T antigen: LT-63 
For 5’-tgcaaggagtttcatcctga-3’, LT-63 Rev 5’-ggttgatgagcatattttactcca-3’, and probe #63 
(Roche Universal Probe Library). Primer-probe set used for HIV-1 vector data in figure 31 
were directed to the RRE cis element: RRE For 5’-agcatctgttgcaactcacagt-3’, RRE Rev 5’-
tttccacagccaggattctt-3’, and probe #148 (Roche Universal Probe Library).  
Northern Blot Analysis. Northern blots were executed as described in chapter 2 methods. 
However, the probe used in figure 24 was a BstEII fragment from pTK1440 generated to the 
5’ end of the vector RNA.  
Real Time qPCR. 293T cells were transduced with 1000ng p24 from concentrated HIV-1 
vector packaged into HIV-1 viral particles. Total cellular DNA was isolated at 24 hours after 
transduction of 293T cells. To collect total DNA transduced cells were lysed in a proteinase 
K solution (10 mM Tris pH 8, 10 mM EDTA pH 8, 0.5% SDS, 0.4 M NaCl, and 200 µg/ml 
proteinase K) for 48 hours at 55°C. Total DNA was extracted with v/v phenol (Invitrogen) 
and v/v phenol/chloroform/isoamyl alcohol (Invitrogen) and then treated with RNase A (20 
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µg; Fermentas) at 37°C for 2 hours. A second round of extractions was performed and total 
DNA was precipitated using standard ethanol precipitation.  
The relative levels of large T antigen cDNA were normalized for -globin levels. 
qPCR for -globin was described previously (100). The primer-probe set for large T antigen 
is as described above in qRT-PCR section. The relative levels were quantitated using the 2-∆Ct 
method as described in chapter 2 methods.   
 
Results 
The HIV-1 Rev/RRE system is required for cis elements from the 5’ UTR to mediate 
efficient RNA encapsidation into HIV-1 viral particles. Results in chapter 2 demonstrate 
that the Rev/RRE system may be part of the encapsidation mechanism. However, it is well 
established that encapsidation is primarily mediated through cis elements in the 5’ UTR, 
predominantly protein-RNA interactions of the nucleocapsid with , intermolecular 
RNA-RNA dimerization via stem-loop 1 of , and presumably intramolecular RNA-
RNA interactions (50, 118, 183, 214). The HIV-1 Rev/RRE, as well as the aforementioned 
protein-RNA and RNA-RNA interactions may comprise a bona fide packaging system that 
may be defined by the capacity to support efficient and specific encapsidation of a 
heterologous RNA into HIV-1 derived viral particles. To characterize the role of the 
Rev/RRE in the context of a packaging system that comprises the 5’ UTR cis elements we 
generated a series of heterologous MLV/HIV vectors (Fig.20A). The entire 5’ UTR was 
either independently incorporated into the heterologous MLV RNA (MLV/HIV RU5PS), or 
inserted in the context of the RRE (MLV/HIV RRE+RU5PS). A diagram of the 5’ UTR is 
depicted in Figure 20B.  Similar to vectors in the results section of chapter 2, heterologous 
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vector RNAs were packaged into viral particles generated from a helper system (Gag/Pol-4X 
CTE) that does not rely upon the Rev/RRE system for nuclear export of RNA, encoding the 
structural and enzymatic proteins (Fig. 20A). Since cis elements in the R and U5 regions 
have also been shown to impact encapsidation (37, 38, 81, 139), the 5’ UTR was also further 
separated into the R/U5 (MLV/HIV RRE+RU5) and  (MLV/HIV RRE+PS) in the context 
of the RRE (Fig. 20A). Each of the vectors was titered on 293T cells by scoring for GFP 
positive cells, and normalized to levels of p24 capsid protein.  
The complete contigent of cis elements from the 5’ UTR (MLV/HIV RU5PS) 
moderately enhanced titers (12 fold) independent of Rev, whereas in the context of the RRE 
(MLV/HIV RRE+RU5PS) Rev dramatically augmented titers (626 fold) compared to the 
basic MLV vector (Fig. 21A); an effect that was visually, and quantitatively, outstanding 
upon transduction of 293T cells with equivalent amounts of p24 capsid protein (Fig. 22A & 
B). Notably, titers of the MLV/HIV RRE+RU5PS vector were 1.07x107 TU/ml, which is in 
the 107-108 TU/ml range of those obtained with standard HIV-1 vectors prior to 
concentration; a comparison that was also observed after normalization to p24. These data 
indicate that the Rev/RRE system and 5’ UTR cis elements synergize to achieve the increase 
in vector titer. Furthermore, to confirm that GFP titers are a result of reverse transcription of 
heterologous MLV vector RNA by the HIV-1 reverse transcriptase, transduction of 293T 
cells was assessed by FACs analysis and fluorescence microscopy following treatment with 
the HIV-1 specific non-nucleoside RT inhibitor, etravirine (Fig. 23A). Etravirine specifically 
inhibited transduction of the MLV/HIV RRE+RU5PS vector packaged into HIV-1 viral 
particles, but did not inhibit transduction of the same vector packaged into MLV viral 
particles (Fig. 23A). As a positive control, a similar effect was observed upon transduction of 
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293T cells with a HIV-1 vector (Fig. 23B). Importantly, these data clearly indicate that GFP 
expression is not a consequence of pseudotransduction, but is dependent upon HIV-1 
directed reverse transcription of the RNA packaged into viral particles. Although Rev 
enhanced titers of the above mentioned vectors containing the RRE, cytoplasmic luciferase 
levels remained relatively similar, indirectly indicating that increased titers were probably not 
a consequence of increased nuclear export of vector RNA (Fig. 21B & C). The titers were a 
clear indication that a comprehensive HIV-1 packaging system may comprise the synergistic 
influences of the Rev/RRE system and cis elements from the 5’ UTR, as well as nucleocapsid 
protein. Considering this possibility, we sought to directly characterize the Rev impact on the 
encapsidation efficiency of heterologous RNAs, containing cis elements from the 5’ UTR, 
into HIV-1 viral particles. Quantitative RT-PCR was employed to quantify vector RNA in 
viral particles, and in producer cells.  
Surprisingly, as shown in Fig. 24A and C, in contrast to the increase in vector titers 
(Fig. 21A), incorporation of the 5’ UTR cis elements into the heterologous MLV vector 
(MLV/HIV RU5PS) did not enhance RNA encapsidation in either the absence or presence of 
Rev. Most importantly, in the context of the RRE (MLV/HIV RRE+RU5PS), however, the 5’ 
UTR cis elements exhibited a 22 fold increase in heterologous vector RNA encapsidation 
into HIV-1 viral particles in the presence of Rev (Fig. 24C). Rev-dependent encapsidation 
was clearly a consequence of enhanced RNA packaged into viral particles (Fig. 24A), not 
increases in cytoplasmic RNA (Fig. 24B). These data demonstrate that the Rev-RRE 
interaction may initially be required to render the RNA amenable for subsequent steps in the 
encapsidation mechanism that conventionally involve cis elements from the 5’ UTR, such as 
interaction between nucleocapsid and the canonical packaging signal. The Rev-dependent 
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enhancement of MLV/HIV RRE+RU5PS vector RNA encapsidation obtained by qRT-PCR 
was bolstered by northern blot analysis showing strong Rev-dependent increases in levels of 
RNA encapsidated into HIV-1 viral particles, despite nominal changes in cytoplasmic vector 
RNA levels (Fig. 24D). Notably, within the cytoplasmic RNAs our probe detects a dominant 
smaller species of vector RNA (termed ‘partial vector RNA’). Although the full-length 
vector RNA is present at lower levels in the cytoplasm, the Rev/RRE system and 5’ UTR cis 
elements impart the ability of the full-length vector RNA to out compete the more abundant 
‘partial vector RNA’ species for packaging into viral particles (Fig. 24D); demonstrating the 
specificity that these components confer upon a RNA for encapsidation.  
Further separation of the 5’ UTR cis elements into the canonical packaging signal 
(MLV/HIV RRE+PS) or R/U5 (MLV/HIV RRE+RU5) did not approach titer/luciferase (Fig. 
25A), or RNA encapsidation (Fig. 25B) levels observed with the vector containing the entire 
5’ UTR and RRE (22 fold, Fig. 24), demonstrating the significance of retaining a fully intact 
5’ UTR. Moreover, the enhanced encapsidation effect of the MLV/HIV RRE+RU5PS 
chimeric vector is dependent upon the complete contingent of 5’ UTR cis elements, since 
dissection of the 5’ UTR cis elements into the canonical packaging signal (MLV/HIV 
RRE+PS) or RU5 (MLV/HIV RRE+RU5) did not result in Rev-dependent increases in 
encapsidation efficiency beyond the 6 fold increase obtained with the MLV/HIV RRE vector 
(Fig. 25B).  
Overall, these data demonstrate that: i) Rev is required for efficient encapsidation of a 
heterologous RNA that is subsequently mediated by RNA-RNA and RNA-protein 
interactions through cis elements in the 5’ UTR; ii) the complete contingent of cis elements 
from the 5’ UTR (R, U5, PBS, and ) are required for encapsidation of a heterologous RNA; 
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iii) cis elements from the 5’ UTR exhibit effects that can enhance heterologous vector titer 
without increasing RNA encapsidation; and iv) a packaging system competent for 
heterologous RNA encapsidation should minimally include the Rev/RRE system, all cis 
elements of the 5’ UTR, and Gag polyprotein. 
 
Mutation of cis elements in the canonical HIV-1 packaging signal mitigates 
encapsidation efficiency, but not Rev/RRE-mediated encapsidation. Data from the gain-
of-function studies described above demonstrate that there are a number of components that 
must function together for a HIV-1 packaging system to achieve efficient encapsidation of a 
heterologous RNA into HIV-1 viral particles. In these studies the innate context of the HIV-1 
cis elements was altered, therefore to bolster these findings mutagenesis and functional 
analysis were used to examine the contribution of HIV-1 cis elements from the 5’ UTR, to 
RNA encapsidation. A previous study demonstrated that the HIV-1 Rev can enhance 
encapsidation of a HIV-1 vector into HIV-1 viral particles (19). In consonance with this 
study, results from three different methods, utilized here, show that HIV-1 Rev can indeed 
augment HIV-1 vector RNA encapsidation (Figs. 26 and 28). A standard HIV-1 vector 
system was used in which the luciferase gene was incorporated upstream of the endogenous 
CMV-GFP transgene cassette (Fig. 26A), therefore luciferase expression could be used as an 
indirect measure of full-length vector RNA in the cytoplasm. Rev enhanced titers of 
normalized vectors 40 fold (Fig. 26B), which were closely reflected in the RNA 
encapsidation levels as shown by northern blot analysis (Fig. 26C), and quantitated by the 
ratio of titer/cytoplasmic RNA exhibiting a 20 fold increase (Fig. 26D). The approximate 2 
fold increase in cytoplasmic RNA revealed by northern blot was previously observed by 
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another lab using qRT-PCR (19). With the capacity to measure Rev-mediated encapsidation 
of an HIV-1 vector, mutagenesis could be used to examine the RNA packaging contribution 
of cis elements from the 5’ UTR.  
 The influence of Rev on encapsidation of a HIV-1 vector with a deletion of the entire 
canonical packaging signal was initially investigated (Fig. 27A). However, it was quickly 
recognized that in the absence of the HIV-1 splice donor in stem-loop 2 (deleted with the rest 
of the canonical packaging signal) the HIV-1 Tat protein must be coexpressed to simply 
maintain expression of HIV-1 vector RNA from a CMV promoter. These results were in 
agreement with a previous study demonstrating that CMV-driven expression from a proviral 
clone is rendered Tat-dependent in the absence of the major splice donor (17). Therefore, 
experiments for figure 27 were executed in the presence of ectopically expressed HIV-1 Tat 
protein. Nevertheless, Rev augmented titers 6 fold (Fig. 27B), and correspondingly enhanced 
encapsidation as revealed by northern blot analysis (Fig. 27C). Indirect measuring of 
encapsidation by ratio of titer/cytoplasmic RNA (quantitated by densitometry from northern) 
exhibited an 11 fold increase in Rev-mediated encapsidation (Fig. 27D). In line with studies 
in chapter 2, and those described above, the Rev/RRE system can enhance encapsidation in 
the absence of cis elements in the canonical packaging signal. The requirement for Tat-
dependent transcription of the vector RNA introduced an additional variable into the system 
that could be avoided by retaining stem-loop 2 with the splice donor sequence, as shown 
previously (117). HIV-1 vectors deleted of stem-loop 1 (contains dimerization domain) and 
the combination of stem-loop 1, 3, & 4 were generated, and assessed for encapsidation 
relative to a standard HIV-1 vector containing all cis elements (Fig. 28A). Deletion of stem-
loop 1 resulted in a 5 fold decrease in titers (Fig. 28B) and 3 fold decrease in the 
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titer/luciferase ratio (Fig. 28C). More dramatic, however, was the composite deletion in stem-
loops 1, 3, & 4 resulting in a 18 fold decrease in both titer (Fig. 28B) and titer/luciferase ratio 
(Fig. 28C). The RNA encapsidation efficiency exhibited a correlative trend in that deletion of 
multiple cis elements (stem-loops 1,3, & 4) in the canonical packaging signal resulted in a 4 
fold decrease in the encapsidation efficiency in the presence of the Rev/RRE system (Fig. 
28D). Despite deletion of cis elements in the canonical packaging signal yielding reduced 
encapsidation efficiency, the Rev/RRE system retained the capacity to augment RNA 
encapsidation for each vector RNA. These results bolster previous findings in that the 
Rev/RRE system can positively influence RNA encapsidation in the absence of canonical cis 
packaging elements. These results also confirm that a complete HIV-1 packaging system 
requires the Rev/RRE system, cis elements in the 5’ UTR, and Gag polyprotein to achieve 
efficient and specific encapsidation.  
 
The HIV-1 Rev/RRE and 5’ UTR cis elements determine specificity for encapsidating 
RNA into HIV-1 viral particles. Manipulating the HIV-1 packaging system, described 
above, to efficiently encapsidate a foreign RNA into HIV-1 viral particles may be a general 
biological phenomenon that can be exploited for RNA encapsidation into retroviral particles 
that are not derived from HIV-1. The heterologous MLV RNA vector system was used to 
examine if the HIV-1 Rev/RRE and 5’ UTR cis elements can mediate packaging of RNA 
into MLV viral particles, thereby resulting in a loss of specificity for HIV-1 viral particles. 
Retention of the MLV packaging signal bestows dual functionality onto the MLV/HIV 
RRE+RU5PS chimeric vector RNA to also allow for packaging into MLV derived viral 
particles (Fig. 29A). Accordingly, this vector was used to examine if the HIV-1 Rev/RRE 
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and 5’ UTR cis elements alter the encapsidation efficiency into MLV viral particles. Direct 
comparison of the chimeric vector to the basic MLV vector revealed that there was little 
impact of the Rev/RRE system on normalized titers or luciferase levels (Fig. 29C and D). In 
fact, transduction with equivalent units of MLV reverse transcriptase resulted in a reduced 
number of transduced cells, compared to the basic MLV vector (Fig. 29B). Moreover, the 
titers were slightly lower than those of the basic MLV vector, resulting in decreased levels 
after normalization to luciferase (Fig. 29E). In contrast to HIV-1 viral particles, these data 
indicated that the HIV-1 Rev/RRE and 5’ UTR cis elements do not influence the packaging 
of RNA into MLV viral particles. 
 Investigation of the encapsidation efficiency into MLV viral particles exposed a 
picture similar to that obtained with the titer/luciferase assays. There was no effect of the 
Rev/RRE and 5’ UTR cis elements on levels of vector RNA in MLV viral particles, or in the 
producer cell cytoplasm (Fig. 30A and B). Consequently, these HIV-1 components also had 
no effect on RNA encapsidation into MLV viral particles (Fig. 30C). These results imply that 
the Rev/RRE system and 5’ UTR cis elements confer specificity onto the heterologous MLV 
vector RNA for encapsidation into HIV-1 viral particles, but provide no advantage for 
encapsidation into MLV viral particles. Using a single RNA system with different packaging 
specificities we were able to demonstrate that HIV-1 and MLV commandeer distinct 
mechanisms to select vector RNAs from the milieu of host cell RNAs to promote RNA 
encapsidation into nascent viral particles.  
 The promiscuous packaging of host cell RNAs into HIV-1 viral particles (188) allows 
for particles to be generated in the absence of a packaging competent viral genomic RNA 
(28). Therefore, there is a need for the virus to have a packaging system that can 
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preferentially package the viruses own genome to maintain viral fitness. Since HIV-1 viral 
particles exhibit a limited capacity for the amount of RNA packaged into viral particles, it 
could be anticipated that a competent packaging system could confer enhanced packaging of 
a specific vector/viral RNA while concomitantly excluding the packaging of nonspecific 
cellular RNA. HIV-1 derived lentiviral vectors are commonly generated in 293T human 
embryonic kidney cells. 293T cells overexpress the SV40 large T antigen, which is also a 
well recognized tumorigenic protein. The specificity of packaging a HIV-1 derived vector 
was compared to that of the large T antigen. HIV-1 vectors were generated in 293T producer 
cells in the absence and presence of HIV-1 Rev protein. Vector RNA was harvested from 
equivalent levels of viral particles and assessed by qRT-PCR. Large T antigen RNA was 
readily detectable as a packaged RNA in viral particles harvested from the media (Fig. 31A), 
and in concentrated viral particles (Fig. 31C). Packaging of large T antigen RNA exhibited 
an inverse relationship with packaging of vector RNA (Figs. 31A and B). In the presence of 
Rev there was a 17 fold decrease in large T antigen RNA (Fig. 31A), whereas HIV-1 viral 
vector RNA was dramatically increased (Fig. 31B). These data demonstrate that the 
specificity conferred upon the vector RNA by the Rev/RRE system can mitigate the 
nonspecific packaging of producer cell RNAs. Nonetheless, this does not eliminate the 
possibility of transferring large T antigen RNA to naïve host cells. Eliminating the potential 
to package large T antigen RNA may require changing the vector producer cell line. The 
SODk0 cell line, developed in our lab (44), is derived from 293 cells (i.e. no large T antigen). 
HIV-1 vectors generated in this cell line do not have large T antigen (Fig. 31C), albeit titers 
may be diminished up to 20 fold. To ascertain if packaged large T antigen RNA can be 
reverse transcribed following transduction total DNA was isolated from SODk0 cells 
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transduced in the absence or presence of the reverse transcriptase inhibitor, etravirine (Fig. 
31D). Large T antigen cDNA was detected only in the absence of etravirine, an indication 
that the large T antigen RNA is reverse transcribed into cDNA. Therefore, the potential exists 
for retroviral vectors produced in 293T cells to transfer large T antigen to host cells targeted 
for gene therapy protocols.  
 
Discussion 
The objective of these studies was to understand how the well characterized cis 
elements in the 5’ UTR, and the Rev/RRE system, function in a concerted manner to achieve 
efficient and specific RNA encapsidation into HIV-1 viral particles. Most importantly, the 
HIV-1 Rev/RRE system was required for cis elements in the 5’ UTR to mediate efficient 
encapsidation into HIV-1 viral particles (Figs 20-24). These studies were bolstered by the 
finding that the canonical packaging signal, in the more natural setting of a HIV-1 vector 
RNA, was necessary to retain efficient encapsidation, as might be expected; however, the 
Rev/RRE system preserved the capacity to enhance encapsidation in the absence of the 
canonical packaging signal (Figs. 26-28). Furthermore, prior mutagenesis studies have 
implicated 5’ UTR cis determinants adjacent to the canonical packaging signal as important 
for efficient RNA encapsidation through loss of function analysis (37, 38, 81, 139). Data 
presented here expand this view by demonstrating that the 5’ UTR cis elements are not 
separable to achieve efficient encapsidation of heterologous RNAs (Fig. 25); quite possibly 
indicating a requirement for intramolecular interactions between cis elements in the R, U5, 
and PBS, with those in the canonical packaging signal, as previously indicated (50, 214). 
These studies are an expansion of the conclusion reached in chapter 2 and coalesce previous 
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work in the field demonstrating that a complete packaging system is comprised of the 
Rev/RRE, cis elements in the 5’ UTR, and Gag polyprotein. 
Lentiviruses may require a sophisticated encapsidation mechanism to ensure that full-
length viral RNAs transcribed in the nucleus can effectively be packaged into nascent viral 
particles at the plasma membrane. Conceivably, the Rev/RRE may impact the cytoplasmic 
distribution of RNA without direct involvement in packaging RNA into viral particles at the 
plasma membrane, a view consistent with the inability to detect HIV-1 Rev in viral particles 
(71). Transferring viral genomic RNA to subcellular sites where the Gag polyprotein is 
available for interaction with the canonical packaging signal would allow for subsequent 
encapsidation by Gag, independent of Rev. As described in chapter 2 Rev is able to recruit a 
number of cellular proteins to the RNA, some of which can alter the subcellular location of 
Rev (47, 56, 80, 147, 180, 189, 196, 222, 223). Additionally, the Rev/RRE system may alter 
the conformation of the 5’ UTR creating a context that is more receptive to an interaction 
with HIV-1 Gag, and subsequent packaging. Recent in vitro evidence indicates that HIV-1 
Rev can influence translation in a concentration dependent manner that does not rely upon 
the RRE, but rather an interaction between Rev and a cis determinant in stem-loop 1 of the 5’ 
UTR (70). At moderate concentrations Rev enhanced translation, but at high concentrations 
translation was inhibited (70). The same interaction was also implicated in RNA 
encapsidation (67), therefore it is plausible that Rev may promote RNA packaging at high 
concentrations, possibly acting as a “switch” between translation and encapsidation. 
Nonetheless, experiments supporting such a mechanism are still required. These studies 
indicate that a Rev mechanism may also depend upon recognition of cis determinants in the 
canonical packaging signal.  
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Understanding that the 5’ UTR is central to the encapsidation mechanism studies 
were executed to examine the contribution of various stem-loops in the canonical packaging 
signal to encapsidation of a HIV-1 vector RNA into HIV-1 viral particles. In agreement with 
studies described in chapter 2, the Rev/RRE system was able to mediate encapsidation upon 
deletion of the entire canonical packaging signal (stem-loops 1-4) from an HIV-1 derived 
vector (Fig. 27). However, as previously demonstrated (17) vector RNA expression was 
rendered Tat-dependent in the absence of the major splice donor; therefore individual stem-
loops were deleted, while maintaining stem-loop 2 with the splice donor.  Deletions of stem-
loop 1 and stem-loops 1, 3, 4 resulted in decreased RNA efficiency of RNA encapsidation 
compared to a fully competent packaging signal (Fig. 28). This is in agreement with a 
previous report demonstrating that deletion of various stem-loops in  impairs RNA 
packaging (89, 117), but does not eliminate packaging and subsequent transduction. 
Accordingly, mutations in the packaging signal can alter specificity, favoring increased 
packaging of non-specific RNAs into HIV-1 viral particles (89).  Furthermore, as 
demonstrated here mutations in the stem-loops did not eliminate the capacity of the Rev/RRE 
system to augment encapsidation of each vector RNA with a mutation in the canonical 
packaging signal. Discerning how the Rev/RRE system influences specific and efficient 
recognition of cis elements in the 5’ UTR by the Gag polyprotein will be an important focus 
of future studies.  
The requirement for the HIV-1 Rev/RRE system in the encapsidation mechanism 
implies that the Rev/RRE may confer specificity onto HIV-1 RNA during the initial steps of 
the mechanism when Rev interacts with RNA in the nucleus. Such a mechanism might 
ensure early selection of viral RNA from the milieu of host cell RNAs, concomitant with 
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transcription in the nucleus. Our data support a role for the Rev/RRE and 5’ UTR cis 
elements in conferring specificity of RNA packaged into HIV-1 viral particles (Figs. 24 & 
29-31). The HIV-1 Rev/RRE did not confer an encapsidation advantage of the heterologous 
RNA into MLV viral particles (Figs. 29 & 30); consistent with the notion that HIV-1 and 
MLV utilize distinct mechanisms to encapsidate viral RNA (53). In the absence of the HIV-1 
Rev/RRE, MLV vector RNA exhibited no added specificity upon packaging into HIV-1 viral 
particles, in agreement with a study showing that a MLV vector RNA was not enriched in 
HIV-1 viral particles relative to cellular mRNAs (188). Nonspecific (yet measurable) 
packaging of MLV RNA raise the concern that stable HIV-1 packaging cell lines (i.e. for 
lentiviral vector production), generated by introducing HIV-1 gag and pol genes with MLV 
vectors (92, 204), have the potential to package, transfer, reverse transcribe, and recombine 
HIV-1 gag and pol genes in recipient cells. Also of concern regarding the use of lentiviral 
vectors in gene therapy protocols is the potential for transfer of nonspecifically packaged 
RNAs derived from vector producer cells.  
Nonspecific packaging of cellular RNAs during generation of nascent HIV-1 viral 
particles has been well documented (152, 162, 188). Importantly, packaged cellular RNAs 
have been shown to be reverse transcribed, and recombine with the packaged viral RNA 
during reverse transcription in a transduced host cell; thereby, potentially being integrated 
and expressed in a naïve host cell (78, 123, 151). With regard to retroviral vector production, 
293T cells were identified to be most amenable for this process through ectopic expression of 
vector particle components (chapter 1, Fig. 5). Most notably 293T cells overexpress the large 
T antigen, which is well recognized to transform cells upon overexpression. Data presented 
here demonstrate that large T antigen RNA is readily packaged into HIV-1 derived viral 
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particles and can be reverse transcribed in naïve host cells (Fig. 31); however, this concern 
can be eased by utilizing cells that do not overexpress large T antigen (Fig. 31). The potential 
for a retrovirus or retroviral vector in this case, to acquire a host cell oncogene, and transfer 
that oncogene to naïve host cells is not an unexpected possibility. The well characterized 
avian Rous sarcoma virus is an oncoretrovirus that has acquired the cellular src-oncogene 
with full capacity to transfer the functional oncogene to naïve host cells (202), and induce 
tumor formation. In addition to the potential for transferring an RNA encoding a tumorigenic 
protein, these data demonstrate that the specificity conferred upon the vector RNA by the 
Rev/RRE system can mitigate the nonspecific packaging of producer cell RNAs (i.e. Rev 
increases packaging of HIV-1 vector RNA while concomitantly reducing nonspecific large T 
antigen RNA).  
Although our system revealed an essential role for the Rev/RRE system in efficient 
and specific RNA encapsidation into HIV-1 viral particles, a discrepancy was observed 
between the efficiency of RNA encapsidation (Fig. 24) and p24 normalized titers (Fig. 21) 
for heterologous vector RNAs harboring the entire contingent of cis elements from the 5’ 
UTR. The larger increase in titers indicates that cis elements from the 5’ UTR may have 
pleiotropic effects that can impact different stages of the viral life cycle (i.e. reverse 
transcription during transduction).  Inclusion of the HIV-1 primer binding site (PBS) and 
flanking 5’ UTR sequences might accommodate more efficient reverse transcription and 
transduction of the heterologous RNA, yielding higher titer in the form of GFP positive cells. 
Efficient reverse transcription from the HIV-1 PBS is accomplished by the specific 
packaging of tRNALys primers into HIV-1 viral particles (1). Furthermore, the tRNAPro 
primers may also promote reverse transcription at a low efficiency from the MLV PBS 
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(normally primed by tRNAPro) in the heterologous MLV vectors that lack a HIV-1 PBS; a 
rationalization consistent with a study showing that, although impaired, HIV-1 replication 
was retained if the HIV-1 PBS was altered to that of MLV (51).  
Using a heterologous MLV RNA system we were able to isolate the encapsidation 
effects of different HIV-1 cis and trans components. Most importantly, however, these 
studies revealed the concerted effects of multiple HIV-1 components through gain-of-
function studies. Conventional loss-of-function studies have implicated several of the 
aforementioned HIV-1 cis and trans components in the encapsidation mechanism, but do not 
reveal the interdependence of these components. These data demonstrate that the HIV-1 
Rev/RRE system is essential for cis elements in the 5’ UTR (including the canonical 
packaging signal) to mediate efficient and specific encapsidation of a heterologous RNA into 
HIV-1 viral particles. Therefore, in addition to its traditional role in nuclear export, the 
Rev/RRE system may have a critical role in making cis elements in the 5’ UTR of HIV-1 
RNA more amenable to RNA-RNA and RNA-protein interactions in the cytoplasm, which 
support subsequent RNA encapsidation. Nonetheless, the combined effects of the Rev/RRE 
system and 5’ UTR cis elements are not limited to encapsidation since these components can 
synergize to yield transduction efficiencies that approach those of standard HIV-1 vectors. 
Heterologous RNAs packaged into HIV-1 viral particles exhibit unique transduction 
properties that could be beneficial for gene therapy protocols, and provide a model system to 
study the molecular virology of retroviruses encountered at different stages of early infection. 
Studies investigating unique transduction properties associated with heterologously packaged 
RNAs are described in chapter 4.   
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Figure 20. Incorporation of HIV-1 5’UTR cis elements into MLV/HIV chimeric vectors. 
A. Full-length MLV/HIV chimeric vector RNAs are expressed from a CMV 
(cytomegalovirus) promoter in transfected 293T cells. MLV and HIV cis elements can be 
distinguished by black underscore. Chimeric vector names are represented as MLV/HIV 
followed by corresponding HIV cis elements incorporated: RRE (Rev Response Element), R 
(repeat), U5 (unique region 5), PS (packaging signal comprised of  [canonical packaging 
signal and into 5’ Gag region]), cPPT (central polypurine tract), PBS (primer binding site). 
Also incorporated are the WPRE (woodchuck hepatitis virus post-transcriptional regulatory 
element), FLuc (firefly luciferase gene), and GFP (green fluorescent protein gene). HIV-1 
Gag-Pol 4X CTE helper construct was used to express structural and enzymatic proteins to 
generate viral particles independent of HIV-1 Rev protein. B. RNA cis elements in the HIV-1 
5’ UTR. TAR and pA comprise most of the R region. Further details are described in figure 
7.   
Adapted by Permission from American Society for Microbiology. Clever, J.L., Miranda Jr., D., & Parslow, 
T.G. RNA Structure and Packaging Signals in the 5’ Leader Region of the Human Immunodeficiency Virus 
Genome. Journal of Virology. 2002. 76(23). 12381-12387. 
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Figure 21. HIV-1 cis elements in the 5’UTR and Rev/RRE system augment vector titers, 
but do not influence cytoplasmic luciferase levels. A. Vector titers normalized to p24 are 
shown in the absence (white bars) and presence (black bars) of Rev. B. Luciferase levels 
normalized to total protein are shown for each vector. C. Titers expressed as a ratio to 
luciferase are shown as arbitrary units (AU). In all graphs the influence of adding HIV-1 cis 
elements to the MLV vector is indicated by fold increases in the presence of Rev relative to 
the standard MLV vector. Error for all bar graphs is expressed as ±S.D. All experiments were 
performed in triplicate. 
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Figure 22. Transduction of 293T cells with chimeric MLV/HIV vectors packaged into 
HIV-1 viral particles. A and B. 293T cells were transduced with equivalent amounts of p24 
capsid protein (50 ng), as determined for each of the indicated chimeric vectors. The 
influence of the HIV-1 Rev/RRE system, and 5’ UTR cis elements, on transduction was 
assessed by fluorescence microscopy (A) and FACscan analysis (B) at 7 days post-
transduction. C. The capacity of the MLV/HIV RRE+RU5PS vector to be stably maintained 
after 4 cell passages was examined by FACscan analysis. The percent GFP positive cells are 
indicated for each FACscan and 293T negative control (NC) cells are shown. 
 
.  
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Figure 23. Transduction of chimeric MLV/HIV RRE+RU5PS and HIV-1 vectors is 
dependent on reverse transcription. 293T cells were transduced in the absence (No RT 
Inhibitor), or presence (+RT Inhibitor), of the HIV-1 specific non-nucleoside reverse 
transcriptase inhibitor, etravirine (100 nM). A. 293T cells transduced with MLV/HIV RRE + 
RU5PS were assessed by fluorescence microscopy and FACscan analysis. B. 293T cells 
transduced with a HIV-1 vector were assessed by fluorescence microscopy.  
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Figure 24. HIV-1 cis elements in the 5’UTR and Rev/RRE system cooperatively 
enhance RNA encapsidation into HIV-1 viral particles. A. Vector RNA was measured by 
qRT-PCR and expressed in arbitrary units (AU). RNA levels for all graphs are shown in the 
absence (white bars) and presence (black bars) of Rev. The influence of adding HIV-1 cis 
elements to the MLV vector is indicated by fold increases in the presence of Rev relative to 
the standard MLV vector. B. Cytoplasmic RNA was isolated from vector producer 293T 
cells at the time of vector harvesting. Relative RNA levels were obtained and recorded as 
done for vector RNA in part A. C. Efficiency of encapsidating RNA into HIV-1 viral 
particles is expressed as a ratio of vector RNA in viral particles to cytoplasmic RNA 
available for encapsidation. Relative levels are expressed like vector RNA in part A. D. 
Northern blot analysis of cytoplasmic and vector RNA isolated from MLV/HIV RU5PS and 
MLV/HIV RRE+RU5PS in the absence (-) and presence (+) of Rev. Vector length RNA 
species were detected with a probe to a region in the 5’ end of the vector, as well as an 
additional RNA species (labeled ‘partial vector RNA’). Cytoplasmic and vector RNAs are 
shown at different exposures of the same blot. Last lane (far right) is a shorter exposure of 
adjacent left lane. Error for all bar graphs is expressed as ±S.D. All experiments were 
performed in triplicate. 
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Figure 25. Cis elements in the HIV-1 5’ UTR are not separable. A. Titers expressed as a 
ratio to luciferase are shown in the absence (white bars) and presence (black bars) of Rev, 
and expressed as arbitrary units (AU). B. Efficiency of encapsidating RNA into HIV-1 viral 
particles is expressed as a ratio of vector RNA in viral particles to cytoplasmic RNA 
available for encapsidation. Encapsidation efficiency is expressed as arbitrary units (AU). In 
all graphs the influence of adding HIV-1 cis elements to the MLV vector is indicated by fold 
increases in the presence of Rev relative to the standard MLV vector. Error for all bar graphs 
is expressed as ±S.D. All experiments were performed in triplicate. 
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Figure 26. Rev/RRE system augments encapsidation of HIV-1 vector RNA into HIV-1 
viral particles. A. Viral particles were produced in 293T cells packaging a standard HIV-1 
vector into HIV-1 viral particles generated from the Gag/Pol 4X CTE packaging construct. 
B. Vector titers normalized to p24 are shown in the absence and presence of Rev. C. 
Northern blot analysis of cytoplasmic (CRNA) and vector RNA (VRNA) isolated from HIV-
1 vector in the absence (-) and presence (+) of Rev. Vector length RNA species were 
detected with a probe to the GFP in the 3’ end of the vector, as well as an additional RNA 
species (labeled ‘GFP RNA’). D. Indirect encapsidation efficiency is represented as a ratio of 
titers to cytoplasmic RNA, which was quantitated from the northern blot. The ratio is 
expressed in arbitrary units (AU). Error (were indicated) for bar graphs is expressed as ±S.D. 
92 
 
 
 
Figure 27. The HIV-1 Rev/RRE system augments encapsidation of a HIV-1 derived 
vector lacking the entire canonical packaging signal. A. HIV-1 ∆  is a standard HIV-1 
vector deleted of the entire canonical packaging signal (stem-loops 1-4). B. Titers expressed 
as a ratio to luciferase are shown in the absence and presence of Rev, and expressed as 
arbitrary units (AU). C. Northern blot analysis of cytoplasmic (CRNA) and vector RNA 
(VRNA) isolated from HIV-1 vector in the absence (-) and presence (+) of Rev. Vector 
length RNA species were detected with a probe to the GFP in the 3’ end of the vector, as well 
as an additional RNA species (labeled ‘GFP RNA’). D. Indirect encapsidation efficiency is 
represented as a ratio of titers to cytoplasmic RNA, which was quantitated from the northern 
blot. The ratio is expressed in arbitrary units (AU). 
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Figure 28. Stem-loop deletions in the canonical HIV-1 packaging signal exhibit reduced 
encapsidation efficiency. A. HIV-1 derived vectors with no deletions (HIV-1), deletion of 
stem-loop 1 in  (HIV-1 ∆SL1), and deletion of stem-loops 1, 3, 4 in  (HIV-1 ∆SL 1, 3, 4). 
B. Vector titers normalized to p24 are shown in the absence and presence of Rev. C. Titers 
expressed as a ratio to luciferase are shown in the absence and presence of Rev, and 
expressed as arbitrary units (AU). D. Efficiency of encapsidating RNA into HIV-1 viral 
particles is expressed as a ratio of vector RNA in viral particles to cytoplasmic RNA 
available for encapsidation. Encapsidation efficiency was determined by qRT-PCR and is 
expressed as arbitrary units (AU). In all graphs the influence of deleting HIV-1 stem-loops 
from the canonical packaging signal of the HIV-1 vector is indicated by fold increases in the 
presence of Rev relative to the standard HIV-1 vector. Error (were indicated) for bar graphs 
is expressed as ±S.D. 
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Figure 29. HIV-1 Rev/RRE and cis elements in the 5’UTR do not influence vector titers 
after packaging into MLV viral particles. A. The standard MLV vector and the MLV/HIV 
RRE + RU5PS chimeric vector RNAs (containing all the HIV-1 5’ UTR cis elements), were 
assessed for encapsidation into MLV derived viral particles produced in 293T cells with a 
MLV Gag-Pol helper construct. B. 293T cells were transduced with equivalent amounts of 
RT units (6x105 CPM), as determined for each of the indicated chimeric vectors. The 
influence of the HIV-1 Rev/RRE system, and 5’ UTR cis elements, on transduction was 
assessed by FACscan analysis at 7 days post-transduction. The percent GFP positive cells are 
indicated for each FACscan. C. Titers of MLV/HIV chimeric vectors were obtained by 
scoring for GFP positive cells following transduction of 293T cells. Titers are expressed as 
transducing units (TU) normalized to the amount of RT units (counts per minute [CPM]). D. 
Normalized luciferase levels were determined in transfected 293T producer cells. Luciferase 
levels were normalized to total cell protein. E. Titers (part A) expressed as a ratio to levels of 
luciferase (part B) shown in arbitrary units (AU). All experiments were executed in the 
absence (white bars) and presence (black bars) of Rev. Error for all bar graphs is expressed 
as ±S.D.   
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Figure 30. HIV-1 Rev/RRE and cis elements in the 5’ UTR do not augment RNA 
encapsidation into MLV viral particles. A. Vector RNA packaged into MLV derived viral 
particles was isolated from equivalent amounts of RT units in the media of 293T producer 
cells. RNA levels were measured by qRT-PCR and are expressed as arbitrary units (AU). 
RNA levels are shown in the absence (white bars) and presence (black bars) of Rev. B. 
Cytoplasmic RNA was isolated from vector producer cells coincident with harvesting vector 
particles. Relative levels are expressed similar to vector RNA in part A. C. Efficiency of 
encapsidating RNA into MLV viral particles is expressed as a ratio of vector RNA in viral 
particles to cytoplasmic RNA available for encapsidation. Error for all bar graphs is 
expressed as ±S.D.  
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Figure 31. The Rev/RRE system confers specific packaging of HIV-1 vector RNA into 
HIV-1 viral particles compared to cellular RNA from 293T producer cells. A. RNA 
packaged into HIV-1 viral particles (vector and cellular) was isolated from equivalent 
amounts of p24 in the media of 293T producer cells. RNA levels were measured by qRT-
PCR. RNA levels for Large T antigen are shown in the absence and presence of Rev. B. 
Examining the same viral particles as those in part A vector RNA levels were measured by 
qRT-PCR in the absence and presence of Rev. C. RNA packaged into HIV-1 viral particles 
(vector and cellular) was isolated from equivalent amounts of p24 as determined from 
concentrated vector particles. Vector particles were produced and concentrated from 293T 
cells, or SODk0 cells. Large T antigen RNA was measured by qRT-PCR (detection was at 
29-30 Ct). D. HIV-1 vector was packaged into HIV-1 viral particles in the presence of Rev. 
293T cells were transduced with equivalent amounts of p24 in the absence or presence of the 
HIV-1 specific reverse transcriptase inhibitor, etravirine (100nM). Total DNA was harvested 
at 24 hours post-transduction. Relative large T antigen cDNA levels were measured by 
qPCR, and normalized to -globin levels (detection was at 37-38 Ct). All data are expressed 
as arbitrary units (AU). N/D respresents no detectable level of RNA as determined by Ct 
values out to 40 cycles.  
Chapter 4 
UNIQUE TRANSDUCTION PROPERTIES OF HETEROLOGOUS CHIMERIC VECTOR 
RNAs DELIVERED BY HIV-1 VIRAL PARTICLES1 
 
 Introduction 
Work presented in chapters 2 and 3 demonstrate that the Rev/RRE system can 
enhance encapsidation of RNA derived from MLV, FIV, and EIAV retroviruses, into HIV-1 
derived viral particles. The combination of the Rev/RRE system and cis elements from the 5’ 
UTR synergistically augmented heterologous MLV vector titers yielding transduction 
efficiencies that approach those of standard HIV-1 vectors. Additionally, the heterologous 
MLV vector was subject to inhibition by a HIV-1 specific reverse transcriptase inhibitor, 
demonstrating that transduction was dependent on reverse transcription by the HIV-1 reverse 
transcriptase. In fact, all heterologous-derived vector RNAs (MLV, EIAV, & FIV) were 
competent for transduction of host cells mediated by HIV-1 structural and enzymatic 
proteins, indicating that these systems may also serve as a model system to investigate the 
functional contributions of cis elements and trans factors that influence host cell 
transduction. Moreover, data in chapter 3 indicate that the chimeric MLV/HIV vectors do not 
integrate following delivery with HIV-1 derived viral particles (Fig. 22). These results 
signify that the chimeric vectors can deliver a transgene as an episomal (nonintegrating) 
lentiviral vector, with potential for use in gene therapy protocols.  
                                                 
1 A portion of the work in this chapter was published by Adam Cockrell, Henriette van Praag, Nicholas 
Santistevan, Hong Ma, and Tal Kafri, titled:The HIV-1 Rev/RRE system is required for HIV-1 5’ UTR cis 
elements to augment encapsidation of heterologous RNA into HIV-1 viral particles (45). 
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In the last decade the use of HIV-1 vector episomes for therapeutic gene delivery has 
garnered much attention as a means to improve retroviral vector safety by reducing the 
potential for genotoxicity arising from an unintended event of vector integration (11, 210). 
Early clinical trials, employing integration competent simple retroviral vectors delivered by 
MLV viral particles, revealed the potential to successfully correct children with the genetic 
SCID-X1 disease; however, the development of T cell leukemia in 3 of 10 patients, revealed 
genotoxicity effects associated with simple retroviral vector integration (75, 76, 157). 
Integration competent HIV-1 derived vectors were pursued as a safer alternative for clinical 
trials. Two recent clinical studies showed benefit to patients receiving therapeutic transgenes 
delivered by HIV-1 vectors (29, 30). However, clinical follow-up in one of the studies 
revealed a myeloid clonal dominance (30), revealing the potential for HIV-1 vector-mediated 
genotoxic effects. Averting genotoxic effects of vector integration may be realized by two 
different strategies: i) targeting integration to specific sites within the host genome; and ii) 
exploiting non-integrating episomal retroviral vector cDNAs for gene delivery (11, 210). 
Targeted integration would be important for therapeutic gene delivery to dividing cells ex 
vivo, such as in the clinical studies mentioned above. In the event that transient gene 
expression is required for treatment in dividing cells, episomal vectors may be applicable. 
However, numerous genetic diseases, such as those of the eye, central nervous system 
(CNS), muscle, and liver may require in vivo administration to tissues predominantly 
consisting of non-dividing cells. HIV-1 derived episomes are especially stable in non-
dividing cells, and are only diluted upon cell division (23, 25, 175), making them desirable 
for gene therapy.   
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 Episomal DNA forms comprise the majority of detectable cDNAs following 
transduction, and they include: 2-LTR circles that form from non-homologous end joining of 
a linear proviral cDNA; 1-LTR circles that can be generated directly as a consequence of the 
reverse transcription process, or through homologous recombination of the LTR’s; linear 
proviral cDNAs that are not competent for integration; and mutant proviral DNAs that may 
be generated by self-integration (34, 46, 169, 203). HIV-1 derived episomal vector formation 
is typically promoted through use of integrase-defective mutants (14, 99, 137, 173, 179, 207, 
219), and vectors with mutations in the attachment (att) sites at the boundaries of the vector 
LTRs (6, 158). Despite the improved safety profile of episomes to diminish the potential for 
insertional mutagenesis, linear cDNA episomal products remain the dominant species, and 
have the potential to instigate genotoxicity through illegitimate integration (i.e. proviral DNA 
integration that is not mediated by a functional integrase). Since the linear episomal species 
are the products of a successful reverse transcription process, it was recently realized that 
interfering with reverse transcription can alter the profile of episomal vector species to favor 
1-LTR circles (99), thereby ameliorating the episome safety profile. The ability to manipulate 
the episomal profile to direct formation of a particular cDNA species would be favorable. In 
addition to therapeutic gene delivery, retroviral vectors provide a platform to investigate the 
molecular virology occurring at different steps of transduction.  
 HIV-1 delivered chimeric MLV/HIV vectors exhibit a transduction profile consistent 
with episomal vector cDNA species (chapter 3), but without modifying the HIV-1 integrase 
or existing MLV att sites. Heterologously packaged vectors may not only be desired for 
therapeutic gene delivery, but can also be of benefit as a model system to understand the 
molecular mechanisms that underlie early events of retroviral infection. In the studies 
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presented here chimeric MLV/HIV, FIV/HIV, and EIAV/HIV vectors were heterologously 
packaged into HIV-1 viral particles to investigate HIV-1 components that confer efficient 
and stable transduction. The studies demonstrate that: i) HIV-1 trans factors (structural and 
enzymatic proteins) are sufficient to deliver heterologous MLV, FIV, and EIAV cDNA 
species to non-dividing, and dividing, cells in vitro and in vivo; ii) HIV-1 integrase is 
sufficient to recognize FIV att sites to support stable transduction of heterologous FIV 
cDNAs, but not EIAV or MLV; iii) stable transduction of cDNAs derived from chimeric 
EIAV/HIV vector RNAs lack the proper att sites for HIV-1 mediated integration; iv) 
episomes derived from heterologously packaged MLV/HIV chimeric RNAs are 
predominantly generated by reverse transcription into 1-LTR cDNA species without 
manipulating att sites or HIV-1 integrase; and v) HIV-1 mediated transduction of 
heterologous MLV/HIV chimeric cDNA species requires not only the proper att sites, but 
more importantly appropriate cis elements (PBS & PPT) for reverse transcription to generate 
a linear cDNA species competent for integration; vi) HIV-1 appears to share a significant 
degree of functional conservation with the non-primate FIV lentivirus, but not EIAV or 
MLV; and, vii) EIAV/HIV and MLV/HIV vectors exhibit in vivo transduction properties that 
may be exploited for therapeutic gene delivery.  
 
 
Methods 
 
Plasmid Constructs. Murine leukemia virus (MLV) and MLV/HIV RRE + RU5PS chimeric 
vector constructs were generated as described in chapters 2 & 3 methods. The MLV/HIV 
RRE vector (pTK1086) described in Fig. 33 was an earlier generation of pTK1332 above, 
which did not have the luciferase gene inserted. The pTK terminology for plasmid constructs 
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refers to the plasmid library in the Kafri laboratory. Chimeric MLV/HIV vectors with 
modified attachment (att) sites, PBS, and PPT, are a derivative of pTK1086 described as 
follows. The following cloning series was used to generate the MLV/HIV att vector: i) a 
MluI/BstEII fragment, containing the MLV 5’ LTR from the MLV vector pTK506 was 
subcloned into pSL301 (Invitrogen) to generate pTK682; ii) pTK682 was used as a template 
for PCR around the entire plasmid wherein primers were designed to change the MLV att 
site to a HIV-1 att site, the region between the MluI/BstEII sites was confirmed by 
sequencing to be correct, an MLV 5’ LTR with HIV-1 att sites,  pTK1349; iii) the 
MluI/BstEII fragment from pTK1349 was cloned into the corresponding region of pTK1086 
to generate pTK1352 (a MLV vector with a 5’ LTR containing the HIV-1 att site and 3’ LTR 
containing the MLV att site); iv) to alter the 3’ LTR a SapI/SacII fragment from pTK1086 
was inserted into pBlueScript, pTK1348, and this was used as a template for PCR around the 
entire plasmid wherein primers were designed to change the MLV att site to a HIV-1 att site, 
pTK1350; and, v) the SacII/SapI fragment from pTK1350 was cloned into the corresponding 
sites in pTK1352 to generate the MLV/HIV att construct termed pTK1354. The following 
cloning series was used to generate the MLV/HIV att + PPT vector: i) pTK1348 was used as 
a template for PCR around the entire plasmid wherein primers were designed to change the 
MLV att and PPT sites to those of HIV-1 (pTK1351) which was sequence verified between 
SacII and U5 in the vector; and ii) the SacII/SapI fragment from pTK1351 was subcloned 
into pTK1352 to generate the MLV/HIV att + PPT chimeric vector, pTK1355. The 
MLV/HIV att + PBS construct was prepared with the following cloning sequence: i) a 
SacII/SapI fragment from pTK1350 was cloned into pTK1086 to generate a chimeric vector 
with a single HIV-1 att site in the 3’ LTR, pTK1356; ii) pTK682 was used as a template for 
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PCR around the entire plasmid wherein primers were designed to change the MLV att site 
and PBS to those of HIV-1 att site and PBS, and the region between the MluI/BstEII sites 
was confirmed by sequencing to be correct, an MLV 5’ LTR with HIV-1 att & PBS sites, 
pTK1353; iii) The MluI/BstEII fragment from pTK1353 was inserted into the corresponding 
sites of pTK1356 to generate the final chimeric vector MLV/HIV att + PBS, pTK1358. The 
final MLV/HIV chimeric vector, MLV/HIV att + PBS + PPT, was generated with the 
following subclonings: i) a SacII/SapI fragment from pTK1351 was inserted into the 
corresponding sites of pTK1086 to generate pTK1357; and ii) a MluI/BstEII fragment from 
pTK1353 was inserted into the corresponding sites in pTK1357 to yield the final chimeric 
vector MLV/HIV att + PBS + PPT, or pTK1359.  
 Construction of the parental EIAV and FIV, and the chimeric EIAV/HIV RRE and 
FIV/HIV RRE, vectors is described in the chapter 2 methods. The EIAV/HIV att + RRE 
vector was constructed as follows: i) for modification of the 3’ LTR att a NaeI fragment from 
pTK728 was cloned into a standard cloning vector in the lab, pTK50, to generate pTK1242; 
ii) pTK1242 was used as a template for PCR amplication around the entire plasmid thereby 
replacing the EIAV att site with the HIV-1 att site, and sequence was confirmed to generate 
pTK1345; iii) similarly for modification of the 5’ LTR att a BglII/NotI fragment from 
pTK728 was cloned into the corresponding sites of pTK50 to generate pTK1241; iv) 
pTK1241 was used as a template for PCR amplification around the entire plasmid thereby 
replacing the EIAV att site with the HIV-1 att site, and sequence was confirmed to generate 
pTK1344; v) the BglII/NotI fragment from pTK1344 was inserted into pTK728 to generate 
pTK1346; and vi) the final construct was generated by inserting the RsrII/PacI fragment 
from pTK1345 into pTK1346, yielding the EIAV/HIV att + RRE vector, pTK1347. The 
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chimeric EIAV/HIV RRE vector containing the liver specific promoter (hAAT) driving 
expression of the firefly luciferase gene was constructed as follows: i) The parental EIAV 
vector UNC 6.1 W-1 was cut with NheI/XbaI and self-ligated to generate pTK827; ii) a 
NotI/SacII fragment from pTK208 was inserted into the respective sites in pTK827, thereby 
constructing pTK829; and iii) a XhoI/NotI fragment from pTK647 containing the hAAT-
FLuc expression cassette, was inserted into the corresponding sites of pTK829, yielding the 
final construct pTK857.  
The packaging constructs supplying necessary structural/enzymatic proteins were 
4XCTE or NRF as described in chapter 2 methods. The Rev and VSV-G expression 
constructs are explained in chapter 2 methods.   
Cells, Viral Particle Production, and Concentration. All are described in chapter 2 
methods.  
HIV-1 p24 Capsid Concentration. Details of this assay were described in chapter 2 
methods. 
MLV Reverse Transcriptase Assay. Details of this assay were described in chapter 3 
methods. 
FACS Analysis. Details of this assay were described in chapter 2 methods.  
Southern Blot Analysis.  293T cells were transduced with indicated chimeric vectors 
packaged into HIV-1 or MLV viral particles, at MOI’s of 5 or 10. Total cellular DNA was 
isolated at 5 days post-transduction (referred to as P0, or no cell passages, in figures), or after 
five passages (P5) of the transduced cells where indicated. To collect total DNA transduced 
cells were lysed in a proteinase K solution (10 mM Tris pH 8, 10 mM EDTA pH 8, 0.5% 
SDS, 0.4 M NaCl, and 200 µg/ml proteinase K) for 48 hours at 55°C. Total DNA was 
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extracted with v/v phenol (Invitrogen) and v/v phenol/chloroform/isoamyl alcohol 
(Invitrogen) and then treated with RNase A (20 µg; Fermentas) at 37°C for 2 hours. A second 
round of extractions was performed and total DNA was precipitated using standard ethanol 
precipitation.  
Regarding studies with the MLV/HIV RRE + RU5PS chimeric vector isolated gDNA 
(10 µg) was digested with BsrGI and DpnI for ~24 hours at 37°C. The gDNA (15 g) from 
transductions with MLV chimeric vectors with modified att, PBS, or PPT sites were digested 
with PflMI, SexAI, and DpnI for ~24 hours at 37°C. The gDNA (15 g) from transductions 
with chimeric EIAV vectors were digested with PvuII, PflMI, and DpnI for ~24 hours at 
37°C. DpnI was included to eliminate putative plasmid DNA carry-over from the 
transfections during vector production in 293T cells. Equivalent amounts of gDNA were 
resolved on 1% agarose gels, transferred to Zetaprobe membrane, and probed to the 5’ or 3’ 
ends of the vector, where indicated, enabling a size distinction between linear, 1-LTR, 2-LTR 
and backbone/integrated forms. Images were captured on BioMax MR Film (Kodak), or by 
phosphorimager (Molecular Dynamics Storm System).  
Real Time qPCR. Total cellular DNA was isolated as described for Southern blot analysis 
and qPCR for vector and -globin were described previously (100). Briefly, vector copy 
number was derived from standard curve produced from FLP9 cells, which contain a single 
copy of HIV-1 vector per diploid genome. One nanogram of total cellular DNA was 
previously calculated to contain 303 copies for -globin per diploid genome, or 151.5 copies 
vector per diploid genome. Primers for vector copy number were designed to the WPRE 
region, which is also in our MLV/HIV chimeric vectors. All primers and PCR reaction 
conditions were described previously (100).  
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Transduction of aphidicolin-arrested 293T cells. In vitro experiments to arrest 293T cells 
in the cell cycle were treated 24 hours prior to transduction with 5g/ml aphidicolin in 6 well 
plates, thereby arresting at the G1/S phase of the cell cycle. Arrested cells were transduced 
24 hours after aphidicolin arrest with 2l (4x105 TU/l) of the indicated vectors to examine 
transduction of non-dividing cells. 293T cells in the absence of aphidicolin were transduced 
with the same volume at the same time that aphidicolin was added to the plates to allow more 
time for detection of GFP expression. Transduced cells were imaged by fluorescence 
microscopy at 48 hours post-transduction for aphidicolin treated cells.   
In vivo experiments in the mouse liver. All care and procedures were in accordance with 
the Guide for the Care and Use of Laboratory Animals (DHHS Publication No. [NIH]85-23), 
and all procedures received prior approval by the University of North Carolina Institutional 
Animal Care and Usage Committee. Balb/c mice were injected intraperitoneally (IP) at 8-10 
weeks of age with equivalent p24 amounts (~100 g) of a single concentrated preparation of 
EIAV/HIV RRE chimeric vector packaged into HIV-1 viral particles (i.e. a single large 
concentrated preparation was equally divided over two mice). Mice were examined for 
luciferase expression in the liver at 3 and 23 weeks post-injection. Luciferin (Promega), 
125mg/kg, was administered IP and measured using the Xenogen IVIS imaging system 
(Xenogen, Hopkinton, MA).   
Generating transgenic animals. All care and procedures were in accordance with the Guide 
for the Care and Use of Laboratory Animals (DHHS Publication No. [NIH]85-23), and all 
procedures received prior approval by the University of North Carolina Institutional Animal 
Care and Usage Committee. The generation of all transgenic animals was executed under the 
direction of Randy Thresher and Kimberly Kluckman within the Animal Transgenic Core 
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facility at the University of North Carolina. Single cell embryos were microinjected into the 
perivitelline space with each of the indicated vectors at 1-100 IU/embryo. Embryos were 
implanted into a pseudopregnant female by 2 days after microinjection of vector. Embryos 
were imaged prior to implanting by fluorescence microscopy. Mice were imaged for GFP 
expression at 16-20 weeks of age. A defined region of the mouse abdomens were cleared of 
hair. Mice were anesthetized with avertin (0.4-0.7mg/g) prior to imaging with a digital 
camera using a GFP filter.  Of the animals imaged 10% of the heterologous FIV/HIV 
transgenic mice were positive for GFP expression. Genomic DNA was extracted from tail 
clipping of adult mice and assessed for presence of proviral vector DNA. Standard PCR was 
performed on the genomic DNA with primers designed to the WPRE for vector and 
endogenous mouse -actin.  
Rat Subjects and Stereotaxic Administration of Retroviral Vectors.  Pathogen-free 
Sprague-Dawley rats were obtained from Charles Rivers. All care and procedures were in 
accordance with the Guide for the Care and Use of Laboratory Animals (DHHS Publication 
No. [NIH]85-23), and all procedures received prior approval by the University of North 
Carolina Institutional Animal Care and Usage Committee. Virus vector infusions and animal 
perfusions were performed in the laboratory of Dr. Thomas McCown at the University of 
North Carolina, as previously described (141). Briefly, rats were anesthetized with 50mg/kg 
pentobarbital and then placed into a stereotaxic frame. Using a 32 gauge stainless steel 
injector and Sage infusion pump, the rats received 3l (at 4x105 GFP TU/l) of MLV/HIV 
RRE chimeric vector (pTK1086) packaged into MLV or HIV-1 viral particles, over a 30 
minute period into the striatum (1.0mm anterior to bregma, 3.0mm lateral, 5.5mm vertical) 
according to the atlas of Paxinos and Watson (171). 6 rats were bilaterally infused with each 
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vector at the same time (i.e. HIV-1 packaged vector was injected into the right striatum, and 
concurrently MLV packaged vector was injected into the left striatum). In the instance of 
chimeric FIV/HIV RRE vector (pTK660) and HIV-1 vector (pTK113) 1l was injected over 
a 10 minute period into the striatum.  
 At 10 days (chimeric FIV vector experiements) or 1 month (chimeric MLV vector 
experiments) after vector infusion, rats received an overdose of pentobarbital (100 mg/kg 
i.p.) and subsequently perfused transcardially with ice-cold 100mM PBS (pH 7.4), followed 
by 4% paraformaldehyde in 100mM phosphate buffer (pH 7.4). After overnight fixation in 
paraformaldehyde-phosphate buffer, 40 m vibratome sections were prepared through the 
striatum and rinsed in phosphate buffer.  
Mouse Subjects and Stereotaxic Administration of Retroviral Vectors. Mice viral vector 
injections and tissue preparation were executed in the laboratory of Dr. Henriette van Praag 
at the National Institute on Aging. Female C57Bl/6 mice (n=10), 3 months old (Jackson 
Labs) were housed in standard conditions with 3-4 mice per cage with food and water 
available ad libitum. All procedures were in accordance with the Guide for the Care and Use 
of Laboratory Animals (DHHS Publication No. (National Institutes of Health) 85-23), and all 
procedures received prior approval by the NIH Institutional Animal Care and Usage 
Committee. All procedures were performed according to animal protocol number, 396-LNS-
2014.  
Mice were anesthetized (Avertin 0.02 mg/ml, 0.5-1.0 ml injection per mouse), and 
MLV retrovirus (n=5 mice), or HIV lentivirus (n=5 mice) was injected stereotactically (2 l 
[4x105 TU/L] using a 5 l Hamilton microliter syringe) into the right striatum (AP= 1.0 mm 
anterior from bregma; lateral= 1.5 mm; ventral=3.0 mm). Studies were executed with the 
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MLV/HIV RRE vector packaged into MLV viral particles, or HIV-1 viral particles generated 
from the ∆NRF helper construct. One month thereafter animals were given an overdose of 
anesthetics and perfused transcardially with cold 4% paraformaldehyde (PFA) in 0.1 M 
phosphate buffered saline (PBS). After 24 hr, brain tissue was equilibrated in 30% sucrose. 
Sequential horizontal sections (40 m) using a sliding freezing microtome (HM450, 
ThermoFisher) were taken through the extent of the striatum and stored in phosphate 
buffered glycerol at -20˚C.  
Immunohistochemistry and Confocal Microscopy. Immunohistochemistry for mouse 
studies was executed in the laboratory of Dr. Henriette van Praag at National Institute on 
Aging. For mouse studies double labeling for the neuronal marker NeuN and GFP was done 
on a 1:6 series of 40-m free-floating horizontal sections as described previously. Sections 
were washed and blocked in TBS with 3% donkey serum and 0.3% Triton X-100 (TBS-plus). 
Primary antibodies raised in two different species were pooled in TBS-plus and incubated for 
48 h at 4°C. The neuronal marker NeuN [mouse monoclonal antibody, (Millipore) 1:100] 
was combined with antibody for GFP [rabbit polyclonal antibody (Millipore), 1:1000]. 
Corresponding secondary antibodies [donkey anti-mouse CY3 and goat anti-rabbit Alexa488 
(Jackson ImmunoResearch Inc.), 1:250] were pooled, and sections were incubated for 4 h at 
room temperature following washing in TBS-plus. Sections were mounted and coverslipped 
with DABCO-PVA.  
 For rat studies immunohistochemisty was executed under the guidance of Dr. Bonnita 
Blake in the laboratory of Dr. Thomas McCown at the University of North Carolina. For 
immunohistochemistry, tissue sections were incubated in 10% normal goat serum and 0.1% 
Triton X-100 in PBS for 45 minutes. Sections were then incubated with primary antibody to 
109 
 
NeuN (1:500, Chemicon) or rabbit anti-GFP (1:500, Millipore) overnight in 3% normal goat 
serum, 0.2% Triton X-100 and PBS. Tissue sections were rinsed in PBS, incubated in 
blocking serum (10% normal goat serum, 0.1% Triton X-100, PBS) for 1 hour and then 
incubated with a secondary antibody (Alexa-fluor 594 goat anti-mouse for NeuN [red, 
Molecular Probes] and goat anti-rabbit Alexa-fluor 488 to detect GFP [Green, Invitrogen]) 
for 1 hour at 4°C. Following 3 rinses in PBS, the sections were mounted on slides and 
coverslipped with fluorescent mounting media. For highly sensitive detection of GFP 
expression by DAB staining in the rat striatum tissue sections the primary antibody was a 
rabbit anti-GFP-biotinylated antibody (1:500, Chemicon). The secondary staining was 
performed according to instructions using a secondary antibody kit (Vectastain Elite ABC 
kit, Vector Laboratories). The DAB staining solution (resuspend lyophilized powder in 10 ml 
water and add to the following: 10 ml 0.2M PBS + 175 l NiNH2SO4 + 200 l CoCl2 + 5 l 
3% H2O2 and filter through 0.2 m filter) was added to the tissues for 10-15 minutes at room 
temperature, carefully monitoring the color of the samples not to turn overly dark. The 
samples were then washed three times with PBS and mounted onto slides using a toluene 
based liquid, TBS SHUR/mount.  
 DAB stained striatum rat brain sections were imaged using a slide analyzer and 
Aperio ImageScope version 10.0 software. For colocalization studies by fluorescence 
detection sections were imaged by confocal scanning laser microscopy (MPE1000, Olympus 
and Laser Scanning Zeiss 510 Meta). Mouse and rat brain sections with GFP positive cells 
were captured with the Zeiss LSM Image Browser software and used to score for GFP, 
NeuN, and colocalization of the two markers by scanning through the z-axis. Scoring 
represents positive cells from brain sections of mice, or rats (n=6, for bilateral injections), 
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transduced with the MLV/HIV RRE vector packaged into MLV (n=5, for mice), or HIV-1 
(n=5, for mice), derived viral particles. 
 
Results 
 
HIV-1 trans factors facilitate in vitro and in vivo transduction of heterologously 
packaged MLV RNA through generation of episomal cDNA species. Depending on the 
type of viral particle carrying a heterologous vector RNA (HIV-1 or parental viral particles), 
a different transduction profile may be anticipated. The transduction profile is indicative of 
molecular mechanisms that govern the various stages of the transduction process 
(attachment, entry, uncoating, reverse transcription, nuclear entry, integration, and gene 
expression) in a host cell. In the context of HIV-1 viral particles GFP positive cells from 
transduction with HIV-1 delivered chimeric MLV/HIV vector were almost completely 
eliminated (Chapter 3, Fig. 22), indicating that GFP may be expressed from episomal DNA 
vector forms not competent for integration. In contrast, in the context of MLV viral particles 
the chimeric vector was retained after multiple cell passages to eliminate episomal vector 
DNA species, as indicated by FACs analysis of GFP positive cells (only about 50% 
reduction, Fig. 32A). The presence of total episomal DNA forms was assessed by qPCR for 
vector copy number (Fig. 32B) relative to copy number of -globin (Fig. 32C). In line with 
GFP results, qPCR quantitation of total vector DNA before and after passaging cells yielded 
a >30 fold decrease in vector DNA after passaging 293T cells transduced with HIV-1 
particles, compared to <2 fold decrease from MLV viral particles (Fig. 32D). MLV/HIV 
chimeric vector RNA delivered by HIV-1 viral particles primarily cedes proviral episomal 
DNA forms that can be composed of 1-LTR, 2-LTR, linear, and mutant forms.  
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Nonintegrating cDNAs are readily lost as a consequence of dilution during cell 
division. However, anticipated therapeutic applications would comprise transgene delivery to 
the preponderance of non-dividing/slowly dividing cells, as previously demonstrated with 
non-integrating HIV-1 derived vectors delivered to the eye, CNS, muscle, and liver (6, 14, 
99, 137, 173, 179, 219). Unique to lentiviral vectors is the ability to establish stable transgene 
expression in non-dividing cells, a barrier encountered by MLV derived vectors delivered by 
MLV viral particles. In vitro delivery of a MLV/HIV RRE chimeric vector (Fig. 33A) by 
HIV-1 viral particles exhibited efficient transduction on 293T cells arrested with aphidicolin 
in the G1/S phase of the cell cycle (Fig. 33B). In contrast, transduction was almost 
completely absent following delivery of the same vector with MLV viral particles (Fig. 33B). 
In vitro transduction of non-dividing cells implies that HIV-1 structural and enzymatic 
proteins are sufficient to ferry an MLV derived vector cDNA species into the nucleus for 
subsequent transgene expression. Nonetheless, the ‘Gold Standard’ for HIV-1 derived vector 
is in vivo transduction of quiescent neurons in striatum of mouse and rat brains.  
HIV-1 mediated delivery of a MLV/HIV RRE chimeric vector that expresses GFP 
(Fig. 33A) demonstrated efficient transduction of mouse brain neurons in the striatum (Fig. 
34A and B). HIV-1 delivered vector (GFP marker) colocalized in neurons stained for the 
neuronal nucleus (NeuN) marker, whereas the same vector delivered with MLV viral 
particles did not exhibit neuronal transduction (Fig. 34A and B); an observation that was 
consistent over multiple brain sections (Fig. 34B). Nonetheless, MLV delivered vector did 
yield a moderate number of GFP positive cells that were not NeuN positive and appeared to 
be morphologically distinct. Similar results were obtained following delivery to the rat brain 
striatum. The extent of transduction in three separate rat brains was observed by indirectly 
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staining for GFP transgene expression from the MLV/HIV chimeric vector using a secondary 
antibody amenable to DAB staining (Fig. 35). This staining method is also highly sensitive 
allowing for detection of low expressing GFP positive cells. The morphology of the dark 
stained cells is consistent with those of neurons, demonstrating HIV-1 viral particles can 
effectively deliver the MLV chimeric vector to neurons. Further affirmation came from 
confocal microscopy studies showing colocalization of cells for GFP expressed from the 
chimeric MLV/HIV vector (green) and the NeuN marker (red), only when the vector was 
delivered by HIV-1 derived viral particles (Fig. 36A & B). Quantification from six rat brains 
demonstrated nearly 100% transduction of neurons when the chimeric MLV/HIV vector was 
delivered by HIV-1 viral particles (Fig. 36B). However, in contrast to the data observed for 
the mouse transduction there were as many GFP positive cells (i.e. vector positive) upon 
delivery with the MLV viral particles (Fig. 36B). These cells appeared to be morphologically 
small, and localized primarily at the injection site (Fig. 36A). These may be a type of 
lymphocyte that can readily divide, thereby amenable to transduction by MLV viral particles, 
but would not be detected in brains were the chimeric vector is delivered by HIV-1 viral 
particles since the episomes would be diluted upon cell division. Nonetheless confirmation 
would require further characterization. Additionally, a higher level of neurons transduced by 
MLV delivered chimeric vector was also apparent in the rat brain striatum (Fig. 36B). The 
distinction between MLV delivery in the rat and mouse brains may be explained by 
differences in delivery. In the mouse studies vector was administered to the striatum of only 
one brain hemisphere, whereas in the rat study MLV and HIV-1 packaged vectors were 
bilaterally administered into opposing brain hemispheres of the same animal. Feasibly, 
concomitant insult to both hemispheres may provoke cellular migration or leakage across the 
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brain hemispheres. Further discourse on this topic can be obtained below. Overall, these data 
are a clear indication that heterologous MLV vector RNAs, packaged into HIV-1 viral 
particles, can assume transduction properties dictated by HIV-1 structural and enzymatic 
proteins; except, however, that reverse transcribed cDNAs cannot integrate, therefore 
transgene expression is primarily from episomes.  
  
HIV-1 trans factors facilitate in vitro and in vivo transduction of heterologously 
packaged EIAV and FIV RNAs. Chimeric EIAV/HIV and FIV/HIV vectors, packaged into 
HIV-1 viral particles, were demonstrated to exhibit efficient in vitro transduction of 293T 
cells as determined by vector titers (chapter 2). Delivery of each chimeric vector was also 
examined through in vivo administration to mice. A chimeric EIAV/HIV vector was 
generated with an expression cassette composed of the liver specific human alpha antitrypsin 
(hAAT) promoter driving expression of the firefly luciferase (FLuc) gene (Fig. 37A).  HIV-1 
viral particle (∆NRF) delivery of the chimeric EIAV/HIV vector by intraperitoneal injection 
exhibited strong luciferase expression at 3 weeks post-injection. However, expression was 
significantly reduced by 23 weeks post-injection, as indicated by the necessity to increase the 
detection sensitivity 5 fold (Fig. 37B). These data are consistent with the possibility that the 
EIAV/HIV chimeric vector is similar to the MLV/HIV chimeric vectors in that expression is 
primarily from episomal cDNA forms. Moderate cell division that occurs in the liver may 
gradually result in a reduction in detectable signal as non-integrated cDNAs are lost to 
dilution effects.  
 HIV-1 mediated delivery of chimeric FIV/HIV vectors exhibit in vivo transduction 
properties that are more similar to HIV-1 derived vectors, rather than MLV/HIV and 
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EIAV/HIV chimeric vectors. A chimeric FIV/HIV vector containing a CMV-GFP expression 
cassette (Fig. 38A) was delivered by HIV-1 viral particles to mouse brain striatum (Fig. 
38B), and to mouse embryos ultimately resulting in the generation of GFP expressing 
transgenic mice (Fig. 38C & D). Similar to the MLV/HIV chimeric vector, the FIV/HIV 
chimeric vector was readily transferred to neurons in mouse brain striatum (Fig. 38B), as 
determined by morphological analysis. More importantly, however, is the fact that transgenic 
mice could be generated through HIV-1 mediated delivery of the chimeric FIV/HIV vector 
(Fig. 38C & D). Since numerous cell divisions are required to generate a transgenic mouse 
from an embryo these data were a clear indication that HIV-1 integrase could mediate 
integration of the chimeric FIV/HIV vector, which is in contrast to what was observed for 
chimeric MLV/HIV and EIAV/HIV vectors. Confirmation of these distinct transduction 
profiles was obtained by transducing 293T cells with each of the chimeric vectors (in this 
case the EIAV/HIV chimeric vector contains a CMV-GFP expression cassette), and 
measuring the percent of cells that were positive for GFP expression before and after 
passaging the cells (Fig. 39). The chimeric MLV/HIV RRE + RU5PS and EIAV/HIV RRE 
vectors were diluted upon passaging the cells, an indication that both are primarily in the 
form of episomes in transduced cells. The FIV/HIV RRE chimeric vector, on the other hand, 
exhibited a high frequency of integration insinuating at least partial recognition and function 
by the HIV-1 reverse transcriptase and integrase proteins.  
 
HIV-1 reverse transcriptase and integrase utilize distinct molecular mechanisms to 
promote chimeric EIAV and MLV episome formation. It is well accepted that stable 
transduction of dividing cells is dependent upon successful integration of a viral/vector linear 
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DNA. The main viral components that facilitate this process are integrase and the appropriate 
attachment (att) sites at the ends of the linear cDNA, which are recognized by the viral 
integrase (Fig. 40). However, the generation of a linear cDNA competent for integration 
requires proper reverse transcription. As previously discussed the cDNA products of reverse 
transcription are not only linear molecules of cDNA capable of integration, but the majority 
are comprised of different types of episomal DNA forms including 2-LTR, 1-LTR, and linear 
molecules that do not integrate (Fig. 40). Mutant circular molecules may also arise as a 
consequence of auto-integration. Aforementioned data suggests that the chimeric EIAV/HIV 
and MLV/HIV vector cDNAs are in the form of episomes, however the types of episomes 
present was not clear from these studies. Southern blot analysis revealed that the chimeric 
EIAV/HIV RRE vector is predominantly comprised of linear episomes, indicating that the 
HIV-1 reverse transcriptase generates linear cDNA vector molecules competent for 
integration (Fig. 41C). However, since stable transduction is not easily attainable, the HIV-1 
integrase may not properly recognize the EIAV att sites. EIAV att sites were replaced with 
those of HIV-1 (Fig. 41A), demonstrating a 9 fold increase in stable transduction following 
dilution of episomal DNA forms by passaging the cells (Fig. 41B). Moreover, changing the 
att sites only moderately altered the episomal profile, possibly reducing the amount of 2-LTR 
circles formed by delivery with HIV-1 viral particles (Fig. 41C). The profiles of both vectors 
when packaged into EIAV viral particles was similar, with the exception that the total 
amount of DNA is less in the lane representing the vector without att sites (Fig. 41C). These 
data demonstrate that the HIV-1 att sites were sufficient to enhance stable transduction 
nearly 10 fold, by providing the appropriate substrate for the HIV-1 integrase.  
116 
 
 The episomal profile of the EIAV/HIV chimeric vector indicated that replacing the att 
sites would be sufficient to confer stable transduction through proper recognition by the HIV-
1 integrase. The molecular mechanisms, however, extend beyond att site recognition by 
integrase to include proper reverse transcription. A previous study indicated that deletion of 
the 3’ PPT from an HIV-1 derived vector shifted the episome profile from linear cDNA 
products to a dominant 1-LTR circle form (99). Interestingly, Southern blot analysis revealed 
that the HIV-1 packaged chimeric MLV/HIV RRE+RU5PS vector (Fig. 42A) exists 
predominantly as a 1-LTR episome that can be diluted following multiple cell divisions 
through passaging (Fig. 42B). A very similar profile was observed using a 3’ probe, with a 
minor amount of detectable linear forms (Fig. 42C), indicating that minuscule amounts of 
linear species of various sizes may be present but not competent for integration. In contrast, 
the same vector delivered with MLV viral particles exhibited a very different profile, 
primarily as integrated DNA accompanied by minimally detectable levels of linear, 1-LTR, 
and 2-LTR episomes (Fig. 42B). These data are in accordance with what was observed in 
figure 32D. The absence of competent linear episomal forms indicates that reverse 
transcription of the chimeric MLV/HIV vector RNA by HIV-1 RT clearly leads to dominant 
1-LTR episomal species that are apparently responsible for the observed GFP expression. 
Furthermore, it can be anticipated that replacing the att sites would not be sufficient to 
recover integration, but rather replacing the MLV PPT & PBS with those from HIV-1 would 
facilitate proper reverse transcription of the chimeric MLV/HIV vector RNA into appropriate 
linear forms that may then be competent for stable transduction in the presence of the HIV-1 
att sites. Indeed, replacing the MLV att sites with those of HIV (Fig. 43A) yielded a minor 
increase in stable transduction as measured by FACS analysis for GFP positive cells (Fig. 
117 
 
43B). Additional modifications to an MLV/HIV RRE chimeric vector included replacing the 
MLV PBS & 3’ PPT with those of HIV-1 in the context of HIV-1 att sites (Fig. 43A). 
Although independently the PBS or 3’ PPT exhibited a significant increase in stable 
transduction, the most dramatic influence was the combined effect of both to yield a >20 fold 
increase in stable transduction (Fig. 43B). The episomal cDNA profiles of these vectors were 
examined by Southern blot analysis (Fig. 44). Blots were probed with either a 3’ probe (Fig. 
44B) or 5’ probe (Fig. 44C). The 3’ probe not only revealed the presence of 1-LTR episomal 
forms but also that there are indeed linear forms present, but apparently not the correct linear 
forms (i.e. linear molecules competent for integration by the HIV-1 integrase) since linear 
forms are nearly absent after probing with the 5’ probe. Apparently, the process of reverse 
transcription generates randomly sized linear products at the 5’ end (Fig. 44A) that are 
truncated to a defined size after cutting with the indicated enzymes, and can only be detected 
with the 3’ probe. Importantly, however, in the presence of the HIV-1 3’ PPT there is an 
increase in linear products detectable by the 5’ probe (Fig. 44C); an indication that the HIV-1 
reverse transcriptase is able to generate linear cDNA products that are amenable to 
recognition by the HIV-1 integrase. Overall these data demonstrate that the HIV-1 reverse 
transcriptase and integrase enzymes can generate distinct episomal profiles for EIAV/HIV 
and MLV/HIV chimeric vectors.  
 
Discussion 
The goal of these studies was to investigate the transduction properties of RNAs 
heterologously packaged into HIV-1 viral particles with the expectation that these studies 
would provide insight into the molecular mechanisms governing retroviral transduction of a 
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host cell. Distinct transduction profiles were observed for three different heterologously 
packaged RNAs: MLV, EIAV, and FIV. For all heterologously packaged vector RNAs the 
HIV-1 structural and enzymatic proteins were capable of mediating transduction in vitro and 
in vivo, and, most importantly, in non-dividing cells (Figs. 33-39). A well established 
biological phenomenon is that MLV viral particles cannot transduce quiescent cells (217), 
thereby indicating that, in the studies shown here (Figs. 33-36), HIV-1 trans factors are 
sufficient for a MLV vector RNA to overcome cell cycle-dependent blocks to transduction. 
Accordingly, another group showed that the HIV-1 capsid protein has a direct role in the 
transduction of non-dividing cells (218), and not previously suspected HIV-1 karyophilic 
viral elements (216). However, although these results demonstrate that HIV-1 trans factors 
could surmount blocks to transduction of non-dividing cells, they could not mediate stable 
transduction of heterologously packaged MLV or EIAV chimeric vector RNAs (Fig. 39). 
Whereas, stable transduction of heterologously packaged FIV vector RNA was readily 
achievable (Fig. 38 & 39). These differences could be distinguished by the potential for the 
HIV-1 reverse transcriptase to generate an appropriate vector DNA substrate (from 
heterologously packaged chimeric MLV, EIAV, & FIV RNAs) competent for recognition 
and processing by the HIV-1 integrase. Although this was partially the case for FIV vector 
DNA, MLV and EIAV vector DNAs remained as distinct episomal species that could be 
effectively eliminated by dilution upon cell division (Fig. 32, 39-44).  
 The generation of a linear vector DNA molecule competent for integration requires 
the reverse transcriptase and its associated RNase H activity to render the appropriate 5’ and 
3’ ends containing attachment (att) sites that can subsequently be recognized and processed 
by the integrase enzyme. Studies presented here demonstrate that HIV-1 reverse transcriptase 
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can mediate reverse transcription of heterologously packaged chimeric MLV, EIAV, and FIV 
vector RNAs. However, FIV was effectively integrated, whereas EIAV and MLV remained 
as episomes. These results are in accordance with previous reports demonstrating efficient 
heterologous packaging and propagation of RNA derived from primate lentiviruses  (184, 
198), as well as the non-primate lentivirus FIV (22), into HIV-1 derived viral particles. These 
studies indicate that not only are the proper FIV linear vector DNAs generated from reverse 
transcription, but also that HIV-1 integrase can recognize and process the att sites to mediate 
integration. Further support for this proposition comes from a study demonstrating that HIV-
1 could support integration of an HIV-1 virus with 5’ and 3’ att sites altered to those of FIV 
with up to 70% efficiency of wild-type, whereas replacement with MLV att sites was less 
than 0.5% wild-type levels (136). These data, combined with data in chapter 2 demonstrating 
that FIV Rev is functionally interchangeable with HIV-1 Rev, provides strong evidence for a 
significant level of functional conservation between the non-primate FIV lentivirus and HIV-
1 at early and late events of retroviral replication. 
 Studies with chimeric EIAV/HIV and MLV/HIV vectors did not reveal a similar 
degree of functional conservation with HIV-1. Although HIV-1 structural and enzymatic 
proteins could mediate reverse transcription, stable transduction was absent; however, each 
of the EIAV/HIV and MLV/HIV chimeric vectors exhibited distinct episomal profiles (Figs. 
41, 42, & 44). The episomal profiles were contingent upon the HIV-1 reverse transcriptase to 
recognize cis elements in the packaged chimeric vector RNA. Proper processing during 
reverse transcription is dependent upon two cis elements employed as primers to initiate 
negative strand (primer binding site [PBS]) and positive strand (3’ polypurine tract [PPT]) 
synthesis (Fig. 40). A recent study demonstrated that the episomal profile is dependent upon 
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the capacity of the HIV-1 reverse transcriptase to recognize the 3’ PPT (99). In the case of 
EIAV/HIV chimeric vector RNAs the HIV-1 reverse transcriptase could effectively 
recognize the EIAV PBS and 3’ PPT to generate episomal products that are predominantly 
linear vector DNAs; therefore, replacing EIAV att sites with HIV-1 att sites were sufficient 
to enhance efficiency of stable transduction. This work is the first evidence for the capacity 
of HIV-1 to mediate reverse transcription of an EIAV-derived vector RNA (Fig. 41), as well 
as integration following att site replacement. Since HIV-1 reverse transcriptase can recognize 
the EIAV PBS and 3’ PPT to generate linear vector DNAs competent for integration, HIV-1 
may be more functionally related to EIAV than MLV.  
Replacing the att sites for MLV/HIV chimeric vectors was not sufficient to recover 
integration, most likely since the dominant episomal form was 1-LTR vector DNAs, and not 
linear forms. Changing the PBS & 3’ PPT, in addition to the att sites, dramatically improved 
integration (Fig. 43). Therefore, in the absence of a PBS & 3’ PPT that can efficiently prime 
negative and positive strand synthesis for the HIV-1 RT, non-specific priming of reverse 
transcription may occur; thereby, altering the episomal profile. Similarly, previous results 
demonstrated that deletion of the HIV-1 3’ PPT altered the episomal profile of a HIV-1 
vector from preferentially linear substrates to 1-LTR circles (99). Other studies have also 
demonstrated that a cognate 3’ PPT is required for proper removal of the PPT primer by the 
RNase H activity of RT to ensure formation of a correct U3 end for subsequent integration 
(32, 33). Regarding the PBS, as discussed in chapter 3 previous studies indicate that HIV-1 
RT can utilize the MLV PBS at reduced efficiency (51); however, exchanging the MLV PBS 
with the HIV-1 PBS augmented stable transduction in the presence of HIV-1 att sites. Like 
the 3’ PPT, a cognate PBS is critical for generating a correct U5 end for subsequent 
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integration (61, 159, 194, 213). In molecular studies presented here two different types of 
MLV/HIV chimeric vectors were utilized, one that only contained the HIV-1 RRE 
(MLV/HIV RRE, Figs. 43 & 44) and HIV-1 RRE + RU5PS (MLV/HIV RRE + RU5PS, Fig. 
42). The MLV/HIV RRE + RU5PS vector also contained the HIV-1 R, U5, & PBS regions in 
the middle of the vector. In both cases Southern blot analysis using a 5’ probe revealed a 
predominant 1-LTR circle form. A 3’ probe revealed a dominant amount of varying sized 
linear forms present for the MLV/HIV RRE chimeric vector that were not integration 
competent (Fig. 44); however, although a 3’ probe for the MLV/HIV RRE + RU5PS 
revealed the presence of linear episomes, the 1-LTR form remained the dominant form (Fig. 
42). The insertion of the HIV-1 PBS could have introduced a dominant negative strand 
initiation site into the MLV vector that, along with the absence of a competent 3’ PPT, may 
have contributed to dramatic increases of 1-LTR episomes. Packaging an MLV RNA 
containing the HIV-1 PBS could have enhanced the efficiency of intiating reverse 
transcription. This concept is in accordance with previous studies demonstrating the frequent 
use of a second PBS site artificially incorporated into a single retroviral RNA (208, 209). 
Nevertheless, experiments include altering the att sites, PBS, and 3’ PPT in the context of the 
HIV-1 RRE + RU5PS may reveal further insights into the mechanism. Furthermore, the 
inherent generation of episomal vectors from heterologously packaged MLV/HIV and 
EIAV/HIV chimeric vector RNAs provides a safe, and innovative, system for the production 
of nonintegrating vectors to deliver therapeutic transgenes.  
  The heterologous MLV/HIV RRE + RU5PS RNA packaging system yields 
transduction efficiencies that approach those of standard HIV-1 vectors (chapter 3). The 
unique capacity of the heterologous vector to remain episomal exposes it to manipulation for 
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therapeutic gene delivery purposes. Episomal vectors have recently been sought as safer 
alternatives to integrating lentiviral vectors for gene therapy protocols requiring transient 
gene expression in dividing cells, or long-term expression in non-dividing cells (11, 210). 
HIV-1 delivery of the chimeric heterologous vector resulted in the dominant formation of 1-
LTR episomal forms (Fig. 42), which was indicative of alterations in reverse transcription. 
Gene expression from the chimeric MLV/HIV system remains a challenge, yet, like non-
integrating HIV-1 vectors (6, 14, 99, 137, 173, 179, 207, 219), expression is detectable 
following in vivo transduction of neurons in the mouse and rat brain striatum (Figs. 34-36). 
Restricting the synthesis of linear episomes through the use of the chimeric MLV/HIV vector 
system may impart improved safety benefits, over conventional non-integrating HIV-1 
vectors, by reducing illegitimate integration.   
The chimeric MLV/HIV vector packaged into HIV-1 viral particles curtails the 
presence of linear episomal forms that may be substrates for illegitimate integration as 
described earlier by Kantor et al. (99), as well as nonhomologous integration at sites of strand 
breakage in the host cell genome. A non-integrating vector that minimizes perturbations of 
the host cell genome would be most desirable for gene therapy protocols. Heterologously 
packaged vectors can also serve as a model system to investigate retroviral cis elements and 
trans factors that influence the transduction process. This is exemplified by the distinct 
transduction profiles of differently packaged chimeric vectors, which provided functional 
evidence demonstrating that the HIV-1 transduction mechanism is most closely related to 
FIV (FIV cis elements are sufficient for HIV-1 to mediate reverse transcription and 
integration), followed by EIAV (EIAV cis elements sufficient for HIV-1 mediated reverse 
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transcription, not integration), and MLV (MLV cis elements not amenable to HIV-1 
mediated reverse transcription or integration).  
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Figure 32. Heterologous MLV/HIV RNAs do not integrate following delivery with HIV-
1 viral particles. A. Transduction of 293T cells with MLV/HIV RRE+RU5PS at 5 days 
post-transduction (no passaging of cells, P0), and after 5 passages of cells (P5). Percent GFP 
positive cells were assessed by FACscan analysis and compared to non-transduced (No 
Vector) 293T cells. B-D. MLV/HIV RRE+RU5PS chimeric vector was packaged into HIV-1 
and MLV viral particles in the presence of Rev. 293T cells were transduced with equivalent 
transducing units for HIV-1 and MLV packaged vectors. Total cellular DNA was harvested 
at 5 days post-transduction (episomal and integrated vector DNA, P0), and after five cell 
passages (integrated vector DNA, P5). Vector DNA copy number as measured by qPCR to 
the WPRE (B), and -globin DNA copy number (C), were determined by qPCR. Data are 
shown without cell passages (P0; white bars) and after 5 cell passages (P5; black bars). 
Vector DNA copy number was normalized to -globin copy number (D), and fold decreases 
in vector DNA levels, after passaging cells, are shown. Error for all bar graphs is expressed 
as ±S.D.    
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Figure 33. In vitro delivery of MLV/HIV chimeric vector by HIV-1 viral particles to 
non-dividing 293T cells. A. An early generation chimeric MLV/HIV RRE vector, similar to 
that utilized in chapters 2 & 3, except that the firefly luciferase gene was not present. B. The 
chimeric vector in part A was packaged into MLV or HIV-1 viral particles for delivery to 
293T cells that were arrested at the G1/S phase of the cell cycle with 5 g/ml aphidicolin.   
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Figure 34. HIV-1 structural and enzymatic proteins can deliver a heterologously 
packaged MLV/HIV chimeric RNA to non-dividing cells in mouse brain striatum. A. 
Mouse brains were injected into the striatum with equivalent transducing units of MLV/HIV 
RRE vector packaged into either MLV (left panels), or HIV-1 (right panels), derived viral 
particles. Brain sections were imaged by confocal microscopy following co-staining for 
neurons (NeuN, red) and vector particles (GFP, green). Images depicting both vector and 
neurons can be seen for MLV (top left and low magnification) and HIV (left top and low 
magnification) viral particles. Independent images of vector and neurons are shown for MLV 
(top middle and top right, respectively) and HIV (left middle and left bottom, respectively) 
viral particles. B. The graph represents the total number of cells scored for GFP only (white 
bars), and colocalized GFP + NeuN (black bars) from 5 mice in each group. Error for bar 
graph is expressed as ±S.D. 
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Figure 35. HIV-1 structural and enzymatic proteins can deliver a heterologously 
packaged MLV/HIV chimeric RNA to non-dividing cells in rat brain striatum. Rat 
brains were injected bilaterally into the striatum with equivalent transducing units of 
MLV/HIV RRE vector packaged into HIV-1 derived viral particles. Brain sections were 
imaged on a slide analyzer following detection of vector derived GFP expression from 
transduced cells by anti-GFP-biotinylated antibody, and subsequent secondary sensitive to 
DAB staining. The images depict the extent of neuronal transduction in the rat brain striatum, 
from three independent rat brains, shown at 10X and 20X magnifications.  
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Figure 36. HIV-1 structural and enzymatic proteins can deliver a heterologously 
packaged MLV/HIV chimeric RNA to non-dividing cells in rat brain striatum. A. Rat 
brains were injected into the striatum with equivalent transducing units of MLV/HIV RRE 
vector packaged into either MLV (bottom panels), or HIV-1 (top panels), derived viral 
particles. Brain sections were imaged by confocal microscopy following co-staining for 
neurons (NeuN, red) and vector particles (GFP, green). Images depicting both vector and 
neurons can be seen for MLV (bottom, far right) and HIV (top, far right) viral particles. 
Independent images of vector and neurons are shown for MLV (bottom, left & middle) and 
HIV (top, left & middle) viral particles. B. The graph represents the total number of cells 
scored for GFP only (white bars), and colocalized GFP + NeuN (black bars) from 6 rats in 
each group. Error for bar graph is expressed as ±S.D. 
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Figure 37. HIV-1 structural and enzymatic proteins can deliver a heterologously 
packaged EIAV/HIV RRE chimeric vector RNA to mouse liver. A. The EIAV/HIV RRE 
vector contains a liver specific promoter (human alpha anti-trypsin promoter) driving 
expression of the firefly luciferase gene. Vector RNAs were packaged into HIV-1 viral 
particles, derived from ∆NRF packaging construct, and produced in 293T cells. B. 
Concentrated vector was delivered intraperitoneally to two separate animals (middle and 
right), and compared to a PBS control (left). Mice were imaged at 3 weeks and 23 weeks 
post-injection. Scale at 23 weeks (400 max) represents a 5 fold increase in sensitivity 
compared to scale shown at 3 weeks (2000 max).  
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Figure 38. HIV-1 structural and enzymatic proteins can stably deliver a heterologously 
packaged FIV/HIV RRE chimeric vector RNA to mouse brain striatum and mouse 
embryos for generation of transgenic mice. A. Heterologous FIV/HIV RRE vector RNAs 
were packaged into ∆NRF derived HIV-1 viral particles, produced in 293T cells. B. 
Concentrated chimeric viral particles were administered to rat brain striatum. GFP expression 
from the vector was captured by fluorescence microscopy. C. Single cell mouse embryos 
were administered concentrated chimeric vector particles into the perivitelline space. GFP 
expression was captured by fluorescence microscopy. D. Transgenic mice were generated 
from tranduced embryos implanted into pseudopregnant females. GFP expression could be 
captured after removal of hair from mouse abdomens. Transgenic animals were confirmed by 
standard PCR for vector and -actin on gDNA, followed by ethidium bromide detection in an 
agarose gel.  
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Figure 39. HIV-1 structural and enzymatic proteins deliver chimeric vector RNAs with 
distinct transduction profiles. Chimeric vector particles were generated in 293T cells with 
each of the indicated vectors packaged into HIV-1 viral particles. 293T cells were transduced 
with the chimeric vector particles and GFP expression was detected at 5 days post-
transduction (P0) or after at least 5 passages of the cells (≥P5) to eliminate episomal cDNA 
forms. GFP expression was detected by fluorescence microscopy and FACScan analysis. The 
percent GFP positive cells are indicated before and after passaging cells.   
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Figure 40. DNA products of retroviral reverse transcription. The diagram begins 
depicting a nearly complete minus (-) strand (black line), which was initiated by the 
tRNALys3 priming reverse transcription from the primer binding site (PBS). The plus (+) 
strand (red line) synthesis was initiated by priming from the 3’ polypurine tract (PPT). Under 
conventional circumstances (-) strand synthesis is completed through displacement of the (+) 
strand, and extension using the (+) strand as template for completion. Concurrently, (+) 
strand is completed using the (-) strand as template to generate a linear form that is 
competent for processing and integration mediated by integrase. In addition, 1-LTR circles 
are proposed to be generated from homologous recombination between the two LTRs, or 
more relevant here in the absence of strand displacement there may be complete extension by 
the reverse transcriptase and ligation of the nicks (indicated in green) at the ends of the 
LTRs. Lastly, the 2-LTR episomal form is commonly generated from linear molecules 
through non-homologous end joining mediated by host cell proteins.       
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Figure 41. HIV-1 att sites augment stable transduction of EIAV/HIV RRE chimeric 
vector. A. The EIAV att sites in the chimeric EIAV/HIV RRE vector were altered to those of 
HIV-1 att sites (red). The vector RNAs were packaged into HIV-1, or EIAV, derived viral 
particles produced in 293T cells. B. 293T cells were transduced with equivalent GFP 
transducting units of EIAV/HIV RRE, and EIAV/HIV att + RRE vectors. Stable integration 
was examined by FACScan analysis for GFP expression after ≥5 passages of transduced cells 
to eliminate episomal forms. C. Southern blot analysis of total DNA purified from 293T cells 
transduced with EIAV/HIV RRE (- att sites) or EIAV/HIV att + RRE (+ att sites) chimeric 
vectors packaged into HIV-1 or EIAV viral particles. Episomal products were differentially 
detected with a 3’ probe following digestion with PvuII + PflMI. The backbone is common 
to all forms between PvuII and PflMI, whereas 2-LTR, 1-LTR, and linear forms can be 
distinguished by size separation.  
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Figure 42. Heterologous MLV RNAs form, predominantly, 1-LTR episomal cDNAs 
following delivery with HIV-1 viral particles.  A. MLV/HIV RRE+RU5PS chimeric vector 
was packaged into HIV-1 and MLV viral particles in the presence of Rev. B & C. 293T cells 
were transduced with equivalent transducing units for HIV-1 and MLV packaged vectors. 
Total cellular DNA was harvested at 5 days post-transduction (episomal and integrated 
vector DNA, P0), and after five cell passages (integrated vector DNA, P5). Southern blot 
analysis of total DNA isolated from 293T cells transduced with MLV/HIV RRE+RU5PS 
vector packaged into either HIV, or MLV, viral particles (as indicated above lanes). DNA 
was digested with BsrGI (B) to distinguish between 2-LTR, 1-LTR, and linear episomal 
forms, as well as the vector backbone which is indicative of integrated vector DNA after 
passaging cells. Independent blots were probed with a 5’ probe (B), or 3’ probe (C). The 3’ 
probe may reveal linear forms not detectable by the 5’ probe.  
 
135 
 
 
Figure 43. Stable transduction of a chimeric MLV/HIV vector requires HIV-1 cis 
elements that prime reverse transcription and facilitate integration. A. The MLV att 
sites, PBS, and PPT in the chimeric MLV/HIV RRE vector were altered to those of HIV-1 att 
sites, PBS, and PPT (red) where indicated. The vector names indicate the HIV-1 cis elements 
incorporated. The vector RNAs were packaged into HIV-1 derived viral particles produced in 
293T cells. B. 293T cells were transduced with equivalent GFP transducing units of each 
chimeric MLV/HIV vector. Stable integration was examined by FACScan analysis for GFP 
expression after ≥5 passages of transduced cells to dilute episomal forms. Stable transduction 
is expressed as the percent GFP positive cells after passaging transduced cells, which was 
determined as a ratio relative to the GFP positive cells prior to passaging. Fold increases in 
stable transduction, relative to the MLV/HIV chimeric vector containing MLV att sites, PBS, 
and PPT.    
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Figure 44. Altering PBS and PPT cis elements in chimeric MLV/HIV vectors changes 
the episomal profile. A. Episomal products of MLV/HIV chimeric vectors (Fig. 43) were 
differentially detected with a 3’ probe (B), or a 5’ probe (C), following digestion with SexAI 
(S) and PflMI (P). The backbone is common to all forms between SexAI and PflMI, whereas 
2-LTR, 1-LTR, and linear forms can be distinguished by size separation. B & C. 293T cells 
were transduced with equivalent transducing units for HIV-1 and MLV packaged vectors. 
Total cellular DNA was harvested at 5 days post-transduction (episomal and integrated 
vector DNA, P0). Southern blot analysis of total DNA isolated from 293T cells transduced 
with chimeric MLV/HIV vectors packaged into either HIV, or MLV, viral particles (as 
indicated above lanes). Independent blots were probed with a 3’ probe (B), or 5’ probe (C). 
The 3’ probe may reveal linear forms not detectable by the 5’ probe. However, the 5’ probe 
can reveal increases in linear forms competent for integration. Different MLV/HIV chimeric 
vectors are indicated by the HIV-1 cis elements incorporated (att sites, PPT, or PBS) below 
each Southern blot.  
 
Chapter 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
 From the perspective of viral pathogenesis, the viral replication process is typically 
divided into two stages early events of infection for the virus to enter a host cell, and late 
events whereby viral RNAs and proteins are expressed, and employed to generate nascent 
viral particles. This makes sense since this order of events will occur in the same host cell. 
However, an alternative perspective could be that the RNA and proteins incorporated into 
newly forming retroviral particles may govern subsequent infection events within a host cell. 
Therefore, one might consider early events of viral replication to engender mechanisms that 
lead to viral particle assembly for HIV-1, as well as other viruses, and how particle assembly 
could influence early infection events within naive host cells. The organization of the 
research in this dissertation reflects the latter sequence of events. The research presented in 
chapters 2 & 3 reveal a central contribution of the Rev/RRE system to the process of 
efficiently and specifically encapsidating RNAs into HIV-1 derived viral particles. The 
conventional canonical packaging signal, , is the dominant cis packaging signal recognized 
by the HIV-1 Gag polyprotein; however, work presented in chapter 3 demonstrates that 
efficient RNA encapsidation also requires cis elements in the 5’ UTR (R, U5, & PBS) that 
are upstream of the canonical packaging signal. Still, most notable was that the entire 5’ UTR 
element lacked the capacity to enhance encapsidation of heterologous RNAs. Only in the 
presence of the Rev/RRE system could the 5’ UTR cis elements dramatically increase RNA 
encapsidation efficiency into HIV-1viral particles (chapter 3). In contrast, the Rev/RRE 
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system could augment encapsidation efficiency of heterologous RNAs into HIV-1 viral 
particles in the absence of a canonical HIV-1 packaging signal (chapter 2). The Rev/RRE 
system positively influenced encapsidation of heterologous RNAs derived from three 
different retroviruses (MLV, FIV, & EIAV) (chapter 2); an indication that this mechanism 
was not dependent on a particular RNA context. Interestingly, each of these encapsidated 
heterologous RNAs exhibited distinct transduction mechanisms, which were dependent on 
the capacity of HIV-1 reverse transcriptase and integrase proteins to recognize cis elements 
in the heterologous RNAs/vector DNAs (chapter 4). Thus, returning to the discussion on 
early and late events of replication, in these studies the heterologous RNAs encapsidated into 
the HIV-1 viral particles determined the transduction profile in subsequent host cells. 
Moreover, these unique heterologous packaging systems may be manipulated for therapeutic 
gene delivery protocols.  
 
HIV-1 Rev Augments Encapsidation of Heterologous RNAs into HIV-1 Viral Particles, 
Independent of the Canonical Packaging Signal.  
 In the absence of a HIV-1 canonical cis packaging signal, or any cis elements from 
the 5’ UTR, the HIV-1 Rev/RRE can mediate an increase in heterologous RNA encapsidated 
into a HIV-1 viral particle (chapter 2, Fig. 13 & 14). Moreover, this increase appears to be 
specific to RNAs harboring the RRE (chapter 2). Since HIV-1 Rev has not been 
demonstrated to be encapsidated into viral particles it might be expected that Rev does not 
mediate the direct incorporation of the RNA into viral particles. Taking this into account, a 
model for this mechanism might be that Rev influences the ability of RRE-containing RNAs 
to concentrate in cytoplasmic locations that make the RNA amenable to interactions with the 
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HIV-1 Gag polyprotein. Even if this were the case, however, the absence of the major HIV-1 
cis packaging element raises the question of how the nucleocapsid protein, within the context 
of the Gag polyprotein, could interact with the heterologous RNA for subsequent 
encapsidation/assembly of viral particles at the host cell plasma membrane. In the absence of 
a canonical packaging signal the nucleocapsid and matrix proteins, in the context of the Gag 
polyprotein, were shown to interact non-specifically with viral RNAs (165, 166). Therefore, 
in the absence of a canonical packaging signal (such as with heterologous RNAs utilized in 
chapter 2) the Gag polyprotein may interact non-specifically with available RNAs. Under 
these circumstances specificity would initially be conferred by the Rev/RRE interaction (the 
Rev/RRE system conferred specificity onto RRE containing RNAs, chapter 2), and the 
capacity of the Rev-RRE interaction to locate RNAs to cytoplamic sites that also harbor 
HIV-1 Gag polyprotein. Although a non-specific interaction, the Gag polyprotein could then 
mediate transport to sites of particle assembly at the plasma membrane. This model is in 
accordance with a series of recent studies indicating that monomer/dimer Gag molecules 
interact with HIV-1 viral RNA genomes in the cytoplasm (116); and, employing highly 
sensitive techniques to examine single particle assembly, they demonstrate that Gag-RNA 
complexes are recruited to sites of particle assembly at the plasma membrane, where further 
multimerization of Gag on the preformed Gag-RNA complexes generates nascent viral 
particles (96, 97). Future experiments to support this model might include examining the 
cytoplasmic colocalization of the heterologous RNAs with HIV-1 Rev and Gag polyprotein. 
Previous evidence indicates that HIV-1 Gag and genomic RNA colocalize at 
perinuclear/centrosomal regions in the cytoplasm (178). Conceivably, the Rev/RRE system 
could mediate transport from the nucleus to such sites in the cytoplasm.  
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Importantly, the Rev/RRE has been demonstrated to recruit a number of host cell 
proteins (41, 71, 199) that may also influence the proposed model. In at least one case, 
ablation of hRIP (human Rev interacting protein) function, a HIV-1 Rev cofactor, precludes 
HIV-1 replication and causes a perinuclear accumulation of viral RNA (223). Apparently, 
interfering with hRIP activity would preclude RNA packaging; however in this study hRIP 
also obviates viral particle production, making it difficult to distinguish between the two 
possibilities. In our heterologous packaging system viral particle production was Rev-
independent so that only the influence of Rev on heterologous RNA encapsidation could be 
measured. Therefore, the heterologous packaging system could be used to isolate the impact 
of cellular proteins on RNA encapsidation into HIV-1 viral particles. Employing a dominant 
negative hRIP protein (223), or shRNA knockdown experiments to a number of identified 
host cell proteins that interact with the Rev/RRE (41, 71, 199), would be very useful in 
parsing the effects of host cellular proteins on RNA encapsidation into HIV-1 viral particles.   
Studies presented in chapter 2 not only reveal the influence of the HIV-1 Rev/RRE 
system on encapsidation, but also the potential for a conserved mechanism with the Rev 
protein from the non-primate lentivirus, feline immunodeficiency virus (FIV). According to 
titers, which may reflect packaged RNA, the FIV Rev (FRev) functioned similar to the HIV 
Rev (HRev) to efficiently increase titers of FIV/HIV chimeric vector RNAs, packaged into 
HIV-1 viral particles. In contrast, Rev from equine infectious anemia virus (EIAV) could not 
augment titers of EIAV/HIV chimeric vector RNAs into HIV-1 viral particles, even though 
HIV-1 Rev could (chapter 2, Fig. 15). Apparently, ERev may commandeer a mechanism that 
is distinct from that of HRev and FRev. Of course future studies should clarify if this is 
indeed a difference in RNA encapsidation. Nonetheless, a previous study indicates that in 
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human cells HIV-1 and EIAV exhibit distinct assembly sites, and that these can be altered by 
changing the RNA trafficking pathway (93). Importantly, a follow-up study indicated that 
efficient HIV-1 assembly is dependent upon correct RNA trafficking, and correct RNA 
trafficking was dependent on the Rev/RRE system (94). Therefore, HRev and FRev may 
share a trafficking pathway, whereby the function is conserved in human cells. Presumably, 
ERev would utilize a different trafficking pathway. Apparently, the difference in trafficking 
does not stem from the use of the CRM1 nuclear export pathway since it was previously 
demonstrated that FRev and ERev also utilize the CRM1 nuclear export pathway (164); thus, 
the differences in trafficking would most likely be contingent upon trafficking in the 
cytoplasm. Also of note, since the HRev could augment encapsidation of the EIAV/HIV 
RRE chimeric vector RNA the difference is probably not a consequence of EIAV cis 
elements in the 5’ UTR (chapter 2, Figs. 14 & 15), but rather differences associated with the 
Rev proteins. Future studies may include the use of colocalization studies with different Rev 
proteins, heterologous RNAs, and Gag to investigate distinct trafficking differences 
attributed to Rev. Exploiting the differences obtained with different Rev proteins will clearly 
be advantageous in deciphering the mechanism of the Rev protein in RNA encapsidation. 
 The dominant function attributed to the Rev protein is nuclear export of intron-
containing HIV-1 RNAs through the CRM1-dependent pathway (58, 59, 155, 163). Nuclear 
export is part of the RNA localization process, therefore may contribute to the fate of RNA in 
the cytoplasm. Manipulating viral RNA cis elements and trans factors that impact nuclear 
export have also been shown to affect viral particle assembly (93, 94, 149, 191, 201). As 
shown here altering the nuclear export pathway severely attenuated the effect of Rev on RNA 
encapsidation (chapter 2, Fig. 19), but did not abolish it; indicating that the pathway of 
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nuclear export may not absolutely determine the cytoplasmic fate of the RNA. More 
important may be trafficking of the Rev/RNA complex in the cytoplasm to sites where the 
Gag polyprotein can efficiently interact with the canonical packaging signal in the RNA.  
 
An Efficient and Specific HIV-1 RNA Packaging System Requires the Concerted Effort 
of the Rev/RRE system and Cis Elements in the 5’ UTR.  
 The HIV-1 Rev/RRE system can clearly augment encapsidation independent of cis 
elements in the 5’ UTR; however, the efficiency of encapsidating a heterologous RNA is 
diminished compared to a construct with the Rev/RRE system and the entire complement of 
cis elements from the 5’ UTR (chapter 3, Fig. 24). Previous studies indicate that the 
Rev/RRE can contribute to RNA encapsidation when the RRE is in the same RNA context as 
cis elements from the HIV-1 5’ UTR (5, 19, 67, 181). These studies, however, did not 
distinguish the encapsidation contribution of the individual HIV-1 components to the 
collective influence of all the components together. The gain-of-function studies presented in 
this work demonstrate for the first time that cis elements in the 5’ UTR (including the 
canonical packaging signal) require the Rev/RRE system to achieve efficient encapsidation 
(chapter 3, Fig. 24). Since the canonical packaging signal is the major cis element recognized 
by the Gag polyprotein, it might have been anticipated that in the presence of the Rev/RRE 
system the canonical packaging signal would be sufficient to achieve efficient encapsidation. 
However, independent incorporation of  (canonical packaging signal) in the context of the 
Rev/RRE system did not exhibit a gain in encapsidation (chapter 3, Fig. 25), which is in 
agreement with prior mutagenesis studies implicating cis deteminants in the R, U5, and PBS 
regions as important for efficient RNA encapsidation (37, 38, 81, 139). Data presented here 
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insinuate that the 5’ UTR cis elements are not separable to achieve efficient encapsidation of 
heterologous RNAs (chapter 3, Fig. 25). Potentially,  there is a requirement for long-range 
intramolecular interactions between cis elements in the R, U5, and PBS, with those in the 
canonical packaging signal, as previously indicated (50, 214). Exploiting the high resolution 
HIV-1 RNA structure, recently elucidated (Fig. 8) (212, 214), may be beneficial in 
generating specific mutations that disrupt identified long-range intramolecular RNA 
interactions, and assess the mutants for encapsidation efficiency in the context of our 
heterologous encapsidation system. Discerning how the Rev/RRE system influences specific 
and efficient recognition of cis elements in the 5’ UTR by the Gag polyprotein will be an 
important focus of future studies. Apparently, RNA encapsidation into HIV-1 viral particles 
may be modeled as at least a two-step mechanism in which: i) the Rev/RRE system confers 
efficient and specific transport of the RNA from transcription in the nucleus to a particular 
location in the cytoplasm; and, ii) Gag interacts with the canonical packaging signal to 
transport the RNA from a cyoplasmic compartment to sites of particle assembly at the plasma 
membrane.  
The requirement for the HIV-1 Rev/RRE system in the encapsidation mechanism 
implies that the Rev/RRE may confer specificity onto HIV-1 RNA throughout step 1 of the 
mechanism, from the time that Rev interacts with RNA in the nucleus. Such a mechanism 
might ensure early selection of viral RNA from the milieu of host cell RNAs, concomitant 
with transcription in the nucleus. In fact, results presented throughout chapters 2 & 3 
demonstrate that this is not a general biological phenomenon, but rather specific to 
heterologous RNAs harboring the RRE cis element. Until now the specificity of the 
Rev/RRE system for RNA encapsidation has not been addressed. Importantly, the concerted 
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effect of the Rev/RRE system and 5’ UTR cis elements observed for RNA encapsidation into 
HIV-1 viral particles was not possible into MLV derived viral particles (chapter 3, Fig. 30); 
consistent with the proposal that HIV-1 and MLV utilize distinct mechanisms to encapsidate 
viral RNA (53, 121).  
There is an apparent requirement for packaging systems that can preferentially 
facilitate packaging of the viruses own genome to maintain viral fitness. Nonspecific 
packaging of cellular RNAs during generation of nascent HIV-1 viral particles has also been 
well documented (152, 162, 188). Data shown here demonstrate that the specificity conferred 
upon the vector RNA by the Rev/RRE system can mitigate the nonspecific packaging of 
producer cell RNAs (i.e. Rev-mediated increase packaging of HIV-1 vector RNA while 
concomitantly reducing nonspecific large T antigen RNA) (Fig. 31). Additionally, packaged 
cellular RNAs have been shown to be reverse transcribed, and recombine with the packaged 
viral RNA during reverse transcription in host cells (78, 123, 152). With regard to retroviral 
vector production, 293T cells were identified to be most amenable for this process through 
ectopic expression of vector particle components. Most notably 293T cells overexpress the 
large T antigen, which is well recognized to transform cells upon overexpression. Data 
presented here demonstrate that large T antigen RNA is readily packaged into HIV-1 derived 
viral particles and can be reverse transcribed in naïve host cells (Fig. 31); however, this 
concern can be eased by utilizing cells that do not overexpress large T antigen (Fig. 31). 
Although reverse transcription of large T antigen RNA indicates a potential to be stably 
introduced into a host cell genome, the frequency of this event may be extremely rare, 
therefore would require a highly sensitive assay for detection. Since this may have broad 
implication regarding the production of lentiviral vectors currently being used in clinical 
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trials (29, 30), considerable effort should be placed on developing a functional assay 
sensitive enough to detect stable transfer of large T antigen.  
The research presented in chapters 2 & 3 reveal a central contribution of the Rev/RRE 
system to the process of efficiently and specifically encapsidating heterologous RNAs into 
HIV-1 derived viral particles. The results define a transferrable HIV-1 packaging system 
comprised of the Rev/RRE, 5’ UTR cis elements, and Gag polyprotein. As mentioned above 
heterologous RNAs packaged during particle assembly in producer cells may influence 
events of transduction in subsequent host cells. Packaging three different heterologous RNAs 
(derived from MLV, EIAV, or FIV) into HIV-1 viral particles exposed distinct transduction 
properties. 
 
Packaging heterologous RNAs into HIV-1 viral particles reveals unique transduction 
properties with applications for gene therapy. 
 The packaging of heterologous vector RNAs into HIV-1 derived viral particles is not 
only a model system for studying RNA encapsidation mechanisms, but has also been 
exploited to investigate retroviral cis elements and trans factors that influence the 
transduction process. HIV-1 structural and enzymatic proteins that comprise viral particles 
can mediate transduction of heterologously packaged RNAs derived from three different 
retroviral vectors: MLV, EIAV, and FIV. These vectors were able to be delivered to dividing 
and non-dividing cells in vitro and in vivo (chapter 4). A well established biological 
phenomenon is that MLV viral particles cannot transduce quiescent cells (217). This is the 
first demonstration that encapsidating a heterologous MLV vector RNA into HIV-1 viral 
particles facilitated transduction, which includes nuclear entry, of a chimeric MLV vector 
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RNA into non-dividing cells in vitro and in vivo (chapter 4 Figs. 33-36). These data 
demonstrate the capacity of HIV-1 structural and enzymatic proteins to confer nuclear import 
into quiescent cells upon a MLV derived RNA, and are in accordance with a study 
demonstrating that the HIV-1 capsid protein is critical for the transduction of non-dividing 
cells (218). The capacity to transduce arrested cells does not appear to be dependent upon cis 
elements in the vector, but rather proteins supplied by the HIV-1 viral particles. Although the 
HIV-1 cPPT (central polypurine tract) was included in our constructs during cloning, and it 
has been suggested to enhance transduction, more recent studies indicate that the previous list 
of HIV-1 karyophilic determinants (matrix, Vpr, integrase, & cPPT) are not required for 
transduction of nondividing cells (182, 216). Our heterologous packaging systems do not 
include Vpr, therefore in agreement with previous studies Vpr is not required for nuclear 
entry. The heterologous packaging system may further be beneficial in examining viral 
protein components that facilitate nuclear import through mutagenesis. Moreover, the cis 
elements and trans factors of the heterologous packaging system can be readily manipulated 
to investigate putative interactions, and the functional contribution of host cell proteins with 
different viral components to mediate transduction.  
 Of the three heterologous vector RNAs packaged into HIV-1 viral particles stable 
transduction was partially achievable with the chimeric FIV/HIV vector (chapter 4, Figs. 38 
& 39), enough such that transgenic mice could be generated from single cell embryos 
(chapter 4, Fig. 38). These results were in line with those previously obtained for 
heterologous packaging and propagation of RNA derived from primate (184, 198), and the 
non-primate FIV (22) lentivirus’s, into HIV-1 derived viral particles. As shown by functional 
studies with FIV Rev in chapter 2 and transduction results in chapter 4, there appears to be a 
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significant degree of functional conservation between FIV and HIV-1 that is not shared with 
EIAV and MLV.  
In contrast to FIV/HIV chimeric vectors, the HIV-1 structural and enzymatic proteins 
did not mediate stable transduction of MLV/HIV and EIAV/HIV chimeric vectors. The 
MLV/HIV and EIAV/HIV chimeric vectors remained as episomes following transduction. 
Molecular analysis revealed that the episomal profiles of MLV/HIV and EIAV/HIV vectors 
were distinct. MLV/HIV vectors exhibited an abundance of 1-LTR episomes and linear 
forms that were not competent for integration (chapter 4, Fig. 42 & 44), whereas the 
episomal profile for chimeric EIAV/HIV vectors was comprised predominantly of linear 
forms (chapter 4, Fig. 41). Interestingly, stable transduction was recovered by correcting 
vector cis elements involved in distinct molecular processes. Regarding EIAV/HIV chimeric 
vectors replacing EIAV att sites with those of HIV-1 was sufficient (chapter 4, Fig. 41); 
however, MLV/HIV chimeric vectors required changing the att sites, as well as the PBS and 
PPT to those of HIV-1 (chapter 4, Fig. 43). Thus, altering EIAV att sites for recognition by 
HIV-1 integrase was minimally necessary for stable transduction of the EIAV/HIV chimeric 
vector; whereas, the MLV/HIV chimeric vectors required altering cis elements for both 
reverse transcription and integration. Clearly, these are the first studies that provide 
functional evidence demonstrating different degrees of functional conservation between 
retroviruses using a single viral packaging system. Episomal vectors that minimize 
perturbations of the host cell genome and remain stable in non-dividing cells would also be 
most desirable for therapeutic gene delivery protocols. The MLV/HIV and EIAV/HIV 
chimeric vectors can clearly transduce non-dividing/slowly dividing cells in vivo, and 
maintain transgene expression (chapter 4, Figs. 34-37); albeit, in the case of MLV/HIV 
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chimeric vectors the low level of GFP expression required the use of antibodies to increase 
detection sensitivity. Nonintegrating lentiviral vectors have recently been pursued as safer 
alternatives to integrating lentiviral vectors demonstrating transduction of the CNS, liver, 
muscle, and eye (6, 14, 99, 173, 179, 219). Despite the improved safety profile of episomes 
to diminish the potential for insertional mutagenesis, linear episomal products remain the 
dominant species, as shown for EIAV/HIV chimeric vectors, and have the potential to 
instigate genotoxicity through illegitimate integration (i.e. viral DNA integration that is not 
mediated by a functional integrase). Since the linear episomal species are the products of a 
successful reverse transcription process, it was recently realized that interfering with reverse 
transcription, through deletion of the 3’ PPT, can alter the profile of episomal vector species 
to favor 1-LTR circles (99), thereby ameliorating the episome safety profile. A similar 
episomal profile is obtained with the MLV/HIV chimeric vectors packaged into HIV-1 viral 
particles (chapter 4, Fig. 42 & 44), indicative of its usefulness in therapeutic gene delivery 
protocols.  
 
Significance 
 The heterologous RNA packaging system utilized here is an innovative universal 
packaging system that facilitates functional investigations of early and late events of HIV-1 
viral replication. The studies presented in this dissertation demonstrate that a competent 
packaging system comprises the concerted effort of multiple HIV-1 cis elements and trans 
factors. As shown here the entire complement of cis elements from the 5’ UTR were not 
sufficient to augment encapsidation of a heterologous RNA into HIV-1 viral particles. 
Importantly, these studies reveal that the Rev/RRE system is required for the 5’ UTR cis 
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elements to positively influence RNA encapsidation. In fact, the data in this dissertation 
demonstrate that the Rev/RRE system can significantly augment encapsidation in the absence 
of all cis elements from the 5’ UTR; albeit, the overall encapsidation efficiency is not 
comparable to heterologous vectors containing the 5’ UTR and Rev/RRE system. As defined 
by the studies in this dissertation a HIV-1 packaging system, capable of conferring efficient 
and specific encapsidation of heterologous RNAs, should minimally comprise the Rev/RRE 
system, 5’ UTR cis elements, and Gag polyprotein. These studies indicate that the 
encapsidation process may constitute at least a two-step mechanism in which: i) the 
Rev/RRE system confers efficient and specific transport of RNA from transcription in the 
nucleus to a particular location in the cytoplasm for subsequent Gag-RNA interaction; and, 
ii) Gag interacts with the canonical packaging signal to transport the RNA from a cyoplasmic 
compartment to sites of particle assembly at the plasma membrane. The same HIV-1 
structural and enzymatic proteins that mediate encapsidation of heterologous RNAs also 
facilitate transduction of chimeric vector RNAs into nondividing cells in vivo. The dominant 
1-LTR episomal profile of transduced MLV/HIV chimeric vector RNAs may have improved 
safety benefits over more conventional nonintegrating lentiviral vectors by reducing the 
potential for illegitimate perturbations of the host cell genome. These innovative vector 
systems may prove beneficial for therapeutic gene delivery to nondividing cells.   
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